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INTRODUCTION 
Back&round 
It is hypothesized that B-carboline-N-methyltransferases (BC-NMT) and 
the neurotoxic products of their catalytic activities, N-methylated 
B-carbolinium cations. (MeBCs+), may play a role in the pathogenesis of 
idiopathic Parkinson's disease (Collins 1994; Collins et al. 1985). This 
hypothesis was originally based on the structural similarity between MeBCs+ 
and neurotoxic 1-methyl-4-phenylpyridinium ion (MPP+ ). In the central 
nervous system of human and nonhuman primates, MPP+ selectively destroys 
the dopaminergic nigrostriatal system of the basal ganglia, resulting in a 
parkinsonian condition (Burns et al. 1983; Burns et al. 1984; Chiueh et al. 1984; 
Langston 1995; Langston et al. 1983). In support of this hypothesis, previous 
work indicates that MeBCs+ share several toxic properties with MPP+ (Albores 
et al. 1990; Cobuzzi et al. 1994; Collins 1994; Collins et al. 1996; Collins et al. 1992; 
Collins et al. 1995; Drucker et al. 1990; Fields et al. 1992; Neafsey et al. 1995; 
Neafsey et al. 1989). In addition, MeBCs+ have been detected in postmortem 
human brain tissue from normal subjects (Matsubara et al. 1993), but such 
studies have not been done in Parkinson's cases. Notably, MeBCs+ are elevated 
in the lumbar cerebrospinal fluid of Parkinson's patients relative to control 
values (Matsubara et al. 1995). 
Relevant to this dissertation was the finding that mammalian brain 
possesses enzymatic activities capable of generating neurotoxic MeBCs+ from 
simple B-carbolines (BCs) (Collins et al. 1992). In tissue homogenates from 
guinea pig and rat brain, various BCs are N-methylated at both their pyridyl 
(2N-) and indole (9N-) nitrogens by S-adenosyl-L-methionine-dependent 
N-methyltransferases (Collins et al. 1992; Matsubara et al. 1992b). These 
activities have been designated as 6C-2N-methyltransfe'rase (BC-2-NMT) and 
BC-9N-methyltransferase (BC-9-NMT), for N-methylation occurring at the 
pyridyl and indole nitrogens of BCs, respectively. Matsubara et al. (1993) 
detected BC-2-NMT activity, but not BC-9-NMT activity, in postmortem normal 
human brain tissue. 
2 
The primary focus of this dissertation is a more detailed investigation of 
the properties of these neurotoxin-producing BC-N-methyltransferases, 
particularly the 2N-methylation activity. 
Specific Aims 
Aim 1 
Characterization of optimal assay conditions used in the assessment of brain 
B-carboline-2N-methyltransf erase (BC-2-NMT) activity. Enzyme 
characterization is a prerequisite to the partial purification of bovine brain 
BC-2-NMT (Aim 2), and to comparison of its activity in human postmortem 
brains from control and Parkinson's disease subjects (Aim 3 ). 
3 
Aim 2 
Partial purification of bovine brain B-carboline-2N-methyltransferase 
(BC-2-NMT) using conventional protein purification techniques. Results from 
this aim should lay the foundation for subsequent studies on BC-2-NMT, 
including determination of its protein sequence, cloning of the gene, and 
perhaps speculation regarding its physiological function. Related to the 
physiological function of BC-2-NMT is the finding that BC-2-NMT activity may 
be due to phenylethanolamine-N~methyltransferase (PNMT). Evidence in 
support of the equivalency of BC-2-NMT and PNMT or a PNMT-like activity is 
presented in this dissertation. 
Aim 3 
Measurement of B-carboline-2N-methyltransferase (BC-2-NMT) and 
B-carboline-9N-methyltransferase (BC-9-NMT) activities in postmortem 
human brains from Parkinson's disease (PD) and control individuals. Brain 
regions evaluated include frontal cortex, substantia nigra, and putamen. This 
study expands upon Matsubara' s original work by including PD brain and two 
additional brain regions in the assessment of both BC-NMT activities. 
CHAPTER 1 
REVIEW OF RELEVANT LITERATURE 
Parkinson's Disease 
Clinical Symptoms and 
Pathogenesis 
Parkinson's disease (PD) is a chronic disorder of the extrapyramidal 
motor system. The disease onset is insidious and progresses slowly, with the 
time from the beginning of the pathological process to manifestation of 
clinical symptoms being several years (Berkow 1977; Koller et al. 1991). 
Clinically, Parkinson's disease is primarily characterized by the following 
motor symptoms: bradykinesia, akinesia, pill-rolling tremor, muscular 
rigidity, postural instability, shuffling gait, lack of facial expression, and 
infrequent blinking. However, nonmotor symptoms occur variably in PD, 
including loss of the sense of smell, depression, dementia, and sensory 
disturbances. In addition, numerous autonomic nervous system disturbances 
have been noted, such as orthostatic hypotension, excessive sweating, 
dermatitis, gastrointestinal symptoms, sexual dysfunction, and urological 
problems (Koller et al. 1995). 
Neuropathologically, PD affects the basal ganglia system, where there is 
specific loss of the dopaminergic, pigmented substantia nigra (pars compacta) 
(Berkow 1977; Koller and Pahwa 1995). Cell bodies in the substantia nigra pars 
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compacta project to the striatum (caudate and putamen), and degeneration of 
the nigrostriatal pathway results in a profound decrease in the 
neurotransmitter dopamine in the striatum. The nigral projections to the 
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putamen are apparently more affected in PD than projections to the caudate 
(Kish et al. 1988). Motor symptoms of PD do not present clinically until striatal 
dopamine decreases to about 20% of control levels (Kollerand Pahwa 1995). In 
addition to nigrostriatal degeneration, neuronal loss frequently occurs in the 
locus ceruleus, nucleus basalis of Meynert, peripeduncular nucleus, and in the 
dorsal motor nucleus of the vagus (Forno 1995, 1996). 
Small intraneuronal inclusions, known as Lewy bodies, are the 
pathological hallmark of PD. Lewy bodies may contain lipofuscin, 
neuromelanin, mitochondria, and other organelles. Common to all Lewy 
bodies are biochemically-altered neurofilament proteins -- Lewy body 
neurofilaments are abnormally phosphorylated, ubiquitinated, proteolyzed, 
and cross-linked (Forno 1996). Definitive pathologic diagnosis of PD must 
include the presence of Lewy bodies in the substantia nigra; however, several 
other dopaminergic, as well as nondopaminergic, brain nuclei often exhibit 
these cytoplasmic inclusions (Forno 1995, 1996). The dopaminergic ventral 
tegmentum may also demonstrate Lewy bodies, both in the presence and 
absence of nerve cell loss. Lewy bodies are frequently present in 
noradrenergic neurons of the locus ceruleus and sympathetic ganglion. 
Several cholinergic nuclei may also exhibit Lewy bodies, including the 
nucleus basalis of Meynert, the peripeduncular nucleus, the Edinger-Westphal 
nucleus, the intermediosacral nucleus, and intestinal autonomic ganglion 
(Forno 1995). The serotonergic dorsal raphe and superior central sulcus often 
display these inclusions. The posterior and lateral cell groups of the 
hypothalamus, the dorsal motor nucleus of the vagus, the cerebral cortex, as 
well as the olfactory tubercle may demonstrate Lewy bodies in PD. Forno 
(1995) states that "the widespread affection of these selected nuclei is such an 
integral part of the disease process that it [presence of Lewy bodies] deserves 
to be considered in relation to the etiology of the disorder." 
Epidemiology 
Epidemiology examines the interrelationships between host, agent, and 
environment in disease. Epidemiologic data related to Parkinson's disease are 
often difficult to interpret due to the long latency period preceding the 
clinical presentation PD (Koller et al. 1991). Roman's recent review of the 
neuroepidemiology of PD addresses the numerous problems associated with 
interpretation of epidemiologic data: specifically, adaptation of universal 
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diagnostic criteria in PD, and improved design of epidemiological studies would 
reduce the problems associated with data interpretation (Roman et al. 1995). 
Parkinson's disease is a disease of aging in that clinical manifestations 
usually are not observed until after age fifty, and it affects 1.5% of the 
population between 70 and 79 years of age (Martilla 1987). Both the 
prevalence and incidence of PD increases with advancing age. The 
prevalence of PD varies geographically -- from 18 cases per 100,000 population 
in China, to 182 per 100,000 in Iceland. Incidence rates worldwide vary 
between 2 to 24 cases per 100,000 population. There is apparently a slightly 
higher preponderance of PD in males than females (Roman et al. 1995). 
In epidemiologic terms, "agent" has application primarily in the study 
of infectious diseases and may have some significance with a subset of 
Parkinson's cases. Fazzini et al. (Fazzini et al. 1992) reported the presence of 
elevated levels of antibodies to coronovirus in the cerebrospinal fluid of PD 
patients. Kohbata et al. (Kohbata et al. 1993) demonstrated the presence of 
antibodies to the soil-pathogen, Nocardia asteroides, in the serum of PD 
patients; moreover, this organism causes a parkinson-like syndrome in mice 
(Kohbata et al. 1991 ). Zack and Tanner (1995) recently reviewed infectious 
diseases and their relevance to PD. The authors conclude that, although there 
is not strong evidence to support a primary role for a single pathogen in PD, 
hypotheses that an infectious process may increase the susceptibility of 
predisposed individuals to the disease merit further investigation. 
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Preliminary data regarding the factors and lifestyles associated with the 
risk for developing PD include living in an industrialized nation, rural living 
and drinking of well-water, a tendency toward less use of alcohol and tobacco, 
less physical activity, and a more rigid preclinical personality (Koller et al. 
1990; Kondo et al. 1993; Tanner 1989). Tanner and Zack (1995) have reviewed 
comorbid conditions proposed to have a relationship with PD; the comorbid 
conditions were endocrine disorders (thyroid disease, diabetes mellitus); 
metabolic abnormalities (cytochrome P450 enzymes, mitochondrial 
dysfunction); mood disorders (depression, anxiety); stroke; atherosclerosis; 
cancer; physiologic stress; head trauma; and drug use. They conclude that 
"none [of these associations] likely contribute to more than a few of all cases 
of Parkinson's disease ..... but [these associations] may provide pieces to the 
etiologic puzzle." 
As mentioned above, metabolic biomarkers that have been studied in 
Parkinson's disease include those enzymes involved in the metabolism of 
xenobiotics. In patients diagnosed with PD sulfur metabolizing enzymes were 
underactive, and monoamine oxidase-B activity was variable. Most pertinent 
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to this dissertation is the demonstration of an impaired metabolism of pyridine 
derivatives in Parkinson's disease, as evidenced by accumulation in the urine 
of N-methylated derivatives of nicotinamide following oral administration of 
the compound. Notably, levels of N-methylated nicotinamide were 100-fold 
greater in PD compared to control subjects -- suggesting either increased N-
methylation of nicotinamide, or decreased catabolism of N-methylated 
nicotinamide in PD (Williams 1995; Williams et al. 1993). 
Etiology 
General Hypotheses 
Etiology refers to the cause of a disease. Parkinsonian symptoms may 
occur during treatment with dopamine antagonists, as a consequence of 
carbon monoxide or manganese poisoning, with cerebral trauma or tumor, and 
following encephalitis (Berkow 1977; Koller and Pahwa 1995). However, the 
cause which underlies idiopathic Parkinson's disease remains a mystery, 
although roles for heredity, infection, metabolic dysfunction, and the 
environment have been proposed (Barbeau 1984). As reviewed by Jenner et 
al. (1992), study of the substantia nigra after death in PD patients reveals the 
following changes, which may provide clues regarding the mechanisms that 
underlie the disease: mitochondrial complex I deficiency, depleted levels of 
reduced glutathione as well as high levels of lipid peroxidation products 
(indicators of oxidative stress), high iron, and low f erritin levels. These 
authors summarize by stating that current views predict an interplay between 
environmental or endogenous agents (toxins) and a genetic predisposition to 
the disease -- an interplay that ultimately manifests in the neurochemical and 
clinical features of Parkinson's disease. 
The environmental toxin theory of the etiology of PD is central to this 
dissertation, and will therefore be addressed in more detail. 
An Environmental Cause for PD? 
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The theory implicating a role for an environmental toxin in PD gained 
impetus with discovery of the selective nigrostriatal toxin 
1-methyl-4-phenyl-1,2,3 ,6-tetrahydropyridine (MPTP) (Langston et al. 1983 ). 
MPTP is a contaminant in meperidine that was illicitly synthesized for "street-
drug" concoctions. Drug-users that injected the meperidine mixtures 
presented in hospital emergency rooms with classic parkinsonian symptoms 
(Langston et al. 1983). Further research showed that MPTP produces a 
parkinsonian-like condition in nonhuman primates (Burns et al. 1983; Davis et 
al. 1979; Langston et al. 1984a; Langston et al. 1983). Furthermore, following 
MPTP administration, postmortem pathological findings included the 
characteristic degeneration of the nigrostriatal pathway was observed in 
nonhuman primates (Burns et al. 1983; Burns et al. 1984; Langston et al. 1984a), 
as well as one human case (Davis et al. 1979). Positron emission tomography of 
18F-labeled dihydroxyphenylalanine (DOPA) uptake appears to be useful in 
assessment of striatal dopamine deficiency, since the rank order of 1 sp - D 0 PA 
uptake was: MPTP-induced parkinsonian subjects < Parkinson's patients 
< asymptomatic MPTP-exposed subjects < normal control individuals (Calne et 
al. 1985). 
MPTP is a lipophilic molecule that crosses the blood brain barrier; it is 
nontoxic prior to bioactivation to its active metabolite, neurotoxic 1-methyl-4-
phenylpyridinium ion (Langston et al. 1984b; Markey et al. 1984). Monoamine 
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oxidase (MAO) catalyzes the oxidation of MPTP to an intermediate, 1-methyl-4-
phenyl-2,3-dihydropyridinium ion (MPDP+); MPDP+ is then further oxidized to 
MPP+ (Chiba et al. 1985; Trevor et al. 1988). Current literature indicates that 
MPTP is a substrate for both MAO-A and MAO-B, but that in brain, glial MAO-B 
preferentially forms MPP+ (Di Monte et al. 1992; Salach et al. 1984). MPP+ is 
actively taken up into dopaminergic neurons via the dopamine transporter 
(Javitch et al. 1985); therein, MPP+ accumulates in mitochondria where it 
inhibits Complex I (NADH dehydrogenase) of the respiratory chain (Nicklas et 
al. 1985; Salach et al. 1984). Inhibition of this complex ultimately results in an 
inability of the mitochondria to carry out oxidative phosphorylation and 
synthesize adenosine triphosphate (ATP) (Chan et al. 1991). As a consequence 
of decreased ATP production, cellular homeostasis is disrupted, and neuronal 
cell death ensues (Mizuno et al. 1988; Nicklas et al. 1985; Salach et al. 1984). 
Inhibition of mitochondrial respiration also places the cell in a state of 
oxidative stress (Takeshige et al. 1979; Zeevalk et al. 1996; Zoccarato et al. 1988). 
The cationic nature of MPP+ is believed to be an important structural feature 
required for toxicity since it likely facilitates pyridinium ion transport into 
dopaminergic cells, and accumulation of the cation down the electrochemical 
gradient into mitochondria (Davey et al. 1992). 
The discovery of MPTP advanced the hypothesis that an environmental 
agent may play a causative, or at least a contributory role in the pathogenesis 
of PD. Although MPTP has not been detected in the environment, several 
chemicals exist both endogenously and exogenously which are structurally 
similar to MPTP or its neurotoxic metabolite MPP+. One such group of 
compounds are the N-methylated B-carbolines (MeBCs+) (Collins and Neafsey 
1985). 
N- Methylated B-C arbolines: 
Structure. Toxicity. and 
Formation 
Structure of N-Methylated BCs 
N-methylated B-carbolines (MeBCs+), particularly the 2N-methylated 
derivatives are structural analogues of MPP+ (Figure 1) (Collinsand Neafsey 
1985). 
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Figure 1. N-methylated BCs are structural analogues of neurotoxic MPP+. 
Toxicity of N-Methylated 6-Carbolines 
N-methylated 6-carbolines (Me6Cs+) are also functional analogues of 
neurotoxic MPP+, because like MPP+, Me6Cs+ exert cytotoxic effects both in 
vitro and in vivo. 
Inhibition of Mitochondrial Respiration 
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Like MPP+, Me6Cs+ inhibit respiration in isolated liver mitochondria 
(Albores et al. 1990; Fields et al. 1992). Several Me6Cs+ inhibit mitochondrial 
respiration at Complex I (N ADH dehydrogenase) almost as effectively as MPP+, 
and inhibition at Complex II (succinate dehydrogenase) is greater by Me6Cs+ 
than by MPP+ (Table 1). In contrast to MPP+, Me6Cs+ also weakly inhibit 
mitochondrial respiration at Complex III (coenzyme Q-cytochrome C reductase) 
(Fields et al. 1992). 
Table 1.--Inhibition of Mitochondrial Respiration 
by MPP+ and MeBCs+ 
Site of Inhibition 
Complex I Complex II 
Compound IC50 <µM) IC50 CµM) 
MPP+ 171 >1200 
2-MeNH+ 1145 n.d. 
2-MeH+ 2850 n.d. 
2-MeHi+ 186 225 
2-MeHo+ 209 225 
2,9-Me2NH+ 90-100 n.d. 
2,9-MezH+ 100 250 
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Table modified from Albores et al. (Albores et al. 1990) and Fields et al. (Fields et 
al. 1992). Key to abbreviations: n.d.=not done, MPP+=l-methyl-4-
phenylpyridinium ion, 2-MeNH+=2-methylnorharmanium ion, 2-MeH+= 2-
methylharmanium ion, 2-MeHi+=2-methylharminium ion, 2-MeHo+=2-
methylharmolium ion, 2,9-Me2NH+=N,N-2,9-dimethylnorharmanium ion, 2,9-
Me2H+=N,N-2,9-dimethylharmanium ion, and ICso=concentration of compound 
that inhibited respiration to 50% of control. See Figure 1 for structures. 
Inhibition of Dopamine Uptake 
Both BCs and MeBCs inhibit dopamine uptake into striatal synaptosomes 
isolated from rat brain, albeit more weakly than MPP+ (Drucker et al. 1990). 
Nonmethylated BCs (e.g, norharman, barman, harmine, and harmol) inhibited 
dopamine uptake with ICsos in the range 12-33 µM. Their 2N-methylated 
derivatives demonstrated IC50s ranging from 15-88 µM. These values are an 
order of magnitude higher than the ICso for inhibition of dopamine uptake by 
MPP+ (0.4 µM). Inhibition of dopamine uptake by 2,9-Me2BCs+ has not been 
evaluated. These data suggest that BCs and MeBCs are substrates for the 
dopamine transporter. A representative MeBC+, 2(14C H 3 )-harmine, has been 
shown to be a substrate for the dopamine transporter as evidenced by its 
partially nomifensin-inhibitable, Na+-dependent accumulation into striatal 
synaptosomes (Drucker et al. 1990). 
Toxicity to PC 12 Cells in Culture 
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Several N-methylated BCs are toxic to PC 12 cells in culture as indicated 
by the release of lactate dehydrogenase into the culture media (Cobuzzi et al. 
1994; Collins et al. 1992). In low energy media (glucose=0.22 mM) the rank 
order toxicity of these proposed neurotoxins was: MPP+ = 2,9-Me2NH + > 2-MeHi+ 
= 2,9-Me2H+ > 2-MeH+. In high energy media (i.e., containing 25x more 
glucose) toxicity due to these compounds was abolished. It was suggested that 
in the presence of high glucose the effects of mitochondrial inhibition 
(decreased ATP synthesis) are compensated for by increased ATP synthesis 
from anaerobic glycolysis (Cobuzzi et al. 1994). In addition, evidence indicates 
that these compounds are toxic to rat primary mesencephalic cultures, 
although not as selectively as MPP+ (Collins et al. 1996; Collins et al. 1995). The 
mechanisms which underlie MeBC+ toxicity have not be clearly elucidated, but 
inhibition of mitochondrial respiration is likely to contribute. 
Nii:rostriatal De~eneration 
Like MPP+, several MeBCs+ cause nigrostriatal damage following 
unilateral stereotaxic injection of the compounds into the substantia nigra of 
rats (Neafsey et al. 1995; Neafsey et al. 1989). Injected MeBCs+ produced nigral 
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lesions that ranged in size from 25 - 94% of the lesion-size produced by MPP+. 
In addition, several compounds reduced ipsilateral striatal dopamine content to 
23 - 64% of control dopamine levels. The most effective MeBCs+ were 2,9-
M e 2NH + and 2,9-Me2H+; both compounds produced nigral lesions that were 
comparable to those produced by MPP+, and reduced striatal dopamine to 37-
42% of control values. 
MeBCs+ in CSP From Control and Normal Cases 
Matsubara et al. (1995) recently detected simple BCs and their 
N-methylated derivatives in the lumbar cerebrospinal fluid (CSP) of control 
subjects and parkinsonian patients. Results show a significantly higher 
quantity of total N-methylated BCs (2-MeBCs+ plus 2,9-Me2BCs+) in the CSP of 
persons with idiopathic PD versus controls; measurements were 85 ± 18 
fmol/ml and 20 ± 4 fmol/ml in PD and controls, respectively. Moreover, 2,9-
M e2NH + was present in the CSP from 12 of 22 PD patients, but absent in control 
CSP. 
MeBCs+ in Normal Human Brain 
Matsubara detected MeBCs+ rn the substantia nigra and parietal cortex of 
postmortem normal human brain tissue (Matsubara et al. 1993, 1996). In the 
substantia nigra 2-MeNH+ (3.14 ± 1.47 pmol/g tissue) and 2,9-Me2NH+ (0.77 ± 
0.12 pmoles/g tissue) were present in all samples (N=4). In the cortex 2-MeNH+ 
(0.17 ± 0.02 pmoles/g tissue) was present in each sample (N=13), and 
2,9-Me2NH+ (0.10 ± 0.02 pmoles/g tissue) was detected in 11 of 13 cases. Neither 
2-MeH+ or 2,9-Me2H+ was detected in the substantia nigra (N=4), but 2 of the 13 
cases demonstrated 2-MeH+ (0.02 ± 0.02 pmoles/g tissue) and 2,9-Me2H + (0.03 ± 
0.02 pmoles/g tissue) in the parietal cortex. 
Formation of N-Methylated BCs in Brain 
Most pertinent to this dissertation is the discovery that MeBCs+ are 
formed from simple BCs via an S-adenosyl-L-methionine (SAM)-dependent 
enzymatic process in the presence of guinea pig and rat brain homogenates 
(Collins et al. 1992; Matsubara et al. 1992b). Moreover, it was later shown that 
normal human brain exhibits J3C-2N-methyltransferase activity, but not J3C-
9N-methyltransferase activity (Matsubara et al. 1993). These BC-N-
methyltransferase activities will be discussed in further detail below 
(Figure 2). 
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Figure 2. Representative B-carboline-N-methyltransferase reactions. 
BC-N-Methyltransferases 
and Their Substrates 
Substrates 
B-carboline 2N-methyltransferase (BC-2-NMT) forms 2-MeBCs+ from 
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simple BCs, such as norharman, harman, and harmine (Collins et al. 1992; 
Matsubara et al. l 992b ). Norharman and harman substrates are present in 
mammalian tissues, including normal human brain (Airaksinen et al. 1981; 
Bosin et al. 1989; Collins 1983; Fekkes et al. 1992; Matsubara 1996; Matsubara et 
al. 1993; Schouten et al. 1986; Shoemaker et al. 1980). Norharman and barman 
levels are higher in the substantia nigra relative to the parietal cortex of 
normal human brains (Matsubara 1996). In the parietal cortex norharman 
and harman were present at 0.58 ± 0.11 and 0.24 ± 0.04 pmoles/g tissue, 
respectively (N=l3). In the substantia nigra norharman and harman were 
detected at 16.00 ± 8.00 and 1.04 ± 0.11 pmoles/g tissues, respectively. 
Interestingly, Kuhn et al. (1995) reported significantly elevated (p=0.01) 
plasma norharman in PD patients (30.0 ± 52.7, range 0-192 pg/ml) compared to 
control subjects (4.9 ± 7.9, range 0-26.5 pg/ml). Mean plasma values for 
harman were elevated in PD but were not significantly different than control 
values. 
The presence in brain of simple BCs, which can serve as substrates of 
the BC-2-NMT, is not surprising given their widespread availability from 
exogenous as well as endogenous sources. Blood-brain barrier penetration of 
representative BCs and 2-MeBCs+ was recently demonstrated by Matsubara et 
al. (1996). He utilized striatal microdialysis to show that NH, 9-MeNH, and 
2-Me NH+ are present in the brain following intraperitoneal (i.p). injection of 
these compounds into C57 /black mice. Blood-brain barrier penetration of 
nonmethylated simple BCs (NH and 9-MeNH) was expected, due to their 
presumably hydrophobic structure; however, entry of the charged MeBCs+ 
<2-MeNH+) was quite surprising. Simple BCs may be formed endogenously by 
the condensation of indoleamines and aldehydes to form 
tetrahydro-B-carbolines, which may be subsequently oxidized to the 
corresponding BC (Melchior et al. 1982; Susilo et al. 1987). Exogenous sources 
of simple BCs include: plants, tobacco smoke, industrial waste, alcoholic 
beverages, soy sauce, and pyrrolyzed tryptophan-rich foods such as meat 
(Adachi et al. 1991; Bosin et al. 1988; Felton et al. 1990; Gross et al. 1993; 
Holmstedt 1982; Rommelspacher et al. 1985a; Rommelspacher et al. 1985b). 
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B-C arboli ne-N -Methyl tr an sf erase( s) 
Two SAM-dependent N-methyltransferase (BC-NMT) activities have been 
detected in guinea pig and rat brain homogenates (Collins et al. 1992; 
Matsubara et al. 1992b). 
The first activity, BC-2N-methyltransferase (BC-2-NMT), catalyzes the 
2N-methylation of simple BCs to form 2-MeBCs+. This activity has also been 
measured in normal postmortem human brain (Matsubara et al. 1993), where 
activity was 1.30 ± 0.42 pmol/h/mg protein in the substantia nigra, and 1.06 ± 
0.26 pmol/h/mg protein in the parietal cortex. Substrates that have been 
identified for BC-2-NMT include: norharman, barman, harmine, 9-
methylnorharman, and 9-methylharmine (Matsubara et al. 1992b). Curiously, 
the soil-residing bacteria, Kitasatosporia setae, possesses an enzyme activity 
that is also able to 2N-methylate norharman (Peczynska-Czoch et al. 1987). 
Whether this N-methyltransferase and BC-2-NMT are the same enzyme 
requires further investigation. 
The second activity, BC-9N-methyltransferase (BC-9-NMT), catalyzes the 
9N-methylation of 2-MeBCs+ to form 2,9-Me2BCs+. Non-methylated BCs do not 
appear to be substrates for BC-9-NMT. It is yet to be determined if BC-2-NMT 
activity and BC-9-NMT activity are due to a single enzyme, or represent distinct 
enzymatic activities. N-methylation of BCs appears to occur sequentially, with 
N-methylation at the pyridyl (2N-) nitrogen preceding indole (9N-) 
methylation. This sequence is predicted because no 9-MeNH was detected in an 
incubation in which norharman was the substrate; 2-MeNH+ and 2,9-Me2N H + 
were the only detectable products. Substrates identified for BC-9-NMT include: 
2-methylnorharmanium, 2-methylharmanium, and 2-methylharminium ions 
(Matsubara et al. 1992b). 
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The pH optimum for BC-9N-methyltransferase activity from guinea pig 
whole-brain homogenate was in the range 8.2-8.3 using a phosphate buffer 
system. The pH optimum for BC-2N-methyltransferase activity was not 
determined. Kinetic parameters for methylation of norharman derivatives at 
a fixed concentration of SAM (8 µM) in crude guinea pig brain homogenates 
were as follows (Matsubara et al. 1992b): 
Activity 
BC-9-NMT 
BC-2-NMT 
Substrate 
2-MeNH+ 
9-MeNH 
17.8 
17.8 
Ymax 
(pmol/h/m~ protein) 
4.9 
2.2 
Previous studies from this laboratory indicate that guinea pig brain BC-
2-NMT activity resides primarily in the nuclear (236.1 pmol/h total activity) 
and microsomal (14.3 pmol/h total activity) subcellular fractions. BC-9-NMT 
activity was found in the nuclear (233.8 pmol/h total activity), microsomal 
(82.7 pmol/h total activity), and mitochondrial (58.6 pmol/h total activity) 
fractions. Neither BC-methyltransferase activity was detected in undialyzed 
cytosol (Matsubara et al. 1992b). 
The regional distribution of both BC-NMT activities was assessed in 
guinea pig brain (Matsubara et al. 1992b). BC-2-NMT specific activity was 
highest in the pons/medulla (6 pmol/h/mg protein) and lowest in the frontal 
cortex (0.5 pmol/h/mg protein). Intermediate BC-2-NMT activity was found in 
the hippocampus, hypothalamus, striatum, and midbrain. Similarly, BC-9-NMT 
specific activity was also highest in the pons/medulla (9 pmol/h/mg protein) 
and lowest in the frontal cortex (2 pmol/h/mg protein). Intermediate BC-9-
NMT activity was detected in the hypothalamus, hippocampus, midbrain, and 
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striatum. Overall, the specific activity of BC-9-NMT was higher than that of 
BC-2-NMT activity in every brain region tested, particularly in the 
hypothalamus. 
Matsubara et al. (1996) recently reported the presence of cerebral 
2-MeNH+ following i.p injection of norharman or 9-MeNH in C57/black mice. 
The author speculated that injected 9-MeNH is demethylated in the liver to 
norharman, and that the norharman is then available for methylation by 
BC-2-NMT to 2-MeNH+. In the same study 2,9-Me2NH + was detected in mouse 
brains following i.p injection of norharman, 9-methylnorharman, or 
2-MeNH+. A most interesting finding is that subchronic treatment with 
norharman or 2-MeNH+ not only selectively reduced nigrostriatal dopamine, 
but also produced bradykinesia in these mice. These experiments are 
consistent with the hypothesis that in vivo formation of MeBCs+ by BC-2-NMT 
and BC-9-NMT reduces striatal dopamine, which produces a parkinsonian 
condition. 
S-Adenosyl-L-Methioni ne-Dependen t 
Me th yl trans f erases 
General 
Enzymes that catalyze S-adenosyl-L-methionine (SAM)-dependent 
methylation of a substrate belong to the E.C. 2.2.1 class as defined by the 
International Enzyme Commission (Barman 1969). A generic SAM-dependent 
methyltransferase reaction is diagrammed in Figure 3. 
I SUBSTRATE I + 
me thy 1 tr an sfe ra s e 
(E.C. 2.2.1) 
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+ 
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Ff I 
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Figure 3. Generic SAM-dependent methyltransferase reaction. 
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All SAM-dependent methyltransferases studied to date are inhibited by 
S-adenosyl-L-homocysteine (SAH) in a competitive manner. Inhibition by 
SAH is not surprising since products often inhibit the enzymes responsible for 
their formation, and SAH is a co-product of SAM-dependent methylation 
reactions. Inhibition by SAH varies, depending upon the enzyme affected, 
with Ki's falling into the 100 nM - 12 µM range (Deguchi et al. 1971; Lawrence 
et al. 1990). Therefore, if an enzyme under study is truly a SAM-dependent 
methyltransferase, inhibition by SAH should be a property of that enzyme. 
BC-NMT inhibition by SAH was not investigated by Matsubara. 
In addition, a peptide inhibitor of methyltransferase reactions has also 
been reported; this peptide is proposed to inhibit many methyltransferases 
via a noncompetitive mechanism (Park et al. 1993). This inhibitor was 
purified from rat liver cytosol, and exhibited the following characteristics: 
29 amino acids, 52% glycine with no basic amino acid residues, and a molecular 
weight of 2584. The authors noted that extensive dialysis is required for 
removal of the inhibitor from tissue homogenates. 
Enzymatic N-Methylation 
of Azaheterocycles 
The presence of a SAM-dependent N-methyltransferase activities have 
been detected in dialyzed cytosolic fractions from rabbit and guinea pig lung, 
kidney, spleen, and brain. These rather nonspecific activities have been 
assigned a number of names including amine-N-methyltransferases A and B, 
indolethylamine-N-methyltransf erase, and arylamine-N-methy l transferase 
(Ansher et al. 1986a; Ansher et al. 1986b). The nonspecificity of these enzymes 
is typified by their ability to N-methylate a variety of azaheterocycles at the 
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pyridyl nitrogen. N-methylation results in the formation of a quaternary 
pyridinium ion; recall that this cationic feature is essential for the 
neurotoxicity due to MPP+. 
Interestingly, pyrido-N-methyltransferase activities (e.g., amine 
N-methyltransferases A and B) -- present in human, monkey, mouse, and 
rabbit brain -- are capable of forming MPTP from precursor 
4-phenyl-1,2,3,6-tetrahydropyridine. These enzymes also act on 
4-phenylpyridine to generate MPP+. As summarized in Table 2, the specific 
activities of these N-methyltransferase activities in mammalian brain 
homogenates (Ansher et al. 1986a) are comparable to the N-methylation 
activities reported toward BCs (Matsubara et al. 1993) and 
tetrahydro-B-carbolines by Matsubara et al. (Matsubara et al. l 992a) . 
Table 2.--N-Methylation of Various Azaheterocycles 
N-Methyltransf erase Ac ti vi ty 
(pmole/h/mi: protein) 
Substrate Human Brain Rat Brain 
4-phenylpyridine (a) 3.7 2.7 
4-phenyltetrahydropyridine (a) 0.17 6.8 
9-methylnorharman (b) 1.30 (cortex) 0.4 
1.06 (nigra) 
tetrahydro-B-carboline (c) 2.6 
Table 2 summarizes data from three investigators: (a) Ansher et al. (1986a) , (b) 
Matsubara et al. (1993), and (c) Matsubara et al. (1992a) . Note that assays were 
not run under identical conditions. 
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Studies indicate that these amine-N-methyltransferases have the 
following properties: (a) reside in the cytosolic fraction of tissue homogenates, 
(b) usually unmeasurable prior to dialysis, and (c) higher in fresh vs. frozen 
tissue (Ansher et al. 1986a; Ansherand Jakoby 1986b). Ansher and Jakoby 
purified these amine-N-methyltransferases A and B from rabbit liver; the 
enzymes have very broad and overlapping specificity for a number of 
primary, secondary and tertiary amines (Ansher et al. 1986a; Ansherand 
Jakoby 1986b). The azaheterocycles tested included the above-mentioned 
pyridine derivatives, as well as isoquinoline, but BCs were apparently not 
evaluated as substrates. Rabbit Ii ver cytosolic activities exhibited pH optima of 
6.2 and 7.8 for transferase A and B, respectively. 
Saavedra et al. (1973) described the distribution of a cytosolic 
nonspecific N-methyltransferase present in the brain of several species, 
including human postmortem brain tissue. That SAM-dependent enzyme 
utilizes tryptamine as well as several other amines as substrates. Similar to 
BC-2-NMT, the enzyme exhibited a KM with respect to SAM of 52 µM and a 
tissue-dependent V max in the range 2 - 15 pmol/h/mg protein. 
Naoi et al. (Naoi et al. 1989a) reported the presence of a cytosolic N-
methyltransferase activity in human brain homogenates that forms 
potentially neurotoxic N-methyl-1,2,3 ,4-tetrahydroisoquinoline from 
tetrahydroisoquinoline (TIQ). Likewise, Matsubara identified a cytosolic 
N-methyltransferase activity present in rodent brain that catalyzes 
methylation at the 2N-nitrogen of tetrahydro-B-carbolines (Matsubara et al. 
1992a). It is conceivable that BC-NMT activity is due to any of the above-
mentioned enzymatic activities. 
General Enzyme Properties 
and Terminolo~y 
This portion of the literature review contains information directly 
related to the content of this dissertation, and therefore is not intended to 
cover enzyme properties and kinetics in detail (Barman 1969; Lehninger 
1975). 
General Characteristics of Enzymes 
The International Enzyme Commission has numerically classified 
enzymes according to the type of reactions that they catalyze (Barman 1969). 
Each characterized enzyme is assigned a number comprised of four figures: 
the first figure places the enzyme in a main group (e.g., group 2 = 
transferases), the second figure identifies the subclass (e.g., subclass = 
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methyltransferases), the third figure represents the sub-subclass, and finally 
the fourth figure is the serial number of the specific enzyme within its sub-
subclass. As noted previously, SAM-dependent methyltransferases belong to 
E.C.2.2.1. 
Nearly all enzymes are proteins with a primary structure composed of 
amino acids linked covalently by peptide bonds; interactions between amino 
acid side-chains give rise to secondary structure which then participates in 
higher order structure. Amino acid side-chains, as well as the a-amino and 
a-carboxyl termini, impart acid-base, polar, and nonpolar properties to 
regions of the protein. These properties are exploited in the purification 
techniques that are described in a subsequent section of this chapter. 
Enzymes catalyze biological reactions, and as catalysts are not consumed 
during the reactions in which they participate. Analogous to other chemical 
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catalysts, enzymes affect reaction rate but not the equilibrium of the reactions 
that they catalyze. 
Properties unique to enzyme catalysts are detailed below and include: 
sensitivity to extremes of temperature, pH, ionic strength, other solvent 
conditions, and specificity toward its substrate(s). 
Sensitivity to Temperature. pH. Ionic Streni;th. Solvents 
Changes in these parameters affect amino acid side-chains of the 
enzyme, leading to alterations in ionization state which affects hydrogen 
bonding and hydrophobic interactions. These changes are often detrimental 
to the physical, chemical, and catalytic stability of the enzyme. 
Substrate Specificity 
Substrate specificity of an enzyme is divided into four categories. 
(1) Absolute specificity. This type of specificity implies that an enzyme will 
act on a single substrate. 
(2) Group specificity. Group specificity applies to enzymes that act on more 
than one substrate, but require certain atomic groupings within those 
substrates. 
(3) Reaction specificity. This type of enzyme requires the least amount of 
specificity, and describes enzymes that do not require strict atomic groupings 
in the vicinity of the reactions that they catalyze. 
(4) Stereochemical specificity. This kind of specificity implies that an enzyme 
will only effect a reaction on one stereoisomer of a given substrate. 
Other Characteristics 
Enzyme catalyzed reactions should exhibit linear formation of product 
as a function of time and protein concentration, assuming that the enzyme 
remains active and substrates are not limiting during the assay. 
Effect of Additives 
Miscellaneous additives may stabilize or destabilize enzymes during 
their assay and purification, as discussed by Scopes (1994a) and Deutscher 
(1990). 
Antioxidants. When enzymes are removed from their intracellular 
environment (reducing conditions) an antioxidant such as dithiothreitol or 
mercaptoethanol is often needed to maintain enzyme stability and activity. 
Protease Inhibitors. Tissue disruption may result in the release of cellular 
proteases; therefore protease inhibitors are often utilized, especially during 
the early steps of enzyme isolation. Commonly used protease inhibitors are 
shown in Table 3. 
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Table 3.--Commonly Used Protease Inhibitors 
[adapted from Scopes (1994a) and Deutscher (1990)] 
Protease Inhibitor 
phenyl methyls u l fo n y l 
fluoride (PMSF) 
benzamidine 
aprotinin 
leupeptin 
antipain 
pepstatin A 
EDTNEGTA 
Protease Class Inhibited 
serine proteases 
serine proteases 
serine proteases 
thiol proteases 
thiol proteases 
acid proteases 
metalloproteases 
Useful Concentration 
0.1-1 mM 
1 mM 
5 µg/ml 
1 µg/ml 
1 µg/ml 
1 µg/ml 
0.1-1 mM 
30 
Metals. Many enzymes require metals for activity, while others are inhibited 
in presence of metals. Transition elements that may affect enzyme activity 
include: Mn2+, Fe2+/3+, Co2+, Ni2+, Cul+/2+, Zn2+, Ca2+, and Mg2+ (Gray 1971). 
Enzyme Terminoloi:y 
Miscellaneous terms associated with enzymes, particularly enzyme 
kinetics, are listed in the GLOSSARY of this dissertation (Barman 1969; Dixon et 
al. 1979b; Lehninger 1975). Other concepts are presented below. 
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Michaelis-Menten equation and kinetics. The Michaelis-Menten equation 
mathematically describes -- for a single-substrate enzyme or often a 
two-substrate enzyme (when one of the substrates is fixed at a saturating 
concentration) -- the relationship between the following parameters: initial 
rate of the reaction (v), substrate concentration [S], and kinetic constants (KM 
and Vmax). 
Reaction: 
Equation: 
Assumptions: 
Graphically: 
[E] + [S] [ES] [E] + [P] 
v = Vmax [SJ I ([S] +KM) 
[P] and [E] interaction is negligible, 
therefore k_2 is negligible, kcat is first-order, 
[SJ, [E], and [ES] in equilibrium (steady-state) 
--------· Ymax 
v 
[S] 
Lineweaver-Burk equation. This equation is a commonly used linear 
transformation of the Michaelis-Menten equation. 
Equation: 1/v = (KM/V max)(l/[S]) + 1/V max 
Graphically: 
1/[S] 
Hanes equation. This is another linear transformation of the Michaelis-
Menten equation. 
Equation: [S]/v = (KM/V max) + ([S]/V max) 
Graphically: 
slope= l!Ymax 
[S]/v 
[S] 
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Dixon Equations and Plots for Inhibition 
Dixon Equation and Plot for 
Competitive Inhibition 
Substrate: [S00] >[S2] >[S1] 
Inhibitor: [I] 
l/v = {KM/(Ymax[SJKi)}[I] + (l!YmaxHl + (KM/[S])} 
Dixon Equation and Plot for 
Noncompetitive Inhibition 
Substrate: [S00] > [S 2] > [SI] 
Inhibitor: [I] 
l/v = {1 + (KM/[S])/(YmaxKi)}[I] + (lNmaxHl + (KM/[S])} 
Ilxon Equation and Plot for 
Uncompetitive Inhibition 
Substrate: [Sool > [S2] >[Si] 
Inhibitor: [I] 
l/v = {l/(YmaxKi)}[I] + (1/YmaxHl + (KM/[S])} 
slope = l/(V maxKi) 
Ki= ll(Vmaxslope) 
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l/v 
[S2] 
[Soo] 
[I] 
l/v 
[S2] 
[I] 
l/v 
[I] 
Literature Related to 
Protein Purification 
General 
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This section of the literature review is intended to be a simple overview 
of applicable protein purification techniques. Enzyme purification may 
include the following general sequence of steps: preparation of tissue extract, 
subcellular fractionation, ammonium sulfate or other bulk precipitation 
techniques, miscellaneous chromatographic methods, and usually 
polyacrylamide gel electrophoresis (Deutscher 1990). 
Total Protein Assays 
UV Absorption at 280 nm and 260 nm 
This is a nondestructive method that is frequently used to monitor 
protein in crude extracts or column effluents. The primary disadvantage of 
this method is its lack of sensitivity. Absorbance at 280 nm is due to the 
presence of tryptophan and tyrosine residues in proteins, as well as nucleic 
acids. Proteins absorb little at 260 nm, a wavelength at which absorbance is 
due primarily to the pyrimidine and purine residues of nucleic acids. 
Therefore, a reasonable estimate of the quantity of protein present in a 
relatively clear sample may be obtained by measuring the absorbance of the 
sample at 280 nm and 260 nm for use in the following equation: 
protein concentration (mg/mL) = 1.55A2so - 0.76A260 
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Lowry Protein Assay 
This method is based upon the interaction of Cu2+ with peptide bonds to 
form a complex; under basic conditions the complex is reduced to Cu 1 +. Folin 
Reagent then interacts with both the complexed Cul+ and the side-chains of 
tyrosine, tryptophan, and cysteine. This interaction slowly imparts a blue 
color to the mixture, which is detected at 500 nm to 750 nm using UV 
spectroscopy. Absorbance at a set wavelength in this range correlates with 
protein concentration in the original sample. Solutions required in this assay 
are described in Scopes (Scopes 1994c) and in Appendix A of this dissertation. 
Coomassie Blue Dye Bindin2 Assay 
This method is based on an observed shift in absorbance from 465 nm to 
595 nm under acidic conditions when protein interacts with the negatively 
charged dye. Side chain groups in proteins that facilitate this interaction 
include those of arginine, histidine, lysine, tyrosine, tryptophan, and 
phenylalanine. Solutions required in this assay are described in Scopes 
(1994c) and in Appendix A of this dissertation. 
Subcellular Fractionation 
This technique could be considered a gross means of protein 
fractionation in that it allows for the separation of many undesirable proteins 
and nonproteinaceous materials from the enzyme of interest based on their 
location in distinct subcellular compartments. Subcellular fractionation 
methodology has been recently reviewed by Storrie and Madde (Deutscher 
1990). Subcellular fractionation is routinely done using modifications of the 
differential centrifugation protocol (Table 4) (Alberts et al. 1989). 
Steps 
low speed 
Table 4. -- Subcellular Fractionation Protocol 
[adapted from Alberts (1989)] 
Centrifu~ation 
Parameters Pellet Contains 
IOOOg, 10 min. whole cells, nuclei, cytoskeletons 
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medium speed 20,000g, 20 min. mitochondria, lysosomes, peroxisomes 
high speed 80,000g' 1 hr. microsomes, small vesicles 
very high 150,000g, 3 hrs. ribosomes, viruses, large 
macromolecules 
Bulk Precipitation Techniques 
This technique exploits the effects of salts or organic solvents on 
protein conformation and consequently protein solubility. Proteins with 
variable amino acid compositions can be separated based on their behavior at 
different electrolyte or solvent concentrations. Commonly used precipitants 
are the neutral salt, ammonium sulfate, or organic solvents such as 
polyethylene glycol, ethanol, or acetone. Bulk precipitation techniques are 
discussed in detail by Scopes (1994a), as well as Englard and Seifer in the 
Methods in Enzymology series (Deutscher 1990). In practice, the precipitant is 
added in small aliquots while the protein extract is stirred at low temperature. 
The mixture is stirred for a defined period and then centrifuged to pellet and 
isolate precipitated proteins. Additional precipitant may then be added to the 
resulting supernatant, the mixture again centrifuged, and so on. Proteins are 
therefore fractionated (precipitated) based on their individual solubilities in 
progressively more concentrated salt solution or organic solvent. 
Chromatographic Methods 
General 
A series of laboratory guides published by Pharmacia are suitable 
primary references for chromatographic isolation of proteins (Pharmacia 
1991; Pharmacia 1993a; Pharmacia 1993b; Pharmacia 1994). These guides 
describe in detail the practical aspects of preparing, using, and maintaining 
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various chromatographic resins. The books "Protein Purification: Principles 
and Practice" by Scopes (1994a) and "Guide to Protein Purification" by 
Deutscher (1990) are also invaluable resources during the development of a 
protein purification protocol. Each of these references was utilized in the 
preparation of the remainder of this literature review. 
In general, all chromatographic methods exploit the properties of the 
protein in solution by differentially promoting or preventing binding of 
proteins to chromatographic resins. Chromatographic resins are 
commercially available that have been chemically modified to possess the 
numerous functional groups and characteristics described below. 
Both ion exchange and hydrophobic interaction chromatographic 
methods are considered high capacity methods because they allow for 
fractionation of samples composed of larger quantities of proteins, as 
compared to lower capacity methods such as gel filtration and affinity 
chromatography. High capacity methods are typically utilized early in 
purification procedures, while lower capacity methods follow later, in order 
of decreasing capacity and/or specificity for the protein to be isolated. 
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Ion Exchange Chromatography 
Ion exchange chromatography (IEC) allows for separation of sample 
molecules as a function of the charge of the exchanger and proteins. Anion 
exchangers contain positively charged groups such as quaternary amines or 
diethylaminoethyl (DEAE); these exchangers interact with negatively-charged 
protein molecules. Cation exchangers, possess negatively charged groups 
such as a sulfonic acid or carboxymethyl (CM) side-chains; these resins 
interact with positively-charged protein molecules. Both pH and ionic 
strength are manipulated in order to affect the interaction of protein with the 
exchanger. For example, proteins are typically applied to an anion exchange 
column under conditions of low salt in buffer at pH 7-9; under these conditions 
many proteins have a net negative charge, and therefore bind to the 
positively-charged exchanger. Proteins are routinely eluted from ion-
exchange matrices using an increasing salt gradient, or less commonly a pH 
gradient. Fractions from the column are collected and assayed for total protein 
content and protein of interest. 
Hydrophobic Interaction Chromatography 
Hydrophobic interaction chromatography (HIC) enables the separation 
of proteins based on their hydrophobicity. HIC matrices contain hydrophobic 
moieties such as simple ethyl to dodecyl alkyl chains or phenyl groups. 
Hydrophobic interactions between proteins and the HIC matrix are favored 
under conditions of high salt and low pH. Temperature and additives may also 
affect HIC interactions, albeit in a less straightforward manner. Therefore, 
samples are usually applied to HIC columns in a high salt buffer, with the same 
buffer being utilized to pre-equilibrate the column. Successive elution of 
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bound protein is often achieved using a gradient of decreasing salt 
concentration. Occasionally organic solvents or other additives are utilized in 
elution buffers for HIC. Column effluent is collected in fractions that are 
subsequently assayed for total protein and proteins of interest. 
Affinity Chromatography 
In general, affinity chromatographic methods take advantage of the 
specificity of an interaction between an enzyme and its substrates or 
inhibitors. A substrate or inhibitor that is specific for the enzyme of interest 
is covalently attached to a suitable chromatographic matrix by conventional 
methods. Dye chromatography is a subset of affinity chromatography, in 
which dye molecules are covalently attached to the matrix. The affinity 
column is equilibrated with sample buffer and then the sample is applied to 
the column. Elution of bound protein may be accomplished using salt or pH 
gradients. Tightly bound proteins are often eluted by a solution containing 
either the substrate/inhibitor or a substrate/inhibitor analogue. 
fractions are assayed for total protein and proteins of interest. 
Gel Filtration Chromatography 
Column 
Gel filtration chromatography (GFC) is synonymous with size-exclusion 
chromatography (SEC). In this method molecules are separated on the basis of 
size; GFC matrices are available with a range of pore sizes which either 
exclude or allow passage of sample molecules. Excluded molecules elute from 
the column first, while molecules that are able to enter matrix pores are eluted 
from the column as a function of decreasing molecular weight. This method 
not only serves to fractionate proteins based on their size, but also has utility 
in the determination of the approximate molecular weight of proteins and 
peptides. These gels are also used to desalt protein and peptide solutions, as 
well as to carry-out buffer exchange on sample solutions. 
Sequence of Chromato2raphic Steps 
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Ion exchange chromatography is routinely used early in a purification 
procedure depending upon the method used to bulk precipitate proteins 
following subcellular fractionation. If ammonium sulfate is used as the 
precipitant, hydrophobic interaction chromatography (HIC) should follow, 
since application to HIC columns is typically achieved under conditions of 
high salt concentration, such as the solutions generated following ammonium 
sulfate precipitation. If polyethylene glycol is used as the precipitant, ion 
exchange chromatography should follow the PEG step, since solutions are 
usually applied to IEC columns under low salt conditions and PEG may interfere 
with HIC. 
Additional Comments 
Reference to other relevant literature, not cited in this chapter 
("Review of Relevant Literature"), is more appropriately included in the 
"Discussion" sections of the individual chapters. 
CHAPTER2 
B-CARBOLINE-9N-METHYL TRANSFERASE 
Back~round 
This chapter is included for completeness and historical purposes. It is 
not presented in as much detail as subsequent chapters, and therefore only 
key studies are considered. Due to BC-9-NMT's novel activity -- methylation of 
an indole nitrogen -- this enzyme was originally the proposed focus of this 
dissertation project. Unfortunately, BC-9-NMT activity could not be 
consistently measured in animal brain, but this activity was consistently 
detected in postmortem human brain (Chapter 5). The BC-9-NMT project was 
eventually abandoned in favor of investigations pertaining to brain BC-2N-
methyltransferase activity; however certain several BC-9-NMT studies are 
described in this chapter. 
Studies presented in this chapter include: (a) determination of kinetic 
constants for BC-9-NMT with respect to S-adenosyl-L-methionine; (b) detection 
of BC-9-NMT activity in guinea pig brain and various rat organs; 
(c) comparison of BC-9-NMT activity in phosphate and TRIS buffer; (d) BC-9-
NMT activity as a function of time; (e) the effect of homogenate dialysis on 
detectable activity; (f) evaluation of BC-9-NMT activity in bovine brain and 
yeast -- these sources were evaluated as possible starting materials for 
purification purposes; and (g) subcellular localization of BC-9-NMT activity 
from bovine brain. 
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Materials and Methods 
Reagents 
B-Carboline substrate, 2-methylnorharmanium iodide (2-MeNH+ ), was 
synthesized in our laboratory according to Matsubara (l 992b). Unlabeled 
S-adenosyl-L-methionine (chloride, iodide, or toluenesulfonate salt) was 
purchased from Sigma Chemical Company. Tritiated S-[methyl-3 H] -
adenosyl-L-methionine (60-85 Ci/mmol) was bought from American 
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Radiolabeled Chemicals or Dupont NEN. All other reagents were appropriately 
pure for their intended use and were utilized as purchased. 
Preparation of BC-9-NMT Source 
Guinea Pi~ Brain 
Frozen guinea pig brain was purchased from either Rockland or Harlan. 
Extract preparation was done at 0-5 °C. Brain was thawed slightly, cut into 
small pieces, and homogenized in a glass homogenizer by a motor-driven 
teflon pestle (5-10 up-and-down strokes @ 100 rpm). In indicated experiments, 
homogenation was accomplished using a Tissuemizer® set at its lowest setting. 
Brain (1 g) was homogenized in 2-10 ml of homogenation buffer, consisting of 
10 mM Na2HP04 (pH 7.4) or 100 mM TRIS (pH 8.3). 
Yeast Extract 
Red Star active dry yeast (5 g) was added to a polypropylene or glass 
centrifuge tube containing 15 ml of 100 mM TRIS buffer (pH 8.3). The mixture 
was vortexed until the powder was completely wetted to form a slurry. Small 
glass beads (0.5-1 mm in diameter, 15 ml in all) were added to the slurry, and 
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the mixture was vortexed vigorously in order to disrupt yeast cell walls. Six 
vortexing cycles (30 seconds per cycle) were carried-out. Between each cycle 
the tube was placed on ice for 2-3 minutes to dissipate heat generated during 
the disruption process. Cell debris was removed from the extract by passage 
through glass wool or centrifugation. 
Bovine Brain 
Bovine brain was utilized in some experiments. Tissue procurement and 
preparation are described in detail in subsequent sections. 
Protein Determination 
A Coomassie blue dye-binding method was utilized as described in Scopes 
(Scopes 1994c ). Details are in Appendix A. 
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The BC-9-NMT Assay 
This activity catalyzes the transfer of the tritiated methyl moiety from 
S-adenosyl-L-methionine (SAM) to 2-methylnorharmanium ion (2-MeNH+) to 
form 2-methyl-9(3H-methyl)-norharmanium ion (2,9-Me2NH+) and S-
adenosyl-L-homocysteine (Figure 4). 
* 
+ 
~ j 3 I Adenine I 
HOOC-C-(CH2)rS-IQC2 I + 
NHz O 
I 2-MeNH+I I SAM I OH a-I 
(sc-9-NMT ) 
H I Adenine I 
HOOC-C-(~H 2 )rS-r~ 
0 
, I 
NH2 ~ 
GI a-I 
+ 
N 
I 
*CH3 
Figure 4. BC-9-NMT assay. Site of tritium label *. Abbreviations: 
2-methylnorharmanium ion (2-MeNH+), 2,9-dimethylnorharmanium ion (2,9-
Me2NH+), S-adenosyl-L-methionine (SAM), S-adenosyl-L-homocysteine (SAH). 
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The BC, 2-MeNH+, was chosen over other substrates (e.g. norharman) since its 
pyridyl position (2N-) is already methylated, allowing for measurement of 
9N-methylation exclusively. This substrate is most like a physiological 
substrate for BC-9-NMT. The assay was performed as previously reported by 
Matsubara et al. (1993) with modifications. Concentrated stock solutions of 
2-MeNH+ and SAM were combined with organ fraction or yeast extract in 1.5 
ml polypropylene microcentrifuge tubes. The SAM was usually dissolved in 10 
mM Na2HP04 buffer (pH 7.4), 2-MeNH+ was prepared in 100 mM Na2HP04 buffer 
(pH 9.5), and tissue homogenate or yeast extract was present in 10 mM Na2HP04 
buffer (pH 7.4 ). However, in indicated studies, substrates and enzyme extract 
were made in 100 mM TRIS buffer (pH 8.3). Stock solution volumes usually 
remained constant across studies, while stock solution concentrations and 
final pH varied depending upon the experiment. Assay volume was typically 
370 µI, comprised of the following stock solutions: 50 µl 3H-SAM, 20 µl non-
radioactive SAM, 200 µl 2-MeNH+, and 100 µl enzyme solution. In assays that 
excluded radioactive SAM, total volume was routinely 200 µl: 50 µ1 each of 2-
MeNH+ and SAM stocks, plus 100 µl enzyme extract. Final concentrations of 
substrates are indicated in individual experiments. The assay was gently 
vortexed and subsequently maintained at 37 °C in a shaking water bath for 15-
60 minutes. 
The reaction was then treated in one of two ways: with or without the 
use of solid-phase extraction (SPE) cartridges. When SPE was excluded from 
the reaction work-up, the assay was terminated by placing the tubes on ice 
and adding 8.6 µI of concentrated perchloric acid (HCI04). Precipitated protein 
was pelleted by centrifugation at 3000g for 5 minutes. If noted, the pellet was 
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resuspended in 0.5-1.0 ml of 0.1 N HC104, centrifuged, and the resulting 
supernatant combined with the first. Combined supernatant was transferred 
to a weighed 1.1 ml conical glass HPLC vial, and the vial plus contents was re-
weighed. After injection of this solution onto the HPLC column, vial plus 
contents were weighed again so that injection weight could be calculated. 
Solid-phase extraction (SPE) cartridges are prefabricated devices that 
contain chromatographic resins (packing material) packaged in 
polypropylene housings. These housings have luer fittings at each end to 
facilitate connection to either a syringe or a vacuum manifold with 
appropriate connectors, which allows for passage of solution through the 
cartridge. Cartridges may contain various quantities (100 mg-1 g) of packing 
material. Packing material is typically silica-based and may be derivatized 
with ion-exchange or reverse-phase (e.g., C 18) functional groups. In general, 
samples are applied to pretreated cartridges; pretreatment often includes the 
same solutions in the subsequent elution of sample components. Use of SPE 
cartridges allows for the separation or enrichment of sample components 
based on the affinity of these components for the packing material under 
various solvent conditions. In the studies reported in this dissertation the 
rationale for the use of ammonium hydroxide, methanol (acetonitrile), and 
acidified methanol (acetonitrile) is discussed in detail in the "Discussion" 
section of this chapter. 
When the SPE procedure was included in the work-up, the BC-9-NMT 
reaction was terminated by placement on ice and addition of 200 µ1 0.5 N HCl04. 
The mixture was centrifuged to pellet precipitated protein (3000xg for 5 
minutes), and supernatant was transferred to a glass culture tube containing 
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100 µl concentrated ammonium hydroxide (NH40H) and 1.0 ml Milli-Q water. 
The protein pellet was vigorously resuspended in 500 µl 0.01 N HCl0-1- and 
centrifuged (3000g for 5 minutes); the resulting supernatant was mixed with 
100 µl 1 N potassium hydroxide and then combined in the glass tube with the 
initial supernatant. 
Contents of the glass tube were slowly applied to a Sep-Pak® C18 Plus 
solid-phase extraction cartridge (Millipore-Waters part no. 20515, 360 mg). The 
SPE cartridge was previously pretreated with 5 ml each of methanol (or 
acetonitrile):5 N acetic acid (3: 1, v/v), methanol or acetonitrile, and 1 % NH40 H 
(w/v) in that sequence. Slow application of all solutions to the cartridge (2 to 5 
drops per second) was achieved using a syringe or a vacuum manifold. 
Following sample application, the extraction cartridge was washed with 5 ml of 
1 % (w/v) NH40H followed by 5 ml methanol or acetonitrile. These two SPE 
fractions and the sample application fraction were analyzed for 2,9-Me2NH+. 
The final eluent (2x2 ml) -- containing 3:1 (v/v) methanol (or acetonitrile): 
5 N acetic acid -- promoted elution of 2,9-Me2 NH+ from the cartridge into a 
clean glass culture tube. This eluate was evaporated to dryness at 30-40 °C 
using a Speed Vac concentrator (Savant Instruments Inc., Hicksville NY). 
Reverse-Phase High Performance 
Liquid Chromatography 
(RP-HPLC) 
BC-9-NMT activity was quantitated by measuring 2-9(3H-methyl)-
Me 2NH+ present in the reaction work-up using RP-HPLC. Details of the HPLC 
method are described in Appendix B. Acidified supernatant -- the solution 
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resulting from the work-up that excluded SPE -- was assayed "as-is". When the 
SPE protocol was used the resulting Speed Vac residue was dissolved in 200 µ1 
HPLC mobile phase or 0.01 N HCl04 by sonication and vortcxing and then 
filtered. Samples were filtered through a 0.45 µm nylon membrane filter 
(Micro-Spin, Chrom-Tech Inc.) prior to injection (10-150 µ1) onto the HPLC 
system. Isocratic HPLC analysis was carried out under ambient conditions on a 
Bondclone 10 µm C18 column (Phenomenex™, 300 mm x 3.9 mm). Mobile phase 
consisted of 17% (v/v) HPLC grade acetonitrile mixed with 83% (v/v) aqueous 
buffer. Buffer contained 1 M sodium phosphate monobasic adjusted to pH 3.5 
with phosphoric acid (final mobile phase pH 4.0 ± 1). The HPLC system was a 
Shimadzu SIL-9A programmable autosampler, a Beckman 1 lOA pump or BAS 
PM40 (0.8 ml/minute), and an in-line radioactive flow detector (Radiomatic 
Instruments Flo-One\B ). Ultima-Flo™ AP (Packard Instruments) liquid 
scintillation cocktail was used at a flow rate of 2.8 ml per minute, resulting in a 
scintillation fluid to mobile phase mixing ratio of 7:2. The radioactive flow 
detector was equipped with a 2.5 ml flow cell and an automatic stream splitter. 
It was necessary to bypass the radioactive flow detector by splitting the HPLC 
column effluent to waste until about 17-18 minutes into the run to reduce 
interference due to tritiated materials (e.g., 3H-SAM) present in the sample. 
Radioactive peak area corresponding to 2,9-Me2N H + (retention time 19-20 
minutes) was integrated using Radiomatic Flo-One\B system software. Peak 
area was reported as total counts per minute (cpm) under the 2,9-Me2NH+ 
curve. Flo-One\B counting efficiency and reaction specific activity were 
determined routinely; this allowed for calculation of pmoles tritiated 2,9-
Me2NH+. 

Strong-Cation Exchange High Performance 
Liquid Chromatography 
(SCX-HPLC) 
An alternate HPLC method was SCX-HPLC with fluorescence detection 
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(see details in Appendix B). Sample preparation was the same as described for 
RP-HPLC. Isocratic SCX-HPLC analysis was carried out under ambient 
conditions on a strong cation exchange column (Vydac catalog #401 TP104, 250 
m mx 4.6 mm). Mobile phase consisted of 50% (v/v) HPLC grade acetonitrile 
mixed with 50% (v/v) aqueous buffer. Buffer contained 300 mM ammonium 
chloride and 200 mM ammonium acetate, adjusted to pH 3.4 with glacial acetic 
acid (final mobile phase pH 4.5 ± 1). The HPLC system included a Shimadzu 
SIL-9A programmable autosampler, a Beckman l IOA or BAS PM40 pump (0.8 
ml/minute), and a Perkin-Elmer LC240 fluorescence detector. Excitation and 
emission wavelengths for detection of 2,9-Me2NH + were 310 nm and 450 nm, 
respectively. Data reporting and integration were achieved with a Shimadzu 
C-R lB Chromatopac reporting integrator. Retention times for relevant BCs 
were: NH @ 6.5-7.5 minutes, 2-MeNH+ @ 9.5-10.5 minutes, 9-MeNH @ 10.5-11.5 
minutes, and 2,9-Me2NH+ @ 14-15 minutes (Figure 6). Peak areas for 2,9-
Me2NH+ standard solutions of known concentration were analyzed in order to 
plot a standard curve. The resulting linear equation was used to calculate the 
concentration of 2,9-Me2NH + present in BC-9-NMT reactions (Figure 7). 
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Figure 6. Rendition of representative SCX chromatogram. Compounds: 
NH=norharman, 2-Me2NH+=2-methylnorharmanium ion, 2,9-Me2NH+=2,9-
dimethylnorharmanium ion. Column (SCX): Vydac 401TP104, 250 mm x 4.6 mm. 
Mobile phase (0.8 ml/min): 50% acetonitrile + 50% pH 3.4 buffer, buffer=300 
mM ammonium chloride + 200 mM ammonium acetate. Fluorescence detection: 
excitation at 310 nm, emission at 450 nm. 
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Figure 7. SCX chromatography standard curve. Refer to Figure 6 for details. 
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First Experiment Replicating the 
BC-9-NMT Activity Reported 
by Matsubara 
Assays (370 µI) contained guinea pig brain homogenate (0.636 mg 
protein), 1.08 mM 2-MeNH+, and SAM (8.1 µM, 4.28 µCi) in sodium phosphate 
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buffer at a final pH of 8.55. Assays were maintained at 37 °C for one hour. The 
SPE procedure was not utilized in the work-up. 
Determination of Apparent Kinetic Constants 
With Respect to the Methyl Donor 
(SAM) 
Assays included guinea pig brain homogenate (0.716 mg protein), 2-
MeNH+ (1.08 mM), 3H-SAM (7.1 or 14.2 µCi), and SAM at a final concentration 
ranging from 10 - 400 µM. Total assay volume was 370 µI and final pH was 8-8.1 
in sodium phosphate buffer. No SPE work-up was done following assay 
incubation at 37 °C for one hour. BC-9-NMT activity -- expressed as pmoles of 
2,9-Me2NH+ formed per hour per mg protein (pmol/h/mg protein) -- was 
determined at each SAM concentration. Due to a technical problem the "10 µM 
SAM" sample was not evaluated. Plotting and curve-fitting were accomplished 
using Kaleidagraph™ data analysis/graphics application software (Abelbeck 
Software). The Lineweaver-Burk analysis was used to plot data and determine 
the kinetic constants, KM and V max (Lehninger 1975). 
TRIS Buffer Compared to Phosphate Buffer and 
BC-9-NMT Activity in Yeast Extract 
All substrates were dissolved in 100 mM TRIS buffer (pH 8.3) instead of 
sodium phosphate buffer; concentrations were 1.08 mM 2-MeNH+ and 500 µM 
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SAM (16.8 µCi). Guinea pig brain was homogenized in the same TRIS buffer 
using a Tissuemizer®; 100 µl of the resulting homogenate (1.132 mg protein) 
was added to each BC-9-NMT assay. Yeast extract, 100 µ1 per assay, contained 
1.338 mg protein. Reactions were prepared in duplicate and maintained at 
37 °C for one hour. One set of incubations was subjected to the SPE procedure 
and the other was not. 
Measurement of BC-9-NMT Activity 
in Various Rat Organs 
Organs were quickly dissected from an ether-anesthetized, adult-female 
Sprague-Dawley rat. Tissues were placed on foil on dry-ice, wrapped, and then 
stored at -80 °C. Rat tissues analyzed for BC-9-NMT activity included: lung, 
liver, kidney, spleen, and thymus. Guinea pig brain was also evaluated and 
served as a comparative control. Tissue homogenates (5 ml buffer per gram 
tissue) were prepared in 100 mM TRIS buffer (pH 8.3) using a Tissuemizer®. 
BC-9-NMT assays contained 1.08 mM 2-MeNH+ and SAM (8.1 µM, 7 .5 µCi) in TRIS 
buffer at a final pH 8.3. Assay volume was 185 µl due to a limited supply of 3H-
SAM. Samples were maintained at 37 °C for one hour. The SPE procedure was 
included in this experiment, and tritiated 2,9-Me2N H + was measured in each 
SPE fraction. Syringes were used to apply sample and eluents to the SPE 
cartridges. 
Fluorescence Detection of 2,9-Me2NH+ Product 
(Rather Than Radioactive Detection) 
Reactions consisted of guinea pig brain homogenate (100 µl, 1.28 mg 
protein), 100 µM 2-MeNH+, and SAM (500 µM) in 100 mM TRIS buffer (pH 8.3). 
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Assays (200 µI) were maintained at 37 °C for one hour. Note that the following 
changes were incorporated into this experiment: no radioactive SAM was used, 
2-MeNH+ concentration was reduced about 10-fold, and assay volume was 
reduced from 370 µI to 200 µI. The SPE procedure was not included in the assay 
work-up. Three distinct types of "blank" assays were evaluated: one lacking 2-
Me NH+, one without SAM, and one with boiled homogenate. Replicate reactions 
(N=3-5) were prepared and analyzed at each condition. 
Fluorescence detection of 2,9-Me2NH+ was achieved using a Perkin-
Elmer LC240 detector: excitation wavelength was 310 nm and emission 
wavelength was 450 nm. These wavelengths were optimal for detection of 2,9-
Dialysis of Guinea Pig Brain 
Homogenate 
Guinea pig brain was homogenized in 5 volumes of 10 mM Na2HP04 (pH 
7.4) containing the protease inhibitor phenylmethylsulfonylfluoride (PMSF). 
A 1.2 ml aliquot of this homogenate was dialyzed against 1 L of IO mM Na2HP04 
(pH 7.4). Dialysis was done at 0-5 °C using SpectraPor 3 (Scientific Products) 
dialysis tubing with a 3500 molecular weight cutoff (m.w.c.o.). 
Assays contained boiled homogenate or undialyzed homogenate (0.640 
mg protein) or dialyzed homogenate (0.524 mg protein). Substrates included 
500 µM 2-MeNH+ and 500 µM SAM in 100 mM Na2HP04 buffer at pH 9.5. Volume 
totaled 200 µI and final pH was 8.5. Six replicates were prepared for each 
condition, and assays were maintained at 37 °C for one hour. Reactions were 
terminated by the addition concentrated HCI04. Strong-cation exchange 
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chromatography with fluorescence detection was utilized to measure 2,9-
Me2NH+ in the reaction work-up. BC-9-NMT activity was expressed as pmoles of 
2,9-Me2NH+ formed per hour per mg protein (pmol/h/mg protein). 
BC-9-NMT Activity in Frozen 
Bovine Brainstem 
Frozen bovine brain was purchased from Pel-Freez and stored at -80 °C. 
Homogenation and subcellular fractionation was similar to the Mizoguchi et al. 
procedure (Mizoguchi 1989). Brainstem (pons and medulla oblongata) was 
thawed, cut into small pieces, and homogenized at 0-5 °C in 4 volumes of buffer 
at 0-5 °C in a glass homogenizer by 6 up-and-down strokes of a motor-driven 
teflon pestle. Homogenation buffer consisted of 0.32 M sucrose, 1 mM NaHC03 
(pH 7.2), 0.5 mM CaCl2, 1 mM MgCJi, and 1 mM PMSF. Homogenate was diluted to 
10% (w/v) with homogenation buffer and filtered through 4 layers of gauze to 
yield crude whole brainstem homogenate. 
Homogenate was centrifuged at 1400g for 10 minutes, and the pellet was 
resuspended in homogenation buffer to 10% (w/v) and re-homogenized. 
Centrifugation at 7 lOg for 10 minutes afforded pellet "P1 ", comprised of nuclei 
and cell debris. The "P1" supernatants were pooled and centrifuged at 13,800g 
for 10 minutes. The resulting pellet was washed and centrifuged at 13,800g for 
10 minutes, yielding "P2" -- theoretically a mixture myelin, mitochondria, and 
synaptosomes. Combined "P2" supernatants were centrifuged at 105,000g for 
60 minutes to produce "P3" and "S3 ", equivalent to microsomal and cytosolic 
(soluble) fractions, respectively. Pellets were diluted in 10 mM Na2HPO.i (pH 
56 
7.4) prior to use in BC-9-NMT assays. Dialysis of crude homogenate or 
subfraction was accomplished in SpectraPor 3 (3500 m.w.c.o.) dialysis tubing 
against 1 L of 10 mM Na2HP04 (pH 7.4). Dialysis was carried-out overnight at 
0-5 °C; dialysis buffer was changed 3-4 times. 
For BC-9-NMT assays, 2-MeNH+ (500 µM) and SAM (370 µM) were 
prepared in 100 mM Na2HP04 (pH 9.5). Final assay pH was 8.3-8.5 and volume 
was 200 µI. Blank assays contained all substrates and boiled homogenate or 
boiled subfraction. Replicates (N=5-7) were prepared at each assay condition. 
Reactions were maintained at 37 °C for one hour and then terminated by HCI04 
addition. Product 2,9-Me2NH+ was quantitated using SCX-HPLC and 
fluorescence detection. 
BC-9-NMT Activity in Fresh 
Bovine Brainstem 
Fresh bovine brain was obtained from Aurora Packing Company 
(Aurora, IL). Brainstem (medulla, midbrain, and pons) was cut into pieces and 
homogenized briefly in a Waring blender at 0-5 °C with 0.32 M sucrose, 1 mM 
NaHC03 (pH 7.2), 0.5 mM CaClz, 1 mM MgClz, 1 mM PMSF, and 1 µg/µI leupeptin. 
Homogenation was subsequently continued in a glass homogenizer using 12 
up-and-down strokes of a motor-driven teflon pestle (1000 rpm). Crude 
homogenate was stirred for 15 minutes in a plastic beaker and then 
centrifuged at 1400g for 10 minutes. The pellet was resuspended in buffer and 
centrifuged at 600g for 10 minutes to yield the crude nuclear pellet ("P1 "). The 
combined supernatants were saved but not assayed in this experiment. Crude 
homogenate or nuclear extract was dialyzed so that BC-9-NMT activity could be 
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compared in undialyzed and dialyzed fractions. 
Reactions (200 µl) at pH 8.3 in phosphate buffer, contained 500 µM 2-
Me NH+, 370 µM SAM, and 100 µl of dialyzed or undialyzed bovine brain fraction. 
Assays were maintained for 1 hour at 37 °C and then terminated by the 
addition of concentrated HCl04. BC-9-NMT activity was calculated by measuring 
2,9-Me2NH+ in the work-up using SCX-HPLC with fluorescence detection. Note 
that this experiment was repeated three times with variable results. 
Results 
First Experiment Replicating 
the BC-9-NMT Activity 
Reported by Matsubara 
BC-9-NMT activity was 4.6 pmol/h/mg protein in guinea pig whole-
brain homogenate. This value is consistent with the activity (4.7 pmol/h/mg 
protein) reported by Collins et al. (1992) under identical experimental 
conditions. 
Effect of S-Adenosyl-L-Methionine 
Concentration on BC-9-NMT 
Activity 
Figure 8 represents the Lineweaver-Burk plot derived for guinea pig 
whole-brain homogenate BC-9-NMT activity as a function of SAM 
concentration. Calculated kinetic constants with respect to SAM were: V max, 
33 ± 12 pmol/h/mg protein and KM, 997 ± 113 µM. 
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Figure 8. Lineweaver-Burk plot for BC-9-NMT activity as a function of SAM 
concentration. Enzyme activity (pmol 2,9-Me2NH + formed/h/mg protein) was 
determined in guinea pig whole-brain homogenate. SAM concentration 
varied from 20 to 400 µM while BC substrate (2-MeNH+) was fixed at 1.08 mM. 
Assay was carried out for one hour at 37 °C at pH 8.05 in phosphate buffer. The 
Lineweaver-Burk equation is shown as well as the equation and coefficient of 
determination (r2) resulting from linear curve-fitting of the data. Values for 
KM and Ymax are calculated values ±standard errors. 
Effect of TRIS Buffer on BC-9-NMT Assay, and 
BC-9-NMT Activity in Yeast 
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Brain BC-9-NMT activity was comparable in TRIS buffer and phosphate 
buffer. Activity was detected in both brain and yeast extracts (Table 5). This 
table also compares the results obtained with and without the SPE work-up. 
"Sample" SPE fraction represents the flow-through from the cartridge during 
application of the initial basified sample to the SPE cartridge and "NH40H" is 
the 1% (w/v) ammonium hydroxide wash fraction. Unexpectedly, 2,9-Me2NH+ 
was detected in "Sample" and "NH4 OH" fractions. As expected, no product was 
found in the methanol fraction off the SPE cartridge. "H+ I ACN" is the 
acidified acetonitrile used to elute tritiated 2,9-Me2 N H + from the cartridge 
but no product was measured here. "Acid" represents the acidified supernatant 
resulting from the reaction work-up that excluded SPE. 
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Table 5.--Brain and Yeast BC-9-NMT Activity in Solid-Phase Extraction 
Cartridge Fractions and Acidified Supernatant 
BC-9-NMT Activity (pmol !him~ protein) 
Fraction 
Sample NH40H H+/ACN I..ailll A.ci.d 
Brain 8.6 12.4 0 21.0 39.8 
Yeast 0 15.0 0 15.0 5.0 
Values are the number of pmoles of 2,9-Me2 N H + in each fraction from the 
solid-phase extraction cartridge. Following BC-9-NMT assay, proteins were 
precipitated by HCl04, resulting supernatant was basified with KOH/NH.iOH, and 
then applied to SPE cartridge. "Sample" = fraction collected during sample 
application to the cartridge, "NH40H" = fraction collected during ammonium 
hydroxide wash, "H+/ACN" = fraction collected during the acidified acctonitrile 
wash, and "Total" is the sum of the 3 fractions. "Acid" is the acidified 
supernatant from assay that did not include the SPE work-up. 
BC-9-NMT Activity in Rat Organs 
Compared to Guinea Pig Brain 
Guinea pig brain and each of the rat organs tested has BC-9-NMT 
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activity (Table 6). Rat thymus exhibited the highest BC-9-NMT activity at 44.6 
pmol/h/mg protein. Note that in liver assays the chromatograms were 
difficult to interpret due to "background" radioactivity; therefore, activity was 
not reported in those fractions. Total BC-9-NMT activity in guinea pig brain 
(22 pmol/h/mg protein) is consistent with the brain "Total" in the previous 
experiment (21 pmol/h/mg protein). Consistent with previous experiment, 
these data suggest that a substantial quantity of tritiated 2,9-Me2N H + was not 
retained by the cartridge during sample application ("Sample") and that 
product was present in SPE fractions other than the acidified methanol eluate 
("H+/MeOH"). No product was found in the methanol wash. The percentage of 
total product recovered in all fractions is represented in parentheses (Table 6). 
Organ 
Brain 
Lung 
Thymus 
Liver 
Kidney 
Spleen 
Table 6.--BC-9-NMT Activity in Guinea Pig Brain 
and Rat Organs 
BC-9-NMT Activity (pmol/h/mg protein) 
Fraction 
Sample NH40H H+/MeOH 
4.2 (19%) 8.9 (40%) 9.1 (41%) 
1.3 (7%) 8.8 (43%) 10.3 (50%) 
4.6 (10%) 23.7 (53%) 16.3 (37%) 
2.8 
0.9 (5%) 9.6 (56%) 6.7 (39%) 
0 (0%) 7.5 (45%) 9.1 (55%) 
Total 
22.3 
20.4 
44.6 
17.2 
16.6 
Values are the number of pmoles of 2,9-Me2 N H + in each fraction from the 
solid-phase extraction cartridge. Following BC-9-NMT assay, proteins were 
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precipitated by HCl04, resulting supernatant was basified with KOH/NH40H, and 
then applied to SPE cartridge. SPE fractions, in order of collection were: 
"Sample" = fraction collected during sample application to the cartridge, 
"NH40H" = fraction collected during ammonium hydroxide wash, "H+/ ACN" = 
fraction collected during the acidified acetonitrile wash, and "Total" is the sum 
of the 3 fractions. 
Fluorescence Detection of 2,9-Me2NH +Product 
(Rather Than Radioactive Detection) 
Fluorescence detection of 2,9-Me2N H + in BC-9-NMT assays is possihle. 
Figure 9 shows that BC-9-NMT activity in "blank" assays is statistically 
different than complete assays when fluorescence detection is utilized to 
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measure 2,9-Me2NH+ formed. "Activity" in blanks is due to 2,9-Me2NH+ present 
in the substrate 2-MeNH+ or other fluorescent compounds unrelated to 2,9-
Me2NH+, but with an identical retention time. Additionally, 2,9-Me2NH+ product 
present in the assays lacking 2-MeNH+ substrate may be due to endogenous 2,9-
Me 2NH+ present in the homogenate itself. Net BC-9-NMT activity (complete 
minus boiled) is 9.6 ± 3.1 pmol/h/mg protein. 
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Figure 9. BC-9-NMT activity in guinea pig brain homogenate with 2,9-Me2NH+ 
measurement by fluorescence detection. Error bars are s.e.m. Complete assay 
is significantly different than assay containing boiled homogenate or assays 
lacking substrate (* p<0.05). All assays were done at 37 °C for I hour at pH 8.3, 
and included guinea pig brain homogenate (1.28 mg protein) that was not 
boiled, except where noted. All assays contained 100 µM 2-MeNH+, except for 
the "No 2-MeNH+" assay. All assays contained 500 µM SAM except for the "No 
SAM" assay. 
Dialysis of Guinea Pig 
Brain Homogenate 
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It appears that dialysis increases BC-9-NMT activity in guinea pig brain 
homogenate, perhaps due to the removal of a low molecular weight inhibitor 
(Figure 10). 
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Figure 10. BC-9-NMT activity in dialyzed guinea pig brain homogenate. Error 
bars are s.e.m. Dialyzed (3500 m.w.c.o.) homogenate is significantly different 
than assay containing undialyzed. homogenate or boiled undialyzed 
homogenate (p<0.0005). All assays were done at 37 °C for 1 hour at pH 8.5, and 
included undialyzed guinea pig brain homogenate that was boiled 
or not boiled (0.640 mg protein), or dialyzed/non-boiled homogenate (0.524 mg 
protein). All assays contained 500 µM 2-MeNH+ and 500 µM SAM. 
BC-9-NMT Activity in 
Frozen Bovine Brainstem 
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BC-9-NMT specific activity in undialyzed bovine brainstem homogenate 
was 14.6 pmol/h/mg protein. Dialysis increased the activity 3-fold, to 46.8 
pmol/h/mg protein. BC-9-NMT activity in undialyzed crude nuclear fraction 
was 121.3 pmol/h/protein. Dialysis of the crude nuclear fraction resulted in a 
complete loss of enzyme activity. No BC-9-NMT activity was detected in 
undialyzed or dialyzed crude mitochondrial, microsomal, or cytosolic 
subfractions. 
BC-9-NMT Activity in Fresh 
Bovine Brainstem 
BC-9-NMT activity in the crude homogenate from fresh bovine 
brainstem was very high at 125.1 pmol/h/mg protein. This activity is 
equivalent to that found in the nuclear extract for the preceding experiment. 
Inconsistent with the previous experiment, undialyzed nuclear fraction 
exhibited 5.9 pmol/h/mg protein BC-9-NMT activity. Samples derived from 
dialyzed crude homogenate or nuclear extract could not be assayed due to an 
autosampler malfunction. 
Repeats of this experiment produced inconsistent results. In the second 
experiment no BC-9-NMT activity was found in either undialyzed crude 
homogenate or nuclear extract. In third experiment, 14.2 pmol/h/mg BC-9-
NMT activity was found in undialyzed crude homogenate; dialysis increased 
activity to 126.0 pmol/h/mg protein. BC-9-NMT activity was not assessed in 
nuclear extract. In the fourth attempt, no activity was detected in undialyzed 
or dialyzed crude homogenate. However, the undialyzed crude nuclear extract 
exhibited a BC-9-NMT specific activity 25.5 pmol/h/mg protein. Dialysis of the 
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nuclear extract abolished BC-9-NMT activity. 
Discussion 
BC-9-NMT activity was detected in guinea pig and bovine brain, several 
rat organs, and even yeast extract. Increasing SAM concentration or extract 
dialysis increased BC-9-NMT activity. Activity in the TRIS buffer was 
comparable to activity in phosphate buffer. 
As will be discussed below, it is speculated that BC-9-NMT activity is quite 
variable from animal to animal. There are indications that this enzyme is 
temperature-labile and that its activity is modified by endogenous dialyzable 
substances. These speculations would explain (in part) the several failed 
attempts, aimed at reproducing Matsubara's work, which preceded the first 
experiment in which BC-9-NMT activity was successfully measured. 
Difficulties in assessment of BC-9-NMT activity are summarized below, 
beginning with a discussion of the solid-phase extraction procedure work-up. 
Solid-Phase Extraction Protocol 
The solid-phase extraction (SPE) protocol includes four steps: sample 
application, NH40H wash, methanol or acetonitrile wash, and finally an 
acidified methanol (acetonitrile) eluate. The SPE procedure was originally 
developed as a means of increasing the sensitivity for detection of 2,9-Me2N H +. 
Use of SPE decreases non-BC tritiated compounds in the sample that contribute 
to background during HPLC analysis. Lower apparent BC-9-NMT activity in 
samples subjected to the SPE procedure versus non-SPE samples is probably 
due to a reduction tritiated background as a consequence of the SPE work-up. 
The majority of this background radioactivity is 3H-SAM and its metabolites. 
The three ring structure of BCs or MeBCs+ predicts that hydrophobic 
forces drive the interaction between these compounds and the C 18 SPE 
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cartridge. Since the cartridge is a silica-based packing-material, under basic 
conditions the matrix silanol groups will be negatively charged. It is 
suspected that a secondary interaction occurs between the negatively charged 
matrix and positively charged MeBCs+ (@ pH > 10). This interaction is 
apparently an important interaction, because when the column or sample is 
not basified, MeBCs+ are not retained by the cartridge (data not shown). The 
NH40H wash is intended to remove unwanted compounds from the cartridge, 
while MeBCs+ are retained. However, if this wash is not basic, MeBCs+ are 
eluted from the column during this step (data not shown). In experiments 
reported here in which 2,9-Me2 NH+ was measured in the "Sample" and 
"NH40H" fractions, it is speculated that either the column or the sample was at 
a pH less than 10. It is also possible, but not as likely, that the radioactive 
compounds detected in these fractions are not 2,9-MezBCs+, but rather 
compounds the exhibit a HPLC retention time similar to that of 2,9-Me2 NH +. 
The methanol or acetonitrile wash (i.e., third step in the elution 
protocol) disrupts hydrophobic interactions and causes elution of BCs (not 
MeBCs+ ). In addition, this solvent serves as a transition solution between the 
NH 40H and the acidified methanol (acetonitrile) wash. It is surmised that 
acidification of the final methanol or acetonitrile eluent is necessary in order 
to protonate silanol groups on the matrix, thereby disrupting the proposed 
electrostatic interaction between the silica matrix and MeBCs+. The 
acetonitrile or methanol is included to further disrupt hydrophobic 
interaction between the matrix and MeBCs+. This eluate effectively promotes 
elution of 2,9-Me2NH+ from the C18 SPE cartridge. 
Effect of SAM Concentration 
on BC-9-NMT Activity 
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Matsubara evaluated the kinetic constants, KM and V max, with respect to 
the BC substrate, but these parameters were not ascertained regarding SAM. 
In the present study the KM for SAM was 560 µM, a concentration that is 70-fold 
higher than the SAM concentration (8 µM) routinely utilized in BC-9-NMT 
assays. Consider the Michaelis-Menten (M-M) equation and the calculated 
velocity under conditions of 8 µM SAM, using KM = 560 µM and V max = 20 
pmol/h/mg protein. 
M-M equation: v = V max [S] I ( KM + [S] ) 
v = reaction velocity 
V max = maximal velocity 
[S] = substrate concentration 
KM= Michaelis constant, experimentally the substrate 
concentration at which velocity is V maxi 2 
The calculated velocity when SAM is 8 µM is 0.3 pmol/h/mg protein, a low 
activity that may not be consistently detectable. Therefore, in subsequent 
experiments SAM concentration was increased to 300-500 µM, 3H-SAM was also 
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increased. Problems associated with increasing assay 3 H-SAM will be 
addressed in a subsequent paragraph. 
Buffer Comparison 
TRIS buffer was evaluated as an alternative to phosphate buffer in the 
BC-9-NMT assay. TRIS is expected to be a better buffer than phosphate since 
the TRIS pKa (8.2) is within the pH range (pH 8-8.5) of the BC-9-NMT assay, 
while the pKa for phosphate buffer (pKa 7 .2) is not within the desired range 
for the BC-9-NMT assay. Results indicate that BC-9-NMT activity was higher in 
pH 8.3 TRIS buffer (39.8 pmol/h/mg protein) compared to previous 
experiments in Na2HP0 4 at pH 8.05. This suggests that BC-9-NMT activity may be 
inhibited somewhat in the presence of phosphate ions and/or the enzyme is 
more active at pH 8.3 compared to pH 8.05. These issues were not addressed any 
further, and TRIS buffer was employed in several of the experiments 
presented below. 
Activity in Yeast and Rat Organs 
BC-9-NMT activity was detected in several rat organs as well as yeast cell 
extract. Enzyme activity was assessed in these preparations in an effort to 
identify a potential starting material for enzyme purification purposes. 
Rationale for Use of Fluorescence 
Detection of 2,9-Me2NH+ 
An unfortunate drawback to increasing SAM in these reactions is the 
concomitant increase in 3H-SAM required so that tritiated 2,9-Me2 NH+ could be 
detected. Excessive use of tritiated SAM is quite expensive and contributes 
significantly to background during HPLC analysis. Therefore fluorescence 
detection was investigated as an alternate method for measuring 2, 9-Me2 NH+ 
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formed by the action of BC-9-NMT. B-Carbolines, particularly N-methylated 
BCs, exhibit fluorescent properties especially at acidic HPLC conditions --
and are consequently amenable to fluorescent detection. In contrast SAM is 
very weakly fluorescent under these same conditions, so a large excess of non-
radioactive SAM could be used in the BC-9-NMT assay with little effect on the 
quality of the chromatogram. 
The advantages of fluorescence detection of 2,9-Me2N H + are that it 
circumvents the requirement for the SPE protocol, eliminates 3H-SAM from 
the J3C-9-NMT assay, and allows for the analysis of a greater number of samples 
per day (use of an autosampler is possible). Because of these advantages, the 
fluorescent assay is much more efficient and more economical than the 
radioactive assay. One dis ad vantage of the fluorescent assay derives from the 
discovery that the substrate 2-MeNH+ contains traces (<0.1 %, w/w) of product 
2,9-Me2NH+. This "background" 2,9-Me2NH+ is bothersome since its level often 
exceeds that of the 2,9-Me2NH + formed by BC-9-NMT. Because of this 
background, 5-7 replicates each of blank and complete assays are required in 
order to achieve statistically significant differences between these two 
conditions. This large number of replicates obviously precludes the use the 
fluorescent assay during the proposed purification of BC-9-NMT. Another 
disadvantage of fluorescent detection is that when a large amount of 2-MeNH+ 
is used in the BC-9-NMT assay, the 2,9-Me2N H + product peak appears as a small 
shoulder peak on the 2-MeNH+ substrate peak. This poor resolution 
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occasionally makes 2,9-Me2NH + quantitation difficult. Attempts at purification 
of 2-MeNH+ to remove trace 2,9-Me2NH+ were fruitless. 
BC-9-NMT Activity as a 
Function of Time 
BC-9-NMT activity as a function of time offered some interesting clues 
regarding the stability of the enzyme or its product. Recall that activity 
increased up to about 15 minutes and then decreased to below detection. This 
suggests that BC-9-NMT is either labile or that another enzyme system present 
in the assay is catabolizing the 2,9-Me2NH+ formed by BC-9-NMT. However, a 
similar time profile was not observed for BC-2-NMT activity (see Chapter 3), 
implying that 2,9-Me2NH+ is not catabolized by endogenous enzymes under 
similar conditions. Unfortunately this BC-9-NMT time-study could not be 
replicated; i.e., BC-9-NMT activity was often measured at the 30 or 60 minute 
time-points in subsequent experiments. 
Inconsistent Detection of Activity 
Over an 8 month period of study. BC-9-NMT activity became rather 
elusive and could not be measured on a consistent basis. The effects of several 
factors on BC-9-NMT activity were assessed. Factors evaluated included: 
characteristics of guinea pig brain (vendor, sex and age of animal); SAM 
vendor; reaction work-up; and removal of endogenous SAH by SAH hydrolase 
plus adenosine deaminase. Often BC-9-NMT activity could not be detected or at 
least distinguished statistically from blanks (except occasionally in yeast 
extracts). Matsubara indicated that he experienced similar difficulties in 
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assessment of BC-9-NMT activity upon his return to Japan. He suggested using 
brain tissue harvested from older animals, increasing SAM concentration, and 
dialysis of brain extracts (to remove endogenous BC-9-NMT inhihitors). As 
reported in this Chapter, increasing SAM concentration did increase BC-9-NMT 
activity; however, increased SAM concentration had no effect on the 
consistency of detection of BC-9-NMT activity. Subsequent evaluation of brain 
harvested from old and young guinea pigs did not affect BC-9-NMT activity. 
Dialysis of brain homogenate was the only strategy that enhanced detection of 
BC-9-NMT activity, and this effect was not dramatic. This is consistent with the 
presence of a dialyzable inhibitor of BC-9-NMT; there are reports of dialyzable 
low-molecular-weight inhibitors of methyltransferases (Park et al. 1993 ). 
Bovine Brain BC-9-NMT Activity 
BC-9-NMT activity was also evaluated in bovine brain -- a potential 
inexpensive and abundant source of enzyme for purification purposes. Bovine 
brainstem was initially tested since Matsubara et al. (1992b) reported highest 
BC-9-NMT activity in guinea pig brainstem. Initial studies, using frozen 
bovine brainstem, confirmed these published results, which showed a 
primarily nuclear localization for BC-9-NMT activity. It is intriguing that 
dialysis of bovine-brainstem whole-homogenate increased BC-9-NMT activity, 
while dialysis of nuclear extract reduced or abolished enzyme activity. This 
suggests that BC-9-NMT may exist in two forms: a non-nuclear form that is 
inhibited by some dialyzable substance and a nuclear form that requires a 
dialyzable factor. 
In contrast to the results for frozen bovine brainstem, in the firs~ 
experiment using fresh bovine brainstem, very little nuclear activity was 
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measured and there was a high level of BC-9-NMT activity rn wholc-
homogenate. It is possible that subtle differences in homogenation between 
this and the previous study may account for these results. Perhaps in the 
present study, nuclei were damaged or disrupted thereby releasing f3C-9-NMT 
into the whole-homogenate. 
Similar to activity from guinea pig brain, bovine brainstem f3C-9-NMT 
activity could not be measured consistently. It was suspected that freezing 
may adversely affect BC-9-NMT activity, but this suspicion was not evaluated 
systematically. 
BC-9-NMT activity was aggressively pursued for at least a year. After 
that, BC-9-NMT and BC-2-NMT activities were re-evaluated in bovine and 
guinea pig brain using RP-HPLC with radioactive detection (data not shown). 
BC-9-NMT activity was undetectable in both samples, while BC-2-NMT activity 
was present in both. Consequently, the investigation of BC-2-NMT began (see 
Chapter 3). 
Noteworthy is the fact that BC-9-NMT activity was later consistently 
measured in postmortem human brain tissue ( see Chapter 5). Briefly, BC-9-
NMT activity in human brain was higher in the 10,000xg supernatant fraction 
than it was in the corresponding particulate fraction. In control tissue 
particulate fraction activity was 7 .8 pmol/h/mg protein (range 0-45 .2 
pmol/h/mg protein) across the brain regions tested, while supernatant 
activity averaged 14.3 pmol/h/mg protein (range 0-67.7 pmol/h/mg protein). 
Consistent measurement of BC-9-NMT in human brain suggests that it may be a 
better source than bovine brain for study of BC-9-NMT activity. 
CHAPTER3 
CHARACTERIZATION OF BOVINE BRAIN 
B-CARBOLINE-2N-METHYL TRANSFERASE 
Back~round 
This chapter describes experiments designed to characterize the 
following properties of bovine brain B-carboline-2N-methyltransferase 
(BC-2-NMT): (a) subcellular localization; (b) apparent kinetic constants, 
Michaelis constant (KM ) and maximal velocity (V max) with respect to its 
cosubstrates 9-methylnorharman (9-MeNH) and S-adenosyl-L-methionine 
(SAM); (c) dependence of activity on protein concentration; (d) pH optimum 
for enzyme assay; (e) activity as a function of assay time; (f) inhibition by S-
adenosyl-L-homocysteine (SAH), a competitive inhibitor of SAM-dependent 
methyltransferases; and (g) the effect of various metals on its activity. 
Delineation of these properties was essential to the development of a sensitive 
and reproducible enzyme assay for use in future studies, including the 
purification of BC-2-NMT from bovine brain (Chapter 4) and comparison of 
BC-2-NMT activity in parkinsonian and normal human brain (Chapter 5). 
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Materials and Methods 
Reagen ts 
6-Carboline substrate, 9-methylnorharman, was synthesized in our 
laboratory using two different methods: according to Matsuhara (Matsubara et 
al. 1992b) or a modification of the method described by Rubottom (Rubotlom et 
al. 1974). The modified Rubottom method is described in Appendix C. Unlahelcd 
S-adenosyl-L-methionine (toluenesulfonate salt) and tritiated S-
[methyl-3H]-adenosyl-L-methionine (60-85 Ci/mmol) were purchased from 
Sigma Chemical and Dupont NEN, respectively. All other reagents were of 
appropriate purity for their intended use and were utilized as purchased. 
Subcellular Fractionation 
Bovine brain (including brainstem) was obtained fresh (Aurora 
Packing Co., Aurora IL), divided sagittally into equal halves, and frozen at -80 
°C for three months. Brain was quickly thawed in a 40 °C water hath, and 
subsequently homogenized in 2 volumes (2 ml/g tissue) of cold buffer "HI" 
using a chilled Waring blender at low speed (3 cycles x 30 seconds per cycle). 
Buffer "'Hl" contained 150 mM potassium chloride (KCI), 1 mM dithiothreitol 
(OTT), 1 mM ethylenediaminetetraacetic acid disodium (EDT A), and 20 mM 
sodium phosphate dibasic (Na2HP04) at pH 7.4. The homogenate was filtered 
through two to four layers of gauze prior to centrifugation. Centrifugation 
was accomplished at 5-10 °C iri a Sorvall RC5B Superspeed centrifuge (SS-34 
rotor) or a Beckman L8-M Ultracentrifuge equipped with a SW28 rotor. 
Centrifugation at 900g (10 minutes), 9000g (15 minutes), and 100,000g (one 
hour) afforded crude nuclear, mitochondrial, and microsomal plus cytosolic 
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fractions, respectively. Crude particulate fractions were diluted with 150 mM 
KCl prior to inclusion in assays; crude cytosol was not diluted. 
For experiments other than subccllular fractionation, bovine brain 
(including brainstem) was obtained fresh (Aurora Packing Co., Aurora IL), 
divided sagittally into equal halves, and frozen at -80 °C for seven months. 
Brain was quickly thawed in a 40 °C water bath, and subsequently 
homogenized in 2 volumes (2 ml/g tissue) of cold "H2" using a chilled Waring 
blender at low speed (3 cycles x 30 seconds per cycle). Solution "H2" contained 
150 mM KCl and 1 mM DTT. The crude cytosolic supernatant was obtained from 
filtered homogenate following sequential centrifugation at 15,000g (30 
minutes) and 100,000g (one hour). Cytosolic supernatant was stored at -80 °C 
in polypropylene tubes in 2-3 ml aliquots. Frozen aliquots were thawed as 
needed for use in 6C-2-NMT assays. For some studies, fresh bovine brain was 
homogenized in buffer "H3" which contained 20 mM K2HP04, 150 mM KCl, 1 
mM DTT, 1 mM EDTA, 1 mM phenylmethylsulfonylfluoride, and 1 µg/ml each 
leupeptin and pepstatin A. Cytosol was obtained and stored as described for 
buffer "H2". Composition of the homogenation buffer had no obvious effect 
on 6C-2-NMT stability or assay. 
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Determination of BC-2-NMT Activity 
This activity catalyzes the transfer of the tritiated methyl moiety from 
SAM to 9-MeNH resulting in the formation of 2-(3H-methyl)-9-MeNH+ and SAH 
(Figure 11) . 
+ 
19-MeNH 
(sc-2-NMT ) 
+ 
2,9-Me2NH+ 
* 
H O-I3 
I I 
HOOC-C-(CH2)2-S-Cl-I2 
I + 
NH2 
I SAM I GI 
H 
I 
HOOC-C-(CH2)2-S-CH2 
I 
NH2 
GI 
Adenine I 
Cl-I 
Adenine I 
a-1 
Figure 11. BC-2-NMT assay. Site of tritium label in molecule marked with *. 
Abbreviations: 9-methylnorharman (9-MeNH), 2-[3H-methyl]-9-
methylnorharmanium ion (2,9-Me2 N H + ), S-adenosyl-L-methionine (SAM), 
S-adenosyl-L-homocysteine (SAH). 
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Use of the norharman, a presumed physiological substrate, rn the assessment 
of BC-2-NMT activity would have been confusing since the reaction product, 2-
MeNH + (refer to Figure 2) is subsequently 9N-methylated by BC-9-NMT; i.e., it 
would be difficult to quantitate the product 2-MeNH+ since it converted to 2,9-
Me2NH +. Therefore, the BC substrate 9-MeNH was used to assess BC-2-NMT 
activity since its indole position (9N-) is already methylated, allowing for 
measurement of methylation occurring exclusively at the 2N- position of the 
BC. It was assumed that 9-MeNH and norharman are similarly 2N-methylatcd 
by BC-2-NMT. This assumption was made based on similar enzyme activities 
reported by Collins et al. (1992) for guinea pig brain catalyzed 2N-methylation 
of 9-MeNH and norharman. BC-2-NMT activity was 2.17 ± 0.17 pmol/h/mg 
protein with 9-MeNH as the substrate. Total BC-2-NMT activity with 
norharman as the substrate was 7 .85 pmol/h/mg protein) -- the total was 
calculated by summing the 2-MeNH+ (4.80 ± 0.06 pmol/h/mg protein) and 2,9-
Me2NH + (3.05 ± 0.05 pmol/h/mg protein) present in the assay. 
The assay was carried out as previously reported by Matsubara ct al. 
(1993) with modifications as detailed below. Enzyme assays were prepared in 
1.5 ml polypropylene microcentrifuge tubes by mixing concentrated stock 
solutions of 9-MeNH and SAM with whole brain homogenate or subfraction. 
Stock solutions of SAM were prepared in water, and 9-MeNH was dissolved in a 
buffer mixture consisting of 50 mM sodium phosphate (Na2HP04) and 50 mM 
bicine at pH 6 to 9. Brain homogenate or subcellular fraction containing 0.014 
to 3.33 mg protein per assay tube was present in buffer "Hl", "H2", or "H3". 
Stock solution volumes remained constant across studies, whereas stock 
solution concentrations and final pH varied depending upon the experiment. 
Assay volume was 370 µl, comprised of the following stock solutions: 50 µl 
3H-SAM, 20 µl non-radioactive SAM, 200 µl 9-MeNH, and 100 µI enzyme 
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solution. The final assay pH, as well as the final substrate and protein 
concentrations are indicated below for each experiment. The assay was gently 
vortexed and subsequently maintained at 37 °C in a shaking water bath for one 
hour, except in the time study. 
Following incubation at 37 °C the assay tube was placed on ice and 
protein precipitated by the addition of 200 µl 0.5 N perchloric acid (HC104). The 
mixture was centrifuged to pellet precipitated protein (7000g for 5 minutes); 
supernatant was transferred to a glass culture tube containing one ml I% 
(w/v) ammonium hydroxide (NH40H, pH IO ± 0.2) and 100 µ1 I N potassium 
hydroxide. The protein pellet was vigorously resuspended in 500 µI 0.01 N 
H C 10 4 and centrifuged (1 O,OOOg for 5 minutes); the resulting supernatant was 
combined in the glass tube with the initial supernatant. Contents of the glass 
tube were slowly applied to a Sep-Pak® Cl8 Plus solid-phase extraction 
cartridge (Millipore-Waters part no. 20515, 360 mg). The cartridge was 
pretreated with 5 ml each of methanol :5 N acetic acid (3: I, v/v ), methanol, and 
1 % NH40H (w/v) in that sequence. Slow application of all solutions to the 
cartridge (2 to 5 drops per second) was achieved using a vacuum manifold. 
Following sample application, the extraction cartridge was washed with 8 ml of 
1 % NH40H followed by 5 ml methanol; these washes were discarded since they 
contained undesired compounds that contributed significantly to background 
radioactivity during subsequent analysis. The final wash (5 ml), containing 
3:1 (v/v) methanol:5 N acetic acid, promoted elution of tritiated 2,9-Me2NH+ 
product from the cartridge into a clean glass culture tube. This eluate was 
evaporated to dryness at 30 - 40 °C using a Speed Vac concentrator (Savant 
Instruments Inc., Hicksville NY). 
Reverse-Phase High Performance 
Liquid Chromatography 
(RP-HPLC) 
Activity of BC-2-NMT was quantitated by RP-HPLC analysis of 
2-(3H-methyl)-9-MeNH+ present in the Speed Vac residue. Residue was 
dissolved in 200 µI HPLC mobile phase by sonication and vortexing. Samples 
were filtered through a 0.45 µm nylon membrane filter (Micro-Spin, Chrom-
Tech Inc.) prior to injection (150 µI) onto the HPLC system. Isocratic HPLC 
analysis was carried out under ambient conditions on a Bondclone I 0 µ C 18 
column (Phenomenex™, 300 mm x 3.9 mm). Mobile phase consisted of 17% 
(v/v) HPLC grade acetonitrile mixed with 83% (v/v) aqueous buffer. The 
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buffer contained 50 mM triethylamine in 250 mM sodium phosphate monobasic 
adjusted to pH 3 with phosphoric acid (final mobile phase was pH 3.4 ± I). The 
HPLC system consisted of a Shimadzu SIL-9A programmable autosampler, a 
Beckman 1 lOA pump (0.8 ml/minute), and an in-line radioactive flow detector 
(Radiomatic Instruments Flo-One\B ). Ultima-Flo™ AP (Packard Instruments) 
liquid scintillation cocktail was used at a flow rate of 2.8 ml per minute 
resulting in a scintillation fluid to mobile phase mixing ratio of 7:2. The 
radioactive flow detector was equipped with a 2.5 ml flow cell and an automatic 
stream splitter. It was necessary to bypass the radioactive flow detector by 
splitting the HPLC column effluent to waste until about ten minutes into the 
run in order to reduce interference due to tritiated materials (e.g., 3 H - SAM) 
present in the sample. Radioactive peak area corresponding to 2,9-Me2NH+ 
(retention time 12-13 minutes) was calculated using Radiomatic Flo-One\B 
system software and resulting integrated peak area was reported as total cpm 
under the 2,9-Me2N H + curve (see Figure 12 for representative radiogram). 
+ ·s.w .~~ s.r.d.-~ 
I 
0 
I 
5 
I 
10 
Time (minutes) 
Figure 12. Rendition of representative HPLC radiogram. Peak represents 
radioactivity due to 2,9-dimethylnorharmanium ion (2,9-Me2NH+) formed at pH 
8.5 by BC-2-NMT in the presence of9-methylnorharman (9-MeNH), S-
adenosyl-:methionine (SAM), and 3H-SAM. Background represents 
radioactivity in the absence of 9-MeNH. Chromatographic separation was 
performed using RP-HPLC as described in text. Column effluent was split to 
waste (s.w.) from 0-9 minutes into analysis, and then split to radioactive 
detector (s.r.d.) from 9-20 minutes. 
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Determination of pH Optimum 
for BC-2-NMT Assay 
Buffers composed of 50 mM bicine (pKa 8.3 ) plus 50 mM Na2HP04 
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(pKa 7.2) spanning the range pH 6.6-9.0 were utilized to prepare 9-MeNH stock 
solutions (1 mM); final 9-MeNH concentration in the assay was 540 µM. 
Duplicate samples were prepared to contain 0.6 mg protein from bovine brain 
cytosol (in "H2"), and SAM at a final concentration of 105 µM (3.6 µCi) in 
addition to 9-MeNH stock at the indicated pH. Final assay pH was determined to 
be identical to the pH of the buffer used to prepare 9-MeNH stock solutions. 
BC-2-NMT activity, expressed as pmoles of 2,9-Me2NH+ formed per hour per mg 
protein (pmol/h/mg protein), was plotted as a function of assay pH. 
Assessment of BC-2-NMT Activity as a Function 
of Protein Concentration 
Bovine brain cytosol in "H2" was concentrated using a Centricon® 30 
concentrator (Amicon ®, Beverly MA). Concentrated cytosol was then serially 
diluted with 150 mM KCl to provide solutions containing various protein 
concentrations for use in the BC-2-NMT assay. Assays were prepared to 
contain: protein (0.014 -3.33 mg per assay), 9-MeNH (540 µM), and SAM 
(105 µM, 4.5 µCi) at pH 8.5. BC-2-NMT-catalyzed formation of 2,9-Me2NH+ 
(pmol/h) was plotted as a function protein concentration in the assay. 
The Effect of Length of Assay Time 
on BC-2-NMT Activity 
Assays contained bovine brain cytosol (0.687 mg protein in buffer 
"H3"), 540 µM 9-MeNH, and 105 µM SAM (2.88 µCi) at pH 8.5. Duplicate samples 
were maintained at 37 °C for 0, 15, 30, 60, 120, and 180 minutes prior to 
termination of assay. The BC-2-NMT-catalyzed formation of 2,9-Me2NH+ was 
plotted as a function of time at 37 °C. 
Determination of Apparent Kinetic Constants 
With Respect to the Methyl Donor 
SAM 
Assays contained bovine brain cytosol in "H2" (0. 79 mg protein), 
9-MeNH (540 µM, pH 8.5), 3H-SAM (2.3 or 6.0 µCi), and SAM at a final 
concentration ranging from 2.6 - 520 µM. BC-2-NMT activity -- expressed as 
pmoles of 2,9-Me2N H + formed per hour per mg protein (pmol/h/mg protein) 
was plotted as a function of SAM concentration. Plotting and curve-fitting 
were accomplished using Kaleidagraph™ data analysis/graphics application 
software (Abelbeck and Synergy Software, Reading PA). Nonlinear curve 
fitting was employed to fit the data to the Michaelis-Menten equation for the 
determination of apparent kinetic parameters, the Michaelis constant (KM) 
and maximal velocity (V max). This program uses the Levenberg-Marquardt 
algorithm to fit data to a user-defined nonlinear equation. Data were also 
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analyzed using a Hanes plot, a linear transformation of the Michaelis-Menten 
equation. 
Determination of Apparent Kinetic Constants 
With Respect to the 8-Carboline 
9-MeNH 
Assays included bovine brain cytosol (0.79 mg protein), SAM (260 µM, 
5.6 µCi), and 9-MeNH at a final concentration ranging from 5 µM to 1 mM at pH 
8.5. Data analysis was achieved as described above. 
Effect of S-Adenosyl-L-Homocysteine (SAH) 
on BC-2-NMT Activity 
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The effect of SAH on BC-2-NMT activity was determined in preparations 
containing bovine brain cytosol in "H3" (1.33 mg protein), 540 µM 9-MeNH, 105 
µM SAM (2.77 µCi), and SAH at pH 8.5. Cytosol was concentrated, and 
endogenous SAH theoretically removed by ultradiafiltration using a 
Centricon® 30 concentrator; ultradiafiltration was carried out against IO mM 
Na2HP04 (pH 7) containing 150 mM KCI. Assays were prepared in duplicate 
and contained SAH ranging from 1 µM to 1 mM. Results are reported as 
percent of control .BC-2-NMT activity in the absence of added SAH. Only the 
linear range of the curve is shown (1 µM - 100 µM) for ease in determination 
of the ICso following linear curve-fitting of the data. 
Effect of Various Metals 
on .BC-2-NMT Activity 
The effect of a number of transition metals on .BC-2-NMT activity was 
determined by adding chloride salts of metals or EDT A at a final concentration 
of 1 mM. Activity was measured in bovine brain cytosol in "H2" or "H3" (0.721 
mg protein) at pH 8.5; substrates were present at 540 µM and 105 uM (3.4 µCi) 
for 9-MeNH and SAM, respectively. Results are reported as percent of control 
.BC-2-NMT activity, control activity is activity in the absence of added EDTA or 
metal chloride. Data were obtained from two different experiments, each with 
its own control. Composition of homogenation buffer ("H2" or "H3") did not 
appear to affect results between studies. 
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Protein Measurement 
Protein was determined using a modified Lowry method as described in 
Scopes (1994a). Details of this method are provided in Appendix A. 
Results 
Subcellular Distribution of 
BC-2-NMT Activity 
Bovine brain BC-2-NMT activity (Table 7) resides predominantly in the 
cytosolic supernatant (72% of total activity), although there is also notable 
nuclear activity (26% of total activity). The cytosolic subfraction also exhibits 
the highest specific activity. Comparable results -- with respect to fraction 
specific activity and subcellular distribution of total activity -- were obtained 
upon subcellular fractionation of guinea pig brain (data not shown). 
Subcellular 
fraction 
Crude 
Nuclear 
Mitochondrial 
Microsomal 
Cytosolic 
Table 7 .--Subcellular Localization of 
BC-2-NMT Activity in Bovine Brain 
% Recovered Specific Activity 
Actiyity Cpmol/hr/m2 protein) 
-------- 4.1 
26.5 1.4 
0.7 1.6 
0.5 3.7 
72.3 21.9 
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Bovine brain was homogenized in 2 volumes (2 ml/g tissue) of cold buffer 
containing 150 mM potassium chloride (KCI), 1 mM dithiothreitol (DTT), I mM 
ethylenediaminetetraacetic acid disodium (EDT A), and 20 mM sodium phosphate 
dibasic (Na2HP0 4) at pH 7.4. Homogenate was filtered through 2-4 layers of 
gauze prior to centrifugation. Centrifugation at 900g (10 minutes), 9000g ( 15 
minutes), and 100,000g (one hour) afforded crude nuclear, mitochondrial, and 
microsomal plus cytosolic fractions, respectively. Crude particulate fractions 
were diluted with 150 mM KCl prior to inclusion in assays; crude cytosol was 
not diluted. 
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pH Optimum for BC-2-NMT Assay 
Under Lhe assay conditions utilized, BC-2-NMT activity increased 
linearly from pH 6.6 to approximately pH 8.0, where activity reached a plateau 
that extended to pH 9.0 (Figure 13). 
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Figure 13. BC-2-NMT activity as a function of assay pH. Buffer system was 
50 mM bicine plus 50 mM Na2HP0 4. Components present included: 0.6 mg 
protein from bovine brain cytosol, 9-MeNH (540 µM), and SAM (105 µM, 3.6 µCi). 
Linearity of BC-2-NMT Activity as a Function of 
Time and Protein Concentration 
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Under assay conditions in which product formation was much less than 
substrate concentration, BC-2-NMT activity increased linearly with respect to 
time (Figure 14) and protein concentration (Figure 15). Least squares curve-
fitting to a linear equation of activity as a function of total protein or time 
showed a highly linear relationship (r=0.996 and 0.980 respectively). 
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Figure 14. BC-2-NMT-catalyzed formation of 2,9-Me2NH + as a function of assay 
time. Assays contained bovine brain cytosol (0.687 mg protein in bicine-
phosphate buffer), 540 µM 9-MeNH, and I 05 µM SAM (2.88 µCi) at pH 8.5. 
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Figure 15. BC-2-NMT-catalyzed formation of 2,9-Me2NH + as a function of 
protein concentration. Assays (37 °C) contained bovine brain cytosol (0.014 -
3.33 mg protein per assay), 9-MeNH (540 µM), and SAM (105 µM, 4.5 µCi) at pH 
8.5. Data not corrected for background therefore line does not pass through 
origin. 
Apparent Kinetic Constants With Respect to Substrates, 
SAM and 9-MeNH 
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The high correlation coefficients (r>0.96) obtained following nonlinear 
curve fitting of the data to the Michaelis-Menten equation indicate that 
BC-2-NMT obeys Michaelis-Menten kinetics with respect to both 9-McNh 
(Figure 16) and SAM (Figure 17) when the non-varied substrate is fixed near 
saturation. Values for KM and V max are reported as parameter value ± standard 
error of that parameter value. Graphical analysis of the data calculates KM and 
V max values of 75 ± 20 µM and 48 ± 3 pmol/h/mg protein with respect to 9-
MeNH (Figure 16). Regarding SAM, estimates of KM and Ymax are 81 ± 21 µM 
and 53 ± 4 pmol/h/mg protein (Figure 17). As shown in Figures 18 and 19, 
linear transformation of the Michaelis-Menten equation and data analysis in 
the form of a Hanes plot generates KM and V max estimates similar to those 
obtained following nonlinear regression analysis of the data. 
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Equation for Nonlinear Curve-Fitting 
BC-2-NMT Activity = V [9-MeNH]/(KM + [9-MeNH]) 
max 
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Figure 16. BC-2-NMT activity as a function of 9-MeNH concentration. Assays 
included bovine brain cytosol (0.79 mg protein), SAM (260 µM, 5.6 µCi), and 9-
MeNH at a final concentration ranging from 5 µM to 1 mM at pH 8.5. 
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Figure 17. BC-2-NMT activity as a function of SAM concentration. Assays at 
pH 8.5 contained bovine brain cytosol in (0.79 mg protein), 9-MeNH (540 µM), 
3H-SAM (2.3 or 6.0 µCi), and SAM at a final concentration ranging from 
2.6 - 520 µM. 
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Figure 18. Hanes plot of kinetic data with respect to 9-MeNH concentration. 
Assays included bovine brain cytosol (0.79 mg protein), SAM (260 µM, 5.6 µCi), 
and 9-MeNH at a final concentration ranging from 5 µM to I mM at pH 8.5. 
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Figure 19. Hanes plot of kinetic data with respect to SAM concentration. 
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Assays (pH 8.5) contained bovine brain cytosol (0.79 mg protein), 9-MeNH (540 
µM), 3H-SAM (2.3 or 6.0 µCi), and SAM at a final concentration ranging from 
2.6 - 520 µM. 
S-Adenosyl-L-Homocysteine (SAH) 
Inhibits BC-2-NMT Activity 
The activity of bovine brain BC-2-NMT is inhibited hy SAH 111 a 
concentration-dependent manner (Figure 20). The ICso for SAH, i.e., the 
concentration of inhibitor producing a 50% reduction in BC-2-NMT aclivity 
compared to control, is 14.8 µM. 
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Figure 20. SAH inhibition of BC-2-NMT activity. Assays (pH 8.5) contained 
bovine brain cytosol (1.33 mg protein), 540 µM 9-MeNH, 105 µM SAM (2.77 µCi), 
and SAH. 
Effects of Transition Metals 
on BC-2-NMT Activity 
Certain transition metals affected BC-2-NMT activity (Table 8). 
BC-2-NMT activity was increased 2-fold in the presence of iron (p<0.05) and 
manganese (p<0.05). Increased BC-2-NMT activity in the presence of calcium 
did not reach statistical significance. Nickel, magnesium and copper did not 
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appear to affect BC-2-NMT activity, but zinc completely inhibited formation of 
2,9-Me2NH+. BC-2-NMT activity was 139% of control in the presence of the 
chelating agent EDT A (1 mM). 
Table 8.--Effect of Transition Metals on BC-2-NMT Assay 
Mllil.a % of Controlc 
Iron 209 ± 0.7 (2) d 
Iron b 231 ± 13 (2) d 
Manganese 192 ± 13 (2) 
Cobalt 146 
Calcium 121 ± 0 (2) 
Nickel 116 
Magnesium 101 
Copper 101 
Zinc 0±0 (2) 
a As chloride salt, 1 mM, 2+ oxidation state 
b 3 + oxidation state 
c Values are mean ± s.d. for (N) replicates 
d Significantly different than control (p<0.05), 
ANOV A followed by Tukey-HSD post-hoc test 
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Discussion 
Enzyme Kinetics 
Fitting of kinetic data to the Michaelis-Menten (M-M) equation indicates 
that BC-2-NMT obeys M-M kinetics with respect to both 9-MeNH and SAM, when 
one substrate is fixed and the other is varied. For guinea pig brain, previous 
studies from this laboratory reported kinetic constants with respect to 9-McNH 
of 17.8 µM and 2.2 pmol/h/mg protein, for KM and V max values, respectively 
(Matsubara et al. 1992b), results that differ from those reported here. Kinetic 
parameters with respect to SAM were not determined in previous studies. 
In addition to species differences (guinea pig vs. bovine), two factors 
may contribute to the difference in kinetic constants reported by Matsubara 
(1992b) and those reported here: (a) SAM concentration utilized between 
studies, and (b) the method of data analysis utilized in each investigation. 
Regarding the effect of SAM concentration, Matsubara determined kinetic 
parameters with respect to 9-MeNH with SAM fixed at 8 µM. The present study 
indicates that 8 µM SAM is well below its KM of 81 µM. In fact, if 8 µM SAM is 
inserted into the M-M equation using the present KM and V max values for SAM, 
the calculated activity is about 5 pmol/h/mg protein, a value comparable to 
the V max described by Matsubara (l 992b ). In the present study, SAM 
concentration was fixed at 260 µM, equivalent to a concentration three times 
its KM; the literature suggests (Dixon et al. l 979a) that a higher SAM 
concentration is more appropriate for testing the adherence of BC-2-NMT to 
M-M kinetics with 9-MeNH as the variable substrate. Increasing SAM 
concentration from 8 µM (the concentration used by Matsubara) to 260 µM (the 
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concentration used in this dissertation), while 9-MeNH is varied, increased the 
V max estimate approximately 20-fold, from 2.2 pmol/h/mg protein for guinea 
pig brain (Matsubara et al. 1992b) to the value reported in this dissertation, 48 
pmol/h/mg protein for bovine brain. 
In addition to the effect of SAM concentration discussed above, data 
analysis methods employed between studies may contribute to the discrepancy 
in the KM for 9-MeNH reported by Matsubara (1992b) and the value reported in 
this dissertation. These researchers utilized a non-weighted Lineweaver-Burk 
linear transformation (double-reciprocal plot) of the M-M equation in data 
analysis. Though commonly used, this plot does not reflect experimental 
error accurately, a point discussed by Cornish-Bowden (Cornish-Bowden 1979). 
In fact, when kinetic data presented here are fitted to the Lineweaver-Burk 
equation, the estimated KM with respect to 9-MeNH was nearly identical to the 
17 .8 µM value obtained by Matsubara. It is noteworthy that close scrutiny of a 
Lineweaver-Burk plot of these data revealed a marked downward curvature of 
data points near the y-axis (data not shown). This observed deviation from 
linearity in the double-reciprocal plot prompted an investigation of other 
options regarding data analysis. 
Nonlinear curve- fitting, which fits the data directly to the Michaelis-
Menten equation, i.e., without linear transformation of the original equation, 
was therefore employed. Use of nonlinear cure-fitting circumvents certain 
problems associated with the use of linear transformation and subsequent 
graphical analysis of nonlinear data. For a review of the applicability of 
nonlinear regression in the analysis of nonlinear data (e.g., enzymatic data) 
the reader is directed to papers by Wilkinson et al. (1961) and Motulsky et al. 
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(1987). Hanes plots of the kinetic data were generated, following the more the 
more familiar linear transformation of the M-M equation, as ref ere need in 
Cornish-Bowden (1979). As shown in Figures 13 and 14, Hanes plots yield 
kinetic parameters that are reasonably close to those obtained with nonlinear 
curve-fitting. 
The V max of bovine brain BC-2-NMT with respect to both substrates is 
quite small. Since V max is derived from the product of enzyme concentration 
and kcat> the small magnitude of V max may indicate that 6Cs are poor substrates 
for this N-methyltransferase (i.e., low turnover number), or that the amount 
of BC-2-NMT present in brain tissue is quite small. BC-2-NMT-catalyzcd 
formation of neurotoxic products in relatively low amounts due to the 
enzyme's low V max• would be consistent with the hypothesis that this N-
methyltransferase could participate in the neuropathogenesis of Parkinson's 
disease -- a disease that takes years to manifest symptoms related to the 
underlying neurodegeneration. It is postulated that the low activity of BC-2-
NMT could result in the generation of small quantities of neurotoxic 2-MeBCs+, 
which over a period of many years would cause the death of sufficient 
neurons to elicit the clinical characteristics of PD. 
Other Properties of BC-2-NMT 
Linearity of BC-2-NMT activity as a function of time and protein 
concentration is fundamental to reliable monitoring of enzyme activity 
during protein purification. Note that enzyme activity was not linear, but 
instead plateaued, with respect to time or protein concentration in 
preliminary experiments which utilized SAM at 8 µM instead of 105 µM (data 
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not shown). The linearity of BC-2-NMT activity through 180 minutes al 37 °C is 
also an indication that the enzyme is thermally stable under these conditions. 
All SAM-dependent methyltransferases studied to date are inhibited by 
S-adenosyl-L-homocysteine (SAH) in a competitive manner (Deguchiand 
Barchas 1971; Lawrence and Robert-Gero 1990). This is not surprising since 
products often inhibit the enzyme responsible for their formation, and SAH is 
a product of SAM-dependent methylation reactions. Inhibition by SAH varies 
depending upon the specific methyltransferase affected, with Ki's falling into 
the 100 nM to 12 µM range. Fifty percent inhibition of BC-2-NMT activity is 
observed when added SAH is present at about 14.5 µM, which corresponds to a 
Ki of 4.5 µM (data not shown), consistent with the behavior of other 
SAM-dependent me thy I transf erases. 
The manganese and iron effects, although not dramatic, are intriguing 
since both metals are associated with parkinsonism (Irwin et al. 1995). 
Manganese miners occasionally display parkinsonian symptoms such as 
bradykinesia. Neuropathologically, the globus pallidus shows extensive cell 
loss but other basal ganglia components, including the substantia nigra may 
also be affected (Mena 1979); however, manganese poisoning is not clinicalJy 
classified as PD. In contrast, aberrant iron metabolism has been suggested to 
play a role in Parkinson's disease (PD); persons afflicted with PD exhibit 
higher than normal free iron (Dexter et al. 1989), and decreased ferritin 
protein in the substantia nigra (Dexter et al. 1990). Hypothetically, if iron is 
indeed elevated in the substantia nigra of persons with PD, this high iron 
concentration could conceivably increase BC-2-NMT activity in that brain 
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region -- leading to local formation of neurotoxic N-methylated B-carholinium 
compounds and subsequent cell death. 
Previously Characterized N-Methyltransferases 
It is possible that BC-2-NMT represents a previously characterized 
enzyme for which B-carbolines were not evaluated as substrates. Saavedra et 
al. (1973) described the distribution of a non-specific N-methyltransferase 
present in the brain of several species, including human postmortem brain 
tissue. That SAM-dependent enzyme utilizes tryptamine as well as several 
other amines as substrates. Similar to BC-2-NMT, the enzyme exhibited a KM 
with respect to SAM of 52 µM and a Ymax in the range 2 -15 pmol/h/mg 
protein, depending upon the tissue. The subcellular distribution and specific 
activity of the non-specific N-methyltransferase described by Saavedra are 
similar to those reported here for BC-2-NMT. However, the regional 
distribution of this enzyme differed from that for BC-2-NMT described by 
Matsubara et al. (1992b). 
Ansher and Jakoby (1986b, 1987) purified amine N-methyltransferases 
A and B from rabbit liver. The enzymes exhibited broad, overlapping 
N-methylating activities toward numerous amines, including several 
azaheterocycles. The azaheterocycles tested included derivatives of pyridine 
and isoquinoline, but B-carbolines were not tested as substrates. It is 
noteworthy that both N-methyltransferases A and B were purified from 
cytosol and both exhibited pH profiles with respect to desmethylimipramine 
and tryptamine that were similar to that of BC-2-NMT toward 
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9-MeNH. Ansher et al. (1986a) also found these amine N-methyltransfcrase 
activities in human, monkey, and rodent cytosolic brain extracts; suhstrates 
included 4-phenyltetrahydropyri<line and 4-phenylpyridine, potential 
precursors of neurotoxic MPP+. Specific activities toward these substrates 
were in the range 0.17-23 pmol/h/mg protein, similar to the values reported 
in the present study. 
In addition, Naoi, et al. (1989a) reported the presence of a cytosolic 
N-methyltransferase activity in human brain homogenates that forms 
potentially neurotoxic N-methyl-1,2,3 ,4-tetrahydroisoquinoline from 
tetrahydroisoquinoline (TIQ). The TIQ-methylating activity exhibited kinetic 
parameters and a pH optimum similar to those of BC-2-NMT. Likewise, 
Matsubara et al. (1992a) identified a cytosolic N-methyltransferase activity 
present in rodent brain that catalyzes methylation at the 2N-nitrogen of 
tetrahydro-B-carbolines. It is conceivable that BC-2-NMT and any of the 
N-methyltransferases described above are the same or least similar enzymes. 
Interestingly, evidence presented in Chapter 6 of this dissertation 
indicates that BC-2-NMT may be due to the epinephrine-synthesizing enzyme, 
phenylethanolamime-N-methyl transf erase (PNMT). 
Cytosolic or Nuclear Localization 
of BC-2-NMT Activity? 
The cytosolic location of BC-2-NMT disagrees with the primarily nuclear 
location of the enzyme previously reported from this laboratory, in which 
guinea pig brain cytosolic activity was undetectable (Matsubara et al. 1992b). 
However, subcellular fraction of guinea pig brain (data not shown) showed a 
subcellular distribution and specific activities that were similar to those 
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reported here for bovine brain. This discrepancy between studies could be due 
to variation in the intensity of homogenation preceding subcellular 
fractionation. Since subcellular enzymatic markers were not utilized to 
monitor fractionation, the cause of the discrepancy remains unknown. 
However, cytosolic BC-2-NMT activity is consistent with the subccllular 
distribution of the N-methyltransferases previously described by Saavedra et 
al. (1973), Ansher et al. (1986a), Naoi et al. (1989a), and Matsubara et al. 
(1992a). 
Conclusions 
The studies presented in this chapter define experimental conditions to 
be utilized in subsequent investigations; specifically BC-2-NMT purification 
from bovine brain cytosol (Chapter 4) and measurement of its activity in 
normal and parkinsonian human brain (Chapter 5). For the proposed studies, 
cosubstrates 9-MeNH and SAM will be present at 540 µM and 105 µM (2-6 µCi) 
respectively; assays will be maintained at 37 °C for 60 minutes at pH 8.5. 
CHAPTER4 
PARTIAL PURIFICATION OF B-CARBOLINE-2N-METHYLTRANSFERASE 
FROM BOVINE BRAIN 
General Comments 
Difficulties 
The assay at present is very labor- and time-intensive and is not 
amenable to utilization in the purification of BC-2-NMT. Only 12 samples may 
reasonably be prepared and analyzed per day. This number is incompatible 
with the number of potential column fractions generated in a typical column 
chromatography procedure, even if alternate fractions are analyzed. 
Moreover, the low activity of BC-2-NMT in combination with the dilute nature 
of column fractions necessitates concentration of each fraction prior to 
incorporation into the BC-2-NMT assay. Concentration using Centricon 
concentrators requires 1-4 hours depending upon the composiLion of the 
fraction. Once the concentrated fraction is prepared, the time required to 
obtain BC-2-NMT activity results for those fractions is detailed below. 
For the maximum of 12 samples: 
• preparation of substrate solutions 
• prepare tubes and BC-2-NMT assays 
• incubation at 37 °C 
• protein prec1p1tation and centrifugation 
• solid-phase extraction procedure 
• Speed Vac drying 
• HPLC analysis (baseline, 3H-SAM, 12 samples) 
• protein assays (another day) 
Total time required (minimum) 
105 
0.5 h 
0.5 h 
1.0 h 
0.5 h 
0.5 h 
2.0 h 
5.0 h 
.LlLh_ 
11 h 
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Recommendations 
It is recommended that a new work-up of the BC-2-NMT assay be 
developed. The incubation of substrates with enzyme is acceptable; however, 
the subsequent work-up and analysis of 2,9-Me2N H + should be modified. The 
new work-up/analysis should be simple, e.g., spectrophotometric analysis of 
2,9-Me2NH+ formed or liquid scintillation counting of tritiated 2,9-Me2NH + 
product. This can only be accomplished if radioactive substrates and products 
can be completely separated either physically (using SPE, liquid extraction) or 
"analytically" based on differences in spectral properties. Separat.ion based 
on spectral characteristics is probably not possible unless a coupled assay is 
developed since BCs, MeBCs+, and SAM exhibit overlapping ultraviolet and 
fluorescent spectra. 
Purification Overview 
General Backi:round 
A series of laboratory guides published by Pharmacia will be the 
primary references utilized during the chromatographic isolation of BC-2-
NMT (Pharmacia 1991; Pharmacia 1993a; Pharmacia 1993b; Pharmacia ). These 
guides describe in detail the practical aspects of preparing, using, and 
maintaining various chromatographic resins. The books "Protein 
Purification: Principles and Practice" by Scopes (1994a) and "Guide to Protein 
Purification" by Deutscher (1990) were utilized throughout BC-2-NMT 
partial-purification. 
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Summary of Results 
A graphical summary of the experimental results to be discussed 
further in this chapter is presented in Figure 21. The starting material for BC-
2-NMT purification was the 100,000xg supernatant from whole bovine-brain 
homogenate. This cytosolic supernatant generally exhibited a BC-2-NMT 
specific activity of 15-20 pmol/h/mg protein, using the assay conditions 
defined in the "Conclusions" of Chapter 3. 
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Figure 21. Summary of BC-2-NMT purification results (details in chapter). 
Key: each bar represents 1-2 steps ju sequence 
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.LJ::il4..l.2,.S..Q.:i .. !i0-80%/DEAE: 60-80% ammonium sulfate fraction from bovine brain cytosol 
dissolved in pH 7 imidazole buffer, then subjected to batch chromatography on DEAE-
Sephadex (anion exchange matrix). BC-2-NMT activity (represented by bar) was eluted 
from the matrix with pH 7 imidazole buffer containing 0.3 M NaCl. 
Green 19/Green 5: Bovine brain cytosol was applied to a Green 19 dye column. eluate from 
this column was applied to a Green 5 dye column. BC-2-NMT activity (represented by bar) 
was eluted from Green 5 dye column using pH 7.4 Na2HP0 4 containing 3 M NaCl. 
DEAE/SAH-Affinjty: DEAE-Sephadex batch chromatography elute (above) applied to an S-
adenosyl-L-homocysteine affinity column. BC-2-NMT activity (represented by bar) was 
eluted from the column with pH 7 imidazole buffer containing I M NaCl. 
BC-Affinity: Bovine brain cytosol in 20 mM Na2HP04 (pH 7.3)/150 mM KC! was applied to 
a 8-carboline affinity column. BC-2-NMT activity (represented by bar) was eluted from the 
column using a I mM buffered norharman solution . 
.LJ::il4..l.2,Sil:t~ supernatant from 40% ammonium sulfate fractionation was applied to a 
octyl-agarose (C8) hydrophobic interaction chromatography column. BC-2-NMT activity 
(represented by bar) was measured in application flow-through. 
lli!Li..l.2,£14~ supernatant from 40% ammonium sulfate fractionation was applied to a 
pentyl-agarose (CS) hydrophobic interaction chromatography column. BC-2-NMT activity 
(represented by bar) was measured in application flow-through. 
Green 19: column chromatography (same conditions as above) on a Green 19 dye column 
60-80% CNH112,s.14.:. the 60-80% ammonium sulfate fraction (desalted) 
40-60% CNH!~s.14.:. the 40-60% ammonium sulfate fraction (desalted) 
Cytosol: bovine brain cytosol, typically the starting material for each step above 
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Ammonium Sulfate Precipitation Experiments 
Theory 
This technique exploits the effect of salt on protein conformation and 
therefore solubility; proteins with variable amino acid compositions can be 
separated based on their behavior at different electrolyte concentrations. This 
method is discussed in detail by Scopes (1994b). In practice, ammonium 
sulfate is added at low temperature and in small portions. The mixture is 
centrifuged to pellet precipitated proteins and additional precipitant is added 
to the resulting supernatant; the mixture again centrifuged, and so on. 
Proteins are fractionated (precipitated) based on their individual solubilities 
in progressively more concentrated salt solutions or organic solvents. 
Materials and Methods 
Preparation of Fractions 
Bovine brain cytosol (12 ml) -- containing 20 mM Na2HP0 4 (pH 7.4), 
150 mM KCl, 1 mM OTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and 
pepstatin A (1 µg/ml) -- was thawed from -80 °C. The aliquot had been stored 
at -80 °C for 2 months prior to use. A sample, representing "control cytosol", 
was retained for protein and BC-2-NMT assays. The starting material was 11.0 
ml of thawed cytosol. Ammonium sulfate precipitation of cytosolic proteins 
was accomplished at 5-10 °C with constant stirring, by adding solid (NH4hS 0 4 
to either cytosol ("0-40% cut") or the supernatant resulting from the previous 
cut. Supernatant and pellet (cut) were separated by centrifugation at 10,000 xg 
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for 10 minutes at 0-5 °C. The following ammonium sulfate fractions were 
prepared: 0-40%, 41-60%, and 61-80% saturation with respect to (NH.1)2S O.t. The 
resulting (NH4)2S 04 pellets were dissolved in 2.0 ml of l 50 mM KCI containing 
10 mM Na2HP04 at pH 7. If necessary, fraction pH was adjusted to pH 7. 
Solutions were filtered through a 0.2 µm polysulfone syringe filter to remove 
particulates and denatured protein. The turbid solution resulting from 
reconstitution of the 0-40% pellet could not be filtered, probably due to the 
presence of large particles or protein aggregates that clogged the filter; 
therefore, the sample could not be desalted and assayed as such. The filtered 
solutions derived from the 41-60% and 61-80% samples (0.5 ml of each) were 
desalted using ultradiafiltration against buffer (150 mM KCI, 10 mM Na2HPO.t at 
pH 7) on a Centricon 30 concentrator. Total protein and BC-2-NMT activity 
were determined in desalted and non-desalted samples, except as noted. 
BC-2-NMT Assay 
Details of the assay and work-up are described in Chapter 3. In this 
experiment reactants were present at the following concentrations: 9-McNH 
(540 µM), SAM (105 µM, 2.98 µCi), and 100 µI of indicated fraction containing 
BC-2-NMT activity. 
Protein Determination 
Protein was assessed using a modification of the Lowry method as 
described in the Appendix A. 
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Results 
"Control cytosol" contained 81 mg of total protein and 2146 pmol/h of 
BC-2-NMT activity -- therefore, its specific activity was 26.6 pmol/h/mg 
protein. Figure 22 depicts BC-2-NMT specific activity present in cylosol and 
indicated (NH4)i S 0 4 fraction prior to desalting the fraction. The sum of lhe 
protein in each (NH4)iS 04 fraction (excluding the 60-80% supernatant) was 41 
mg; this represents 51 % of the protein present in the original cytosol. With 
respect to BC-2-NMT activity, 1023 pmol/h (48% of the original cytosolic 
activity) was recovered in the summed (NH4)zS 0 4 fractions. 
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Figure 22. BC-2-NMT activity in crude cytosol and fractions resulting from 
precipitation with ammonium sulfate. Fractions were not desalted prior to 
assays. Values next to bars represent BC-2-NMT activity in that fraction. 
The results presented in Figure 23 indicate that desalting (NH4)2S 04 
fractions prior to use in BC-2-NMT assays increases the measured BC-2-NMT 
activity. Total protein was affected less drastically by desalting. 
~ 
0 
00 
83.9 
~- 66.6 
~ 
0 
\0 
42.2 
~. 22.9 Not Desalted Desalted 
0 20 40 60 80 
BC-2-NMT SPECIFIC ACTIVITY 
(pmol/h/mg protein) 
100 
Figure 23. The effect on BC-2-NMT activity of desalting ammonium sulfate 
fraction. Fractions were desalted using ultradiafiltration on a Ccntricon 30 
concentrator. 
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Discussion 
The presence of ammonium sulfate affects both the Lowry protein and 
the BC-2-NMT assays. The Bradford assay would be a better choice regarding 
protein measurement in these samples since it is not affected by the presence 
of (NH4)iS04 (Petersen 1983). This experiment shows that removal of (NH.ihSO.i 
from the fraction prior to its utilization in the BC-2-NMT assay increases the 
measured specific activity 1.2 to 1.8-fold. 
Screenin~ Experiment for Bindin~ of BC-2-NMT to Ion-Exchani;e 
ChromatoJi:raphy Matrices in Batch Mode 
as a Function of Buffer pH 
Theory 
Ion exchange chromatography allows for separation of molecules based 
on charge; anion exchangers contain positively charged groups such as 
quaternary amines or diethylaminoethyl (DEAE), which interact with sample 
molecules possessing negative charges. Cation exchangers, possess negatively 
charged groups such as a sulfonic acid or carboxymethyl (CM) side-chains; 
these resins interact with sample molecules that are positively charged. Both 
pH and ionic strength are manipulated in order to affect the interaction of 
sample molecules with the anion exchanger. In general, low ionic strength 
conditions favor binding to ion exchangers. Lower pH buffers (pH 4-8) are 
used in cation chromatography, and higher pH buffers (pH 5-9) are used in 
anion chromatography. Proteins are then eluted using an increasing salt 
gradient. Fractions from the column are collected and assayed for total protein 
content and protein of interest. 
Materials and Methods 
Ion-Exchange Resins 
Ion-exchange resins were obtained in the dry-state from Pharmacia. 
Technical information pertaining to each of the Sephadex resins is 
summarized in Table 9. 
Table 9.--Properties of Evaluated Ion-Exchange Resins 
Description 
Functional group 
Matrix 
Particle size 
Capacity 
Swelling Ratio 
Ion-Exchange Resin 
DEAE Sephadex A-50 
weakly basic 
anion exchanger 
diethyl aminoe th yl 
cross-linked dextran 
40 - 120 µ 
3.5 ± 0.5 mmoles/g 
varies with pH 
and ionic strength 
CM Sephadex C-50 
weakly acidic 
cation exchanger 
carboxymethyl 
cross-linked dextran 
40 - 120 µ 
4.5 ± 0.5 mmoles/g 
varies with pH 
and ionic strength 
Sephadex resins (10 g) were swelled in about 500 ml of IO mM Na2HP0 4 
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(pH 7.4) and subsequently stored in a capped jars at room temperature. These 
resins were equilibrated in other buffers as indicated in subsequent 
experiments. 
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Ion-Exchange Buffers 
Buffers were prepared as 1 M stock solutions that were diluted to the 
required strength for individual procedures. The respective buffer salt was 
dissolved in Milli-Q water, the pH was adjusted using either NaOH or HCI, and 
the solution was diluted with Milli-Q water to the final volume. The huffcr and 
corresponding pH utilized in anion and cation exchange chromatography 
protocol are summarized in Table 10. 
Table 10.--lon-Exchange Chromatography Buffers 
Anion Exchange Buffers llH Supplier 
Piperazine chloride 5 Sigma 
Bis-tris chloride 6 Sigma 
Bis-tris chloride 7 Sigma 
Tris hydrochloride 8 Sigma 
Ethanolamine chloride 9 Sigma 
Cation Exchange Buffers 
Sodium acetate 5 Merck 
Sodium malonate 6 Eastman 
(di basic) 
Sodium phosphate 7 Fisher 
(mono basic) 
HEPES (sodium salt) 8 Sigma 
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Batch Chromatof;raphy 
Bovine brain cytosol (6 ml) -- containing 20 mM Na2HPO.i (pH 7.4), 
150 mM KCI, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and 
pepstatin A (1 µg/ml) -- was thawed from -80 °C. The aliquot had heen stored at 
-80 °C for 3 days prior to use. The sample was concentrated 4-fol<l to 1.25 ml 
using a Centricon 30 concentrator. 
Ion-exchange resins were equilibrated at room temperature using the 
buffers (diluted to 0.05 M) listed in Table 11. Approximately 1.5 ml of each 
Sephadex slurry was transferred to a 1.5 ml microcentrifuge tube. The tubes 
were centrifuged briefly in order to pack the gel, and the resulting 
supernatant was discarded. The appropriate buffer (100 µI) and 100 µI of 
concentrated cytosol were added to each of the tubes containing packed resin. 
The contents of the tubes were mixed on a lab rocker for 15 minutes at room 
temperature. Sephadex gel was settled with a brief centrifugation, and 150 µI 
of the resulting supernatant was transferred to a clean microcentrifuge tube. 
Supernatants were analyzed for BC-2-NMT activity and total protein. 
BC-2-NMT Assay 
Assay components were present as follows: 9-MeNH (540 µM), SAM (150 
µM, 3.72 µCi), and 100 µI of concentrated cytosol or 100 µI of supernatant 
derived from one of the nine ion-exchange chromatography conditions 
described above. Assay volume was 370 µI, pH was 8.5, and assay was 
maintained at 37 °C for one hour. Details of the BC-2-NMT assay may be found 
in Chapter 3. 
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Protein Determination 
Protein was determined as described in the Appendix A. 
Results 
DEAE-Sephadex Chromato~raphy 
As depicted in Figure 24, BC-2-NMT activity is retained by the anion 
exchange resin more extensively than total protein, and retention of BC-2-
NMT activity increases as pH increases. The largest difference between BC-2-
NMT activity bound and total protein bound occurs at pH 7. 
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Figure 24. Binding of total protein and BC-2-NMT to DEAE-Sephadex as a 
function of equilibration buffer pH. 
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CM-Sephadex Chromato~raphy 
As shown in Figure 25, BC-2-NMT activity binds to the cation exchanger 
to a lesser degree than total protein. BC-2-NMT binding appears to increase as 
a function of increasing equilibration pH. The greatest difference between 
percentage of BC-2-NMT activity and total protein bound occurs at 
pH 5. 
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Figure 25. Binding of total protein and BC-2-NMT to CM-Sephadex as a function 
of equilibration buffer pH. 
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Discussion 
BC-2-NMT generally sticks to both cation and anion exchange resins, 
suggesting that this enzyme is relatively hydrophilic and probably possesses 
both positively and negatively charged patches in its structure. The ideal 
circumstance would be chromatographic conditions in which most of the BC-2-
NMT activity is bound along with very little total protein, or conversely, a 
condition that binds BC-2-NMT activity inefficiently and total protein to a high 
degree. In the screening experiment, at least 60% of applied total protein and 
BC-2-NMT activity are bound by these resins at each pH evaluated. However, 
the greatest difference between BC-2-NMT activity and total protein bound was 
observed at pH 7 for the anion exchanger, and at pH 5 for the cation exchange 
resin. Since a higher percentage of applied BC-2-NMT activity was retained by 
the anion-exchange resin than by the cation-exchange resin, anion exchange 
chromatography at pH 7 was investigated in subsequent experiments. 
Screening Experiment for Binding of BC-2-NMT to 
DEAE-Sephadex in Batch Mode at pH 7 
as a Function of Ionic Strength 
Materials and Methods 
Batch Chromato~raphy 
Bovine brain cytosol (8 ml) containing 20 mM Na2HP04 (pH 7.4), 150 
mM KCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin 
A (1 µg/ml) -- was thawed from -80 °C. The aliquot had been stored at -80 °C 
for 1.5 months prior to use. Prior to concentration on a Centricon 30, the 
aliquot was filtered through a 0.22 µ polysulfone syringe filter (13 mm 
diameter). The filtered sample was concentrated to 25-30 µI overnight in the 
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coldroom. The Centricon retentate was diluted and quantitatively transferred 
to a clean microcentrifuge tube using 600 µl of equilibration buffer (0.05 M 
BIS-TRIS buffer at pH 7). 
Equilibration buffers #2 -#10, of increasing ionic strength (I), were 
prepared as detailed in Table 11 by mixing 5.0 ml of 0.5 M BIS-TRIS buffer (pH 
7) with the listed volume of NaCl stock solution (0.45 M). All solutions were 
brought to a final volume of 50 ml using Milli-Q water. The pH of each buffer 
solution was between pH 6.9-7. 
Table 11.--Preparation of NaCl-BIS-TRIS Buffer Solutions 
for DEAE-Sephadex Batch Chromatography 
Buffer 0.45 M NaCl I = Final Ionic 
# (ml) Strength CM) 
1 0 0.05 
2 5 0.10 
3 10 0.15 
4 15 0.20 
5 20 0.25 
6 25 0.30 
7 30 0.35 
8 35 0.40 
9 40 0.45 
10 45 0.50 
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Initially 25 ml of DEAE-Sephadex was equilibrated in buffer #1 and then 2 ml 
of this slurry was transferred to each of ten 13 x 75 mm glass culture tuhes. 
The tubes were centrifuged briefly in order to pack the gel (1 ml), and the 
resulting supernatant was discarded. The gel in each of the ten tuhes was then 
equilibrated using one of the ten buffers listed in Table 11, transferred to a 1.5 
ml microcentrifuge tube, centrifuged briefly, and the supernatant from gel 
was discarded. The appropriate buffer (80 µl) and 40 µl of concentrated cytosol 
were added to each of the tubes containing packed resin. The contents of the 
tubes were mixed on a lab rocker for 15 minutes at room temperature. The 
resin in each tube was packed by brief centrifugation, and then 50 µl of the 
resulting supernatant was transferred to a clean microcentrifuge tube. 
Supernatants were analyzed for BC-2-NMT activity and total protein. 
BC-2-NMT Assay 
Assay components were present as follows: 540 µM 9-MeNH (275 µl of a 
727 µM stock), 150 µM SAM (20 µL of a 1.928 mM stock), 3.35 µCi 3H-SAM (in 50 
µL), and 25 µl of control cytosol or supernatant derived from one of ten anion-
exchange chromatography conditions described above. Control cytosol was 
prepared by mixing 40 µl of concentrated cytosol with 80 µl of 150 mM KCI. 
Total assay volume was 370 µl, pH was 8.5, and assay was maintained at 37 °C for 
75 minutes. Details of the BC-2-NMT assay and subsequent analysis described 
in Chapter 3. 
Protein Determination 
Total protein was determined using a modified Lowry method as detailed 
in Appendix A. 
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Results 
The sample equilibrated at 0.05 M ionic strength could not be analyzed 
due to a technical problem; therefore results begin with the 0.1 M condition. 
As Figure 26 shows, 70% of the applied BC-2-NMT activity and 45% of total 
protein was retained by DEAE-Sephadex at pH 7 when the ionic strength was 
0.1 M (0.05 M bis-tris buffer plus 0.05 M NaCl). BC-2-NMT binding generally 
decreased as ionic strength increased (except at I = 0.25 M) up to 
I = 0.4 M, where BC-2-NMT retention by the matrix appeared to decrease. 
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Figure 26. Binding of total protein and BC-2-NMT activity to DEAE-Sephadex at 
pH 7 as a function of equilibration buffer ionic strength. 
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Discussion 
A high salt concentration is required to disrupt the electrostatic 
interaction between BC-2-NMT and the positively charged chromatography 
matrix. About 25% of the applied BC-2-NMT activity remains bound to the 
anion-exchange chromatography matrix at I=0.3 M, this suggests that BC-2-
NMT is a relatively hydrophilic, negatively-charged protein. Increased 
binding of BC-2-NMT to the matrix at I > 0.35 M may be due to a change on BC-2-
NMT structure at the higher ionic strength resulting in an exposure of ionic 
groups that may then interact with the matrix. The increased binding could 
also be the result of experimental error. Based on these results a proposed 
DEAE-Sephadex batch chromatography protocol might begin with 
equilibration of matrix and cytosol application at pH 7 in 0.05 M bis-tris buff er 
containing 0.05 M NaCl. The resin would then be washed with equilibration 
buffer to remove loosely bound proteins. Elution of BC-2-NMT could be 
accomplished using 0.05 M BIS-TRIS buffer (pH 7) containing 0.25-0.30 M NaCl 
(total I = 0.30 - 0.35 M). This idea was evaluated in the subsequent experiment. 
DEAE-Sephadex Batch Chromato~raphy 
Scale-Up 
Materials and Methods 
Bovine brain cytosol (55 ml) in 20 mM Na2HP0 4 (pH 7.4), 150 mM KCl, 1 
mM OTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin (1 µg/ml) 
was used in this study; the aliquot had been stored at -80 °C for 2 months prior 
to thawing. An 1 ml aliquot was retained for control assays, and the remaining 
54 ml was stirred magnetically in a polypropylene beaker in an ice-water 
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bath. A 60 - 80% ammonium sulfate pellet was obtained according to 
fractionation procedures previously described. The pellet was dissolved rn 8 
ml 0.05 M imidazole buffer at pH 7. The solution was filtered through a 0.2 µm 
polysulfone syringe filter prior to simultaneous ultradiafiltration and 
concentration on a Centriprep 30 concentrator to a final volume of 1.85 ml. An 
150 µl aliquot was retained for assays, and the remaining 1.7 ml was mixed with 
about 20 ml of DEAE-Sephadex that had been previously equilibrated in 0.05 M 
imidazole buffer (pH 7). The BIS-TRIS buffer used in previous studies was not 
available in sufficient quantity for this study, so imidazole buffer was 
substituted. The mixture was agitated gently on a lab rocker for 20-30 minutes 
at room temperature. Resin was recovered by vacuum filtration on a Buchner 
funnel and the resulting filtrate saved (9.9 ml). The resin was washed while 
on the funnel with 5 ml of equilibration buffer; filtrate volume was 4.4 ml. 
The resin was transferred to a polypropylene tube containing 3 ml of 0.05 M 
imidazole buffer (pH 7) plus 3 M NaCl. The mixture was agitated for 30 minutes 
as described above. The slurry was filtered to recover eluate (7 ml). Initial 
cytosol and subsequent fractions were analyzed for total protein and BC-2-NMT 
activity. 
BC-2-NMT Assay 
Assays were done according to details presented elsewhere (Chapter 3). 
Duplicate assays were prepared for each fraction evaluated; assays contained 
9-MeNH (540 µM), SAM (105 µM, 3.65 µCi) at pH 8.5 plus 100 µl concentrated 
column fraction or initial cytosol. In addition, blank assays were prepared 
which lacked 9-MeNH, but contained all other components. 
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Protein Determination 
The modified Lowry method was used in the assessment of total protein 
in cytosol and column fractions (Appendix A). 
Results 
The overall yield of BC-2-NMT activity from this procedure was poor 
(7%). The purification from cytosol to the final 0.3 M NaCl eluate was 14.4-fold. 
Results are summarized in Table 12 and include initial cytosol, desalted 60-80% 
(NH4 )zS04 fraction ("60-80%"), and high salt eluate from the DEAE-Sephadex 
("0.3 M NaCl"). The percentages in parentheses in Table 13 represent the 
fraction yield from initial cytosol. The purification factor is the increase in 
specific activity from the previous step. 
Table 12.--Purification Results for Ammonium Sulfate Fractionation 
Followed by DEAE-Sephadex Batch Chromatography 
Protein BC-2-NMT Specific Activity Purification 
Fraction Cmi:) (pmole/h) Cpmol/h/m ~) Factor 
Cytosol 396 10098 25.5 
60 - 80% 28 1056 (10%) 37.7 1.5 
0.3 M NaCl 1.96 721 (7.1 %) 368 9.8 
A 60%-80% (NH4)zS 04 fraction prepared from bovine brain cytosol (100,000 x g 
supernatant) was dissolved in pH 7 imidazole buffer (equilibration buffer), 
and applied in batch-mode to DEAE-Sephadex resin. After washing the resin 
with equilibration buffer, BC-2-NMT was eluted with pH 7 imidazole containing 
0.3 M NaCl. 
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Discussion 
Excessive loss in total BC-2-NMT (90%) suggests that the 60-80% 
(NH4)2S04 fractionation-step should be excluded from subsequent studies. 
These results are encouraging with respect to purification using batch 
chromatography on DEAE-Sephadex. A nearly IO-fold purification was 
achieved during batch chromatography, and the yield for this step alone was 
reasonable at 68%. Suggestions for future studies include: DEAE-Sephadex 
batch chromatography under these conditions except exclude the (NH4)2S 0 4 
fractionation step, and to use dialysis to bring bovine brain cytosol to resin 
equilibration conditions (0.05 M imidazole buffer, pH 7) prior to mixing with 
resin. 
Binding of BC-2-NMT Activity to 
Dye Chromatography Columns 
Background 
Dye chromatography is a subset of affinity chromatography, in which 
polycyclic-aromatic dyes are covalently attached to a chromatography matrix 
such as agarose. Interaction between dye and enzyme may occur 
biospecifically as a result of the structural similarity between certain dyes and 
nucleotide cofactors required by the enzyme. Conversely, interaction between 
the immobilized dye and protein of interest may be nonspecific, via ionic or 
hydrophobic mechanisms. 
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Materials and Methods: 
Dye Screening Experiment 
Column Chromatoi:raphy 
Dye resin Test Kit No. RDL-9 was purchased from Sigma Chemical 
Company (St. Louis, MO). Column bed volumes were pre-packed at 2.5 ml; the 
multi-dye test kit contained nine columns with different dye-agarose 
substitutions. Characteristics of the nine columns supplied in the kit are listed 
in Table 13. 
Table 13.--Components of Multi-Dye Test Kit 
Cataloi: # Dye Substitution Identification 
CB-5 Cibacron Blue Cib. Blue 
RG5-5 Reactive Green Green 5 
RBI0-5 Reactive Brown Brown 10 
RB72-5 Reactive Blue 72 Blue 72 
RB4-5 Reactive Blue 4 Blue 4 
RY86-5 Reactive Yellow 86 Yellow 86 
RY3-5 Reactive Yellow 3 Yellow 3 
RR-120-5 Reactive Red 120 Red 120 
RG-19-5 Reactive Green 19 Green 19 
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Each dye column was equilibrated with 5-10 column volumes of 
equilibration buffer in the coldroom at 0-5 °C; buffer contained 10 mM 
Na2HP04 at pH 7.3. It was necessary that bovine cytosol be present in the same 
buffer prior to application to dye columns; therefore, solvent exchange on a 
PDlO desalting column (Sephadex G-25M, Pharmacia) was utilized to prepare 
cytosol in equilibration buffer. 
Bovine brain cytosol in 20 mM Na2HP04 (pH 7.4), 150 mM KCl, 1 mM OTT, 
1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin (1 µg/ml) was used 
in this study; the aliquot had been stored at -80 °C for 5 months prior to use. 
Details of solvent exchange procedure follow: each of three Pharmacia PDlO 
columns was equilibrated with equilibration buffer. Cytosol (2.5 ml) was added 
to each desalting column, and protein was eluted using 3.5 ml of equilibration 
buffer. Eluates (10.5 ml total) from these columns were collected and 
combined; 1.5 ml was retained and represented "control cytosol". 
One ml (3 .2 mg protein) of "control cytosol" was applied to each of the 
nine equilibrated dye columns at 0-5 °C. Flow-through from each column was 
collected independently into 13 x 100 mm polypropylene tubes. Columns were 
washed with 6.0 ml of equilibration buffer; this wash was combined with the 
previous column flow-through (total volume 7.0 ml). A control sample was 
prepared by mixing 1.0 ml of "control cytosol" with 6.0 ml of equilibration 
buffer to yield 7 .0 ml total sample volume. Samples were evaporated to dryness 
using a Speed Vac concentrator at ambient temperature. Each residue was 
reconstituted using 500 µI of Milli-Q water. The pH of each sample was in the 
range 7-8 as expected. These solutions were assayed for total protein and BC-2-
NMT activity as described below. 
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The goal of the screening experiment was to identify one "positive ( + )" 
column and one "negative (-)" column. By definition the "positive" column 
binds most of the BC-2-NMT activity and less total protein, whereas the 
"negative" column binds very little BC-2-NMT activity and a relatively high 
quantity of total protein. 
BC-2-NMT Assay 
Assay components were present as follows: 9-MeNH (540 µM), SAM (150 
µM, 3.69 µCi), and 100 µl of concentrated cytosol or column fraction. Assay 
volume was 370 µl, pH was 8.5, and assay was maintained at 37 °C for one hour. 
Details of the BC-2-NMT assay are in Chapter 3. 
Protein Determination 
Total protein was determined using a modified Lowry method as detailed 
in the Appendix A. 
Results: Dye Screening Experiment 
As Figure 27 shows, the "Green 19" column retained approximately 60% 
of the total protein applied and did not bind any detectable BC-2-NMT activity; 
therefore, the "Green 19" column was defined as the "negative" column. The 
"Green 5" column bound all of the applied BC-2-NMT activity and 60% of the 
applied protein; the "Green 5" column was therefore designated the "positive" 
column. "Yellow 86" and "Yellow 3" dye columns retained little if any protein 
or BC-2-NMT activity. 
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Figure 27. Total protein and .BC-2-NMT activity retained by various dye 
chromatography columns. Values above the bars represent .BC-2-NMT activity 
(pmol/h/mg protein) of column eluate. "Green 19" is designated "negative" 
since it does not bind .BC-2-NMT. "Green 5" is designated "positive" since it 
retains 100% of the applied activity. 
Discussion: Dye Screening Experiment 
These results suggest that the "Green 19" and "Green 5" dye 
chromatography columns may be used in sequence for the purification of BC-
2-NMT activity from bovine brain cytosol. Specifically, bovine brain in 
equilibration buffer could be applied to the "Green 19" column. The "Green 
19" column flow-through combined with the column wash could subsequently 
be applied to a "Green 5" column. .BC-2-NMT activity could then be eluted from 
the "Green 5" column using a high salt buffer or other eluent. The proposed 
experiment is presented below. 
Materials and Methods: 
Chromatography on Green Dye Columns 
Experiment 1 
Column Chromato~raphy 
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Cytosol used in this experiment contained 20 mM Na2HP04 (pH 7.4), 150 
mM KCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pcpstatin 
(1 µg/ml); the aliquot had been frozen at -80 °C for 14 months. PDIO desalting 
columns were utilized to bring bovine brain cytosol to equilibration buffer 
conditions (10 mM Na2HP0 4 at pH 7.3). All subsequent steps were carried-out rn 
the coldroom at 0-5 °C. "Green 19" and "Green 5" columns (2.5 ml) were 
equilibrated using 5 column volumes of equilibration buffer. A portion of Lhe 
PD 10 column eluate was reserved for control assays. 
The PDlO column eluate (5.4 ml) was applied to the "Green 19 
(negative)" column and the column was washed with 5 ml of equilibration 
buffer. Sample application flow-through and wash were combined (10.0 ml 
total). A 2.0 ml aliquot of this solution was concentrated using a Centricon 30 
concentrator. The remaining solution (8.0 ml) was applied to the "Green 5 
(positive)" column. This column was washed with 5 ml of equilibration buffer, 
and the wash was combined with flow-through from sample application (12.0 
ml total). A 2.0 ml aliquot was concentrated completely using a Centricon 30 
concentrator. BC-2-NMT activity was eluted from the "Green 5 (positive)" 
column with 5 ml 10 mM Na2HP0 4 containing 2 M NaCl (pH 7.3). Eluate was 
collected (5.0 ml) and a 2.0 ml aliquot was concentrated as described above. 
Centricon 30 concentration was achieved overnight in the coldroom. 
Centricon retentates (25-30 µl) were diluted in 300 ul of equilibration buffer; 
these concentrated solutions were used in the BC-2-NMT and protein assays. 
132 
BC-2-NMT Assay 
Assay components were present as follows: 9-MeNH (540 µM), SAM (105 
µM, 3.01 µCi), and 100 µl of concentrated cytosol or column fraction. Assay 
volume was 370 µl, pH was 8.5, and assay was maintained at 37 °C for one hour. 
Details of the BC-2-NMT assay are in Chapter 3. 
Protein Determination 
Total protein was determined using modified Lowry method as detailed 
in the Appendix A. 
Results: 
Chromatography on Green Dye Columns 
Experiment 1 
Results are shown in Table 14. 
Table 14.--Recovery of BC-2-NMT Activity and Total Protein During 
Reactive Green Dye Column Chromatography 
Volume BC-2-NMT Protein Specific Activity 
Fraction Lmll Cpmol/h) ~ (pmol/h/mg) 
Cytosol (applied to 5.4 426 13.46 31.6 
"Green 19" column) 
"Green 19" wash plus 10 583 7.68 75.9 
flow-through (W/FT) 
"Green 19" W/FT 8 466 6.14 75.9 
applied to "Green 5" 
""Green 5" wash plus 12 301 4.09 73.6 
flow-through 
"Green 5" eluate 5 82 0.63 130 
(2 M NaCL/buffer) 
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These data are summarized graphically in Figure 28. "Green 19 
(negative)" column results were similar to the results obtained in the 
screening experiment: in the present study 43% of the total protein applied to 
the column was retained by the "Green 19" column, since 57% of applied 
protein was measured in the flow-through plus wash from this column. As 
predicted from the screening experiment, none of lhe applied BC-2-NMT 
activity was bound by the "Green-19" column. However, the "Green 5 
(positive)" column results differed from those in the screening experiment: 
in this study 67% of applied protein (compared to 40% previously) and 64% of 
applied BC-2-NMT activity (0% previously) were present in the flow-through 
plus wash from the "Green 5" column. In other words, in this experiment 
only 36% of the BC-2-NMT activity that was applied to the "Green 5" column 
was retained by that column, whereas in the screening experiment 100% 
retention was observed. Most of the BC-2-NMT activity retained by the "Green 
5" column was effectively eluted from that column by the buffered 2 M NaCl 
wash, while 18% of the applied activity remained bound to the "Green 5" 
column after 2 M NaCl elution. 
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Figure 28. BC-2-NMT activity in fractions from reactive green dye columns. 
Chromatographic steps: (1) Cytosol was applied to the "Green 19" column. (2) 
Flow-through and wash from the "Green 19" column was applied to the "Green 
5" column. (3) "Green 5" column was washed with buffered 2 M NaCl to elute 
BC-2-NMT activity. 
Discussion: 
Chromatography on Green Dye Columns 
Experiment 1 
The major difference in from this study compared to the screening 
experiment is the lack of complete retention of BC-2-NMT by the "Green 
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(positive)" column. There are three possible explanations for this observation: 
(1) the previous experiment is not reproducible, (2) the "Green 5" column 
capacity was exceeded in this study with respect to protein and specifically BC-
2-NMT binding, or (3) the column was contaminated from previous study and 
binding efficiency consequently decreased. A new "Green 5" column with an 
8-fold greater bed volume will be utilized in "Experiment 2". If the steps 
beginning with the "Green 5" sample application are considered: 77% of the 
protein applied to the column is accounted for in either the "Green 5" flow-
through/wash (67%) and salt elution (10%) from the column. BC-2-NMT 
activity recovered in those two fractions were 82%; i.e., 64% of the BC-2-NMT 
activity applied to the "Green 5" column was found in the column flow-
through plus wash, while 18% of the applied activity resided in the high salt 
eluate from the column. This suggests that 23% of the total protein and 18% of 
the BC-2-NMT activity, respectively -- actually applied to the "Green 5" column 
remained bound to that column after the high salt wash. 
A modification of this experiment incorporated the use of clean 
Reactive Green Dye columns, each with an 8-fold greater bed volume. In 
addition, the final NaCl wash was increased from 2 M to 3 M NaCl. The details of 
that experiment are described below. 
Materials and Methods: 
Chromatography on Green Dye Columns 
Experiment 2: Scale-Up 
Column Chromato~raphy 
Reactive Green 19 on 4% beaded agarose (catalog no. R-2882) and 
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Reactive Green 5, crosslinked on 4% beaded agarose were obLained from Sigma 
Chemical Company (St. Louis, MO). Slurries of each dye chromatography 
matrix were filled into each of two empty 12 cm x 1.5 cm EconoPrep 
polypropylene columns (BioRad); each bed volume was approximately 20 ml. 
Dye columns were equilibrated with 5-10 column volumes of equilibration 
buffer in the coldroom (0-5 °C); buffer contained 10 mM Na2HP04 at pH 7.3. It 
was necessary that bovine cytosol be present in the same buffer prior to 
application to dye columns; therefore, solvent exchange on a PDlO desalting 
column (Sephadex G-25M, Pharmacia) was utilized to prepare cytosol in 
equilibration buffer. Bovine brain cytosol in 20 mM Na2HP0 4 (pH 7.4), 150 mM 
KCl, 1 mM DTT, and 1 mM EDT A was used in this study; the aliquoL had been 
stored at -80 °C for 1 month prior to use. The solvent exchange procedure was 
identical to previous experiments. 
Brain cytosol (9.4 ml) was applied to the equilibrated "Green 19" dye 
column at 0-5 °C. The column was washed with 20 ml of equilibration buffer. 
Flow-through from sample application was combined with column wash (27 
ml), and a 5.0 ml aliquot was concentrated to 500 µl using a Ccntricon 30 
concentrator. The concentrate was used for total protein and BC-2-NMT assays. 
The remaining unconcentrated eluate from the "Green 19" column (22 ml) was 
applied to the equilibrated "Green 5" column. This column was washed with 20 
ml of equilibration buffer, and this wash was combined with the sample 
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application flow-through (41 ml total). A 5.0 ml aliquot was concentrated to 
500 µ1 using a Centricon 30 concentrator. BC-2-NMT activity was eluted from 
the "Green 5" column with 10 mM Na2HP04 (pH 7.4) containing 3 M NaCl, and a 
5.0 ml sample of this eluate was concentrated to 500 µI. 
BC-2-NMT Assay 
Assays were done according to details presented elsewhere (Chapter 3). 
Duplicate assays were prepared for each fraction evaluated; assays contained 
9-MeNH (540 µM), SAM (105 µM, 3.65 µCi) at pH 8.5 plus 100 µl concentrated 
column fraction or initial cytosol. In addition, blank assays were prepared 
which lacked 9-MeNH, but contained all other components. 
Protein Determination 
The modified Lowry method was used in the assessment of total protein 
in cytosol and column fractions (Appendix A). 
Results: 
Chromatography on Green Dye Columns 
Experiment 2: Scale-Up 
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As summarized in Table 15, this 2-step procedure resulLed in a 17-fold 
purification from cytosol and an overall 9% yield of BC-2-NMT activity. 
Table 15. --Purification Results: Green Dye Chromatography 
BC-2-NMT Protein Specific Activity 
Fraction (pmol/h) (mg) (pmol/h/mg) Purification Yield (%) 
Cytosol 846 45.3 18.7 ------- 100 
"Green 19" 859 11.3 76.0 4 102 
"Green 5" 16 5.2 3.1 -------
(wash) 
"Green 5" 62 0.2 310 17 9 
(NaCl) 
Bovine brain cytosol in equilibration buffer (10 mM Na2HP04 at pH 7.3) was 
applied to a "Green 19" column. The column was washed with equilibration 
buffer. This wash combined with initial eluate was applied to a "Green 5" 
column, the column was washed. BC-2-NMT was eluted using 10 mM Na2HP0 4 
containing 3 M NaCl. 
Note that since a 5 ml aliquot was removed from the "Green 19" column 
flow-through, actual BC-2-NMT activity applied to "Green 5" column was 700 
pmole/h (9.2 mg protein). Very little BC-2-NMT activity (16 pmolc/h or 2% of 
applied) was removed from the "Green 5" column as a consequence of washing 
the column with equilibration buffer. In contrast, 56% (5.2 mg) of the total 
protein applied to the "Green 5" column was eluted from the column during 
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the wash step. The final wash, composed of 20 mM Na2HP0 4 (pH 7.4) and 3 M 
NaCl, eluted 62 pmoles/h BC-2-NMT activity (9% of applied) in 0.2 mg of 
protein. This indicates that 622 pmole/h BC-2-NMT activity and 3.8 mg protein 
remained bound to the "Green 5" column. 
Discussion: 
Chromatography on Green Dye Columns 
Experiment 2: Scale-Up 
This study indicates that dye chromatography on Reactive Green 19 and 
Reactive Green 5 matrices may be useful in the purification of J3C-2-NMT. As 
expected, none of the BC-2-NMT activity was retained by the "Green 19 
(negative)" column. Total protein bound to the "Green 19" column was 34 mg, 
equivalent to 75% of applied protein; this value is higher than the expected 40-
60%. The increased retention of total protein is likely due to the ratio of 
applied protein to column bed volume between studies. In this study this ratio 
was 2.3 (mg protein:column volume) and in the previous investigations the 
ratio of applied protein to column volume was greater. 
The larger column volume probably accounts for the poor yield of BC-2-
NMT activity from the "Green 5" column. Improved recovery from the "Green 
5 (positive)" column may be possible by using (1) a larger wash volume, (2) a 
"Green 5" column with a smaller bed volume, (3) an alternate eluent (e.g., 
dilute acetic acid, reactive green dye 5). 
Hydrophobic Interaction Column 
Chromatography of BC-2-NMT 
Background 
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Hydrophobic interaction chromatography (HIC) enables the separation 
of molecules based on their hydrophobicity. Hydrophobic interactions 
between sample components and the HIC matrix are favored under conditions 
of high salt. Therefore, samples are usually applied to HIC columns in a high 
salt buffer, with the same buffer being utilized to equilibrate the column. 
Successive elution of bound protein is achieved using a either a step or 
continuous gradient of decreasing salt concentration. Collected fractions are 
assayed for total protein and protein of interest. 
Materials and Methods: Screening Experiment 
at Low Ionic Strength 
Column Chromatography 
A "Hydrophobic Interaction Chromatography Test Kit" (kit no. MAA-8) 
containing eight pre-packed 2.5 ml columns was obtained form Sigma 
Chemical Company (St. Louis, MO). Columns were manufactured to contain 
hydrophobic ligands of a discrete carbon number covalently attached to 
agarose (agarose--(CH2)nCH3) as indicated in Table 16. 
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Table 16.--Components of HIC Test Kil 
Car hons (#) Catalog # HJC Matrix 
2 E 1879 ethyl agarosc 
3 p 5268 propyl agarose 
4 B 6882 butyl agarose 
5 p 5393 pentyl agarose 
6 H 1882 hexyl agarose 
8 0 6376 octyl agarose 
10 D 3013 decyl agarose 
12 D 2264 dodccyl agarose 
Columns were conditioned with 10 column volumes of equilibration buffer 
at room temperature and then stored in the coldroom. Equilibration buffer 
contained: 150 mM KCl, 20 mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM DTT, and 10% 
glycerol. A 50 ml aliquot of bovine brain cytosol (in equilibration buffer) was 
thawed from storage at -80 °C ( 1 month). In the coldroom, a 2.5 ml sample of 
cytosol was applied to each HIC column. The sample application flow-through 
(''S") from each column was collected into polypropylene tubes and placed on 
ice. Each column was subsequently washed with 3 column volumes (7 .5 ml) of 
cold equilibration buffer. The washes ("W") were collected into 
polypropylene tubes and saved on ice. Finally, each column was eluted with 
2.5 ml of dilute buffer containing 20 mM Na2HP04 (pH 7.4), 1 mM EDTA, and 1 
mM DTT. Eluates ("E") were saved as above. All fractions (''S", "W", and "E") 
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were analyzed for total protein content, but only "S" and "E" fractions were 
assayed for BC-2-NMT activity. 
BC-2-NMT Assay 
Assays were done according to details presented elsewhere (Chapter 3 ). 
Assays contained 9-MeNH (540 µM), SAM (105 µM, 3.208 µCi) at pH 8.5 plus 100 µl 
column fraction or original cytosol. 
Protein Determination 
The modified Lowry method was used in the assessment of total protein in 
cytosol and column fractions (Appendix A). 
Results: Screening Experiment 
at Low Ionic Strength 
Figures 29 and 30 show the percentage of applied protein or BC-2-NMT that 
was not retained by each HIC column; i.e., the plot shows the percentage of 
applied protein or BC-2-NMT found in the sample application flow-through 
(''S") or final eluate ("E") fractions for each column. 
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Figure 29. Total protein and BC-2-NMT activity not retained by HIC columns 
during sample application under low ionic strength (I = 0.17 M) conditions. 
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Figure 30. Total protein and BC-2-NMT activity eluted from HIC columns using 
a buffer of lower ionic strength (I = 0.02 M) than application buffer. 
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Table 17 shows the percentage of applied total protein that was recovered in 
column fraction (''S", "W", and "E"), the sum total of those fractions, and the 
calculated amount of total protein remaining on the column. 
Table 17 .--Total Protein Recovered in Each Fraction 
From HIC Columns 
Column 
C-2 
C-3 
C-4 
C-5 
C-6 
C-8 
C-10 
C-12 
7 
3 
3 
0 
0 
0 
4 
0 
% of Applied Total Protein in Fraction 
97 
110 
96 
0 
123 
6 
8 
3 
0 
0 
2 
4 
8 
2 
6 
4 
104 
113 
101 
4 
131 
8 
18 
7 
On Column 
0 
0 
0 
96 
0 
92 
82 
93 
Bovine brain cytosol in 150 mM KCI, 20 mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM 
DTT, and 10% glycerol (equilibration buffer) was applied to each column, and 
the column flow-through collected (''S"). Columns were washed with 
equilibration buffer ("W"). Final eluate ("E") consisted of equilibration 
buffer lacking 150 mM KCI. 
Discussion: Screening Experiment 
at Low Ionic Strength 
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This experiment would have been more meaningful and complete if BC-
2-NMT activity had also been measured in the wash ("W") fraction, since 
without those values it is impossible to conclude if this activity was in the wash 
fraction or was retained by the column after all treatments. As Table 17 
indicates much of the total protein was removed from the shorter-carbon 
chain HIC columns by the initial wash, whereas the longer-chain HIC columns 
retained total protein quite efficiently. It is possible that substantial BC-2-NMT 
activity may have been removed from the columns during the wash. The 
cytosolic samples were applied under relatively low ionic strength conditions 
because doing so would allow for cytosol to be used directly after subcellular 
fractionation, without the need for solvent exchange, thereby eliminating one 
step. The results with this approach were discouraging since much of the BC-
2-NMT activity did not bind to the HIC columns under these conditions, and that 
loosely bound protein (and possibly BC-2-NMT) was removed from several of 
the columns during the wash step. Therefore, the experiment was repeated 
under conditions which favor hydrophobic interactions, namely sample 
application under high ionic strength conditions. 
Materials and Methods: Screening Experiment 
at High Ionic Strength 
Column Chromato2raphy 
HIC columns were equilibrated in the coldroom with buffer composed of 
2 M (NH4)iS04, 150 mM KCl, and 20 mM Na2HP04 (pH 7.3). An aliquot of bovine 
brain cytosol (30 ml, 89 mg protein, 2296 pmol/h BC-2-NMT) in 150 mM KCl, 20 
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mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM DTT, and 10 % (v/v) glycerol was 
thawed from -80 °C; the aliquot had been frozen for 2 months. The cytosol was 
stirred magnetically and maintained in an ice-water bath while solid 
ammonium sulfate was added to the cytosol to make it 2 M with respect to 
(NH4)zS04 -- equivalent to 45% saturation with respect to (NRi)zS 0 4 . 
Subsequent steps were conducted as described previously in this chapter. The 
supernatant resulting from the 0-45% (NH4)zS 0 4 fraction was applied to 
equilibrated HIC columns (2 ml per column), and sample application flow-
through was collected into polypropylene tubes on ice. Columns were then 
washed with 6 ml of equilibration buffer. This wash was combined with 
sample application flow-through (8 ml total). A "control" sample was 
prepared by mixing 2 ml of the 0-40% (NH4)zS 0 4 supernatant with 6 ml of 
equilibration buffer. These solutions were concentrated completely on 
Centricon 30 overnight. Control solution did not concentrate completely 
(volume = 750 µl); therefore 750 µl of 10 mM Na2HP04 (pH 7.4) was added to the 
other Centricon retentates. The concentrated samples were utilized in total 
protein and BC-2-NMT assays. 
BC-2-NMT Assay 
Assays were done according to details presented previously (Chapter 3). 
Assays contained 9-MeNH (540 µM), SAM (105 µM, 3.325 µCi) at pH 8.5 plus 100 µl 
concentrated column fraction or concentrated control cytosol. 
148 
Protein Determination 
The modified Lowry method was used in the assessment of total protein 
in cytosol and column fractions (Appendix A). 
Results: Screening Experiment 
at High Ionic Strength 
Figure 31 reflects the quantity of total protein and BC-2-NMT activity, 
represented as percent of applied, present in the combined sample application 
flow-through plus wash fractions that is total protein and BC-2-NMT not 
bound by the HIC columns. 
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Figure 31. Total protein and BC-2-NMT activity not bound by HIC columns at 
high ionic strength conditions. Values above bars represent BC-2-NMT 
activity in a given fraction. 
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Discussion: Screening Experiment 
at High Ionic Strength 
Since the control solution did not concentrate completely (750 µI 
remained), 750 µI of IO mM Na2HP04 (pH 7.4) was added to the other retentates. 
The control should have been concentrated completely like the other samples, 
because the control was really no longer a true control since it contained a 
high concentration of ammonium sulfate compared to other samples. As a 
consequence, "control BC-2-NMT activity" was low, due to presence of the high 
salt concentration. Therefore, based on previous experience, an assumption 
was made that about 50% of original cytosolic activity was recovered in the 0-
46% (NH4)2S04 supernatant (31 ml), giving 1150 pmol/h BC-2-NMT (calculated) 
and 52.4 mg protein (measured). This is equivalent to 3.4 mg protein and 74 
pmole/hr BC-2-NMT activity applied to each column (per 2 ml). These values 
were used to calculate the percentage of applied protein or BC-2-NMT residing 
in respective column fractions. 
Data indicate that total protein was more effectively retained by the HIC 
matrices than BC-2-NMT in nearly all cases. At high salt conditions, greater 
than 100% of the applied BC-2-NMT activity did not stick to the C3, C4, C6, CS, 
and CIO columns, suggesting that BC-2-NMT is not a very hydrophobic protein. 
The observation that more than 100% recovery was obtained in these fractions 
suggests that: the assumptions in the preceding paragraph are incorrect (i.e., 
applied activity was higher than calculated) or that an inhibitor of BC-2-NMT 
was retained by these columns. No blank BC-2-NMT assays were analyzed in 
this study, therefore it is also possible that the reported BC-2-NMT activity is 
inflated due to a high amount of nonspecific background. Furthermore it is 
possible that column capacity for BC-2-NMT may have been exceed under these 
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conditions. The next section describes experiments in which blank assays 
were prepared, and chromatography repeated under these conditions using C5 
and CS columns with larger bed volumes. 
Materials and Methods: 
C5 and CS HIC Column Chromatography 
Scale-Up 
Column Chromato~raphy 
Pentyl-agarose (catalog #P-5393) and octyl-agarose (catalog #0-6376) 
HIC matrices were obtained from Sigma and filled into each of two 20 ml 
polypropylene EconoPrep columns (BioRad). Columns were equilibrated in the 
coldroom with buffer containing: 2 M (NH4)zS04, 150 mM KCI, 20 mM Na2HP04 , 1 
mM EOTA, and 1 mM OTT. 
A 35 ml aliquot of bovine brain cytosol in 150 M KC!, 20 mM Na2HP0 4, 1 
mM EOTA, and 1 mM OTT was thawed from -SO °C (stored 1 month). The aliquot 
was stirred and chilled in an ice-water bath during the addition of 9 .17S g of 
solid (NH4)zS 0 4 (equivalent to 45% saturation). The pH of the mixture was 
adjusted to pH 7 .3. Ammonium sulfate precipitation was accomplished as 
previously described in this chapter. A two ml aliquot of the supernatant (3S 
ml total) was ultradialyzed and concentrated on a Centricon 30 (final volume = 
300 µl). 
The remaining 0-45% (NH4)zS04 supernatant was applied to each of the 
two HIC columns (1 S ml per column). Sample application flow-through was 
collected and saved on ice in a 150 ml polypropylene container with lid. Each 
column was washed with 40 ml (2 column volumes) of equilibration buffer, 
and this wash was combined with the original column fraction (total volume = 
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55 ml). A 4 ml aliquot of each column fraction was ultradialyzed and 
concentrated on a Centricon 30 concentrator. Final volume of each 
concentrate was 350 µI in 10 mM Na2HP0 4 buffer at pH 7.3. Total protein and BC-
2-NMT activity were measured in each concentrated column fraction, desalted 
0-45% (NH4)2S 04 supernatant, and original cytosol. 
BC-2-NMT Assay 
Assays were carried out according to details presented previously 
(Chapter 3). Assays were prepared in duplicate to contain 9-MeNH (540 µM), 
SAM (105 µM, 2.445 µCi) at pH 8.5 plus 100 µI concentrated column fraction, 
desalted/concentrated (NH4h S 0 4 fraction, or initial cytosol. 
Protein Determination 
The modified Lowry method was used in the assessment of total protein 
in cytosol and column fractions (Appendix A). 
Results: 
CS and C8 HIC Column Chromatography 
Scale-Up 
These results are inconsistent with those in the previous experiment 
where a tremendous increase in specific activity was observed with HIC. 
Purification from cytosol through HIC column eluate was 4.4-fold for the C5 
column eluate, and 5.2-fold C8 column eluates. BC-2-NMT and total protein 
present at each step of purification is summarized in Table 18. Fractions 
include initial cytosol, the supernatant resulting from the 0-45% (NH4)iS 04 
"precipitation step ("0-45%), the material applied to each HIC column, and the 
1S2 
quantity of protein and BC-2-NMT measured in the column flow-through plus 
wash ("Ff /W") fractions from each of the HIC columns ("CS" and "C8). 
Fraction 
Cytosol 
0 - 45% 
HIC applied 
cs (Ff/W) 
C8 (Ff/W) 
Table 18.--Hydrophobic Interaction Chromatography 
Purification Results 
Protein 
331.4S 
86.42 
40.93 
2.743 
1.829 
BC-2-NMT 
Cpmol/h) 
9800 
4236 
2049 
3SS 
281 
Specific Activity 
Cpmol/h/m~) 
29.6 
S0.1 
S0.1 
129.4 
1S3.7 
Supernatant ("0-4S%") obtained following 0-4S% (NH4hS 0 4 fractionation of 
bovine brain cytosol was divided in half and applied to equilibrated pentyl (CS) 
and octyl (C8) columns ("HIC applied"). Composition of equilibration buffer 
was 2 M (NH4)zS04, lSO mM KCl, 20 mM Na2HP04, 1 mM EDTA, and 1 mM OTT. The 
column flow-through and subsequent wash were combined and analyzed ("CS 
Ff/W" and "C8 Ff /W"). 
As expected, ammonium sulfate precipitation resulted in a 1.7-fold 
purification of BC-2-NMT activity from bovine brain cytosol; yield of enzyme 
activity was 44%. For the "CS" column, approximately 83% of the applied BC-2-
NMT activity, and 93% of the total protein remained in association with the 
column following the wash-step. For the C8 column 86% of the applied BC-2-
NMT, and 96% of applied total protein remained bound to the column. 
Discussion: 
CS and CS HIC Column Chromatography 
Scale-Up 
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The enhanced binding of BC-2-NMT activity relative to total protein may 
be due to the increase in bed volume utilized in this study compared lo the 
previous experiment. Based on this experiment, which incorporated better 
controls, it is concluded that the previous experimental results which showed a 
tremendous increase in BC-2-NMT using this protocol were in error. 
Preparation and Evaluation of S-Adenosyl-L-Homocysteine-
Sepharose Affinity Chromatoi;raphy Column 
Materials and Methods: 
SAH-CH-Sepharose Affinity Chromatography 
Couplin~ Reaction 
The goal was to prepare an affinity chromatography matrix in which 
SAH was covalently attached to CH-Sepharose 4B. This was accomplished at 
acidic conditions by reacting CH-Sepharose-4B with SAH in the presence of a 
carbodiimide (Figure 32). 
SAH-CH-Sepharose column was prepared according to Harvima et al. 
(1985) and Pharmacia technical literature (Pharmacia l 993a). The primary 
reactants were purchased from Sigma Chemical Company (St. Louis, MO): 
Reactant 
S-adenos yl-L-homoc ysteine 
1-e thyl-3-(3-di methyl ami nopropyl)-
carbodiimide (HCl salt) 
6-Aminohexanoic acid-Sepharose 4B 
(CH-Sepharose 4B) 
FWT 
384.4 
191.7 
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Catalog # 
A-9384 
E-1769 
A-8769 
The supplier provided the following information regarding the CH-Sepharose 
4B chromatography matrix: 
Matrix: Sepharose 4B 
Activation: cyanogen bromide 
Spacer: provides an 8-atom spacer when ligands are coupled to free 
carboxy groups using a carbodiimide coupling agent 
Extent of Activation: 10-14 µmoles per ml of gel (40-56 µmoles/g dry) 
Form: lyophilized powder stabilized with lactose and dextran 
Swelling Ratio: 1 g swells to approximately 4 ml of gel 
6-aminohexanoic acid 
Sepharose 4B 
generic 
carbodiimid 
~ ,.NR1 + 
Sepharose-NH-(CHz)5-C-O-C 
'NR2 
0 
II 
Sepharose-NH-(CHz)5-C-NH-CH-(CHz)z-S-CHz 
I 
CXDH 
HzN.., 
fH-(CHz)z-S-
HXC 
+ 
ID GI 
I SAH-C H-Sepharose Affinity Column 
ID a-1 
Figure 32. Preparation of S-adenosyl-L-homocysteine (SAH) Sepharose 
affinity chromatography column. 
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The CH-Sepharose 4B (2 g, 80-112 µmoles active groups) was swollen in 
20 ml of 0.5 M NaCl, and then washed on a scintered glass funnel with 500 ml 
0.5 M NaCl followed by 100 ml Milli-Q water at pH 6. SAH (100 mg, 260 µmoles) 
was dissolved in 15 ml of Milli-Q water at pH 4.6-6. The SAH solution was added 
to the CH-Sepharose 4B with minimal stirring on a magnetic stir plate. The 
carbodiimide (235 mg, 1.23 mmoles) was added as a solid in small amounts to the 
stirred SAH and CH-Sepharose mixture. The mixture was transferred to a tube, 
capped, and mixed by rocking on a lab rocker plate. The pH of the coupling 
reaction was checked during the first hour to assure that it remained between 
pH 4.6 and pH 6. The reaction was rocked at room temperature overnight (15-
20 hours). No blocking reaction was done, and the affinity gel was washed 
extensively with Milli-Q water to remove urea product, unreacted SAH, and 
carbodiimide. The gel was stored at 0-5 °C in 2 M KCl and 10 mM K2HP04 (pH 
6.5). The extent of coupling of SAH to CH-Sepharose 4B was not determined. 
Column Chromato~raphy 
Approximately 1 ml of the SAH-CH-Sepharose 4B affinity gel was filled 
into a polypropylene 1 cc tuberculin syringe fitted with a stopcock and 
silanized glass wool plug at the outlet. The column was equilibrated with 10 ml 
of 0.05 M imidazole buffer (pH 7) containing 0.3 M NaCl. The sample (3.5 ml) 
that was applied to the affinity column was the 0.05 M imidazole buffer (pH 7)/ 
0.3 M NaCl eluate derived from DEAE-Sephadex batch chromatography protocol 
described previously in this chapter. The sample application flow-through 
was collected, and a 1.5 ml portion concentrated to 150 µI on a Centricon 30 
concentrator. The column was washed with 2 ml of 0.05 M imidazole buffer 
(pH 7) containing 1 M NaCl. This wash was collected and a 1.5 ml aliquot 
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concentrated to 150 µI. The concentrated solutions were analyzed for BC-2-NMT 
activity and total protein. 
BC-2-NMT Assay 
Details of the assay, work-up, and RP-HPLC analysis are discussed in 
Chapter 3. Assays (pH 8.5) were maintained at 37 °C for one hour. The 
reactions consisted of 9-MeNH (540 µM), SAM (105 µM, 3.30 µCi), and 100 µI of 
respective concentrated column fraction. 
Protein Determination 
Protein measurements were carried-out using a modified Lowry method 
as detailed in Appendix A. 
Results: SAH-CH-Sepharose 4B 
Affinity Chromatography 
Total protein and BC-2-NMT activity recovered in each fraction are 
summarized in Table 19. 
Table 19.--SAH-CH-Sepharose Affinity Chromatography 
Protein BC-2-NMT Specific Activity 
Fraction (mg) Cpmol/h) (pmol/h/mg) 
Applied 0.756 102 135 
Flow-through 0.525 12.3 23.4 
1 M NaCl wash 0.166 32.2 194 
(buffered) 
SAH column equilibrated in 0.05 M imidazole buffer contanung 0.3 M NaCl. 
Sample "Applied" to column was the 0.3 M NaCl eluate from DEAE-Scphadex 
chromatography discussed in a previous section of this chapter. Column 
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"Flow-through" was collected, and then BC-2-NMT was eluted from the column 
with 0.05 M imidazole buffer containing 1 M NaCl ("l M NaCl wash"). 
Regarding total protein: 91 % of the applied protein was accounted for in 
the initial flow-through fraction (0.525 mg, 69%), and following the buffered 1 
M salt wash (0.166 mg, 22%). These results indicate that 0.065 mg (9%) of the 
total protein applied to the column remained bound to the SAH-CH-Sepharose 
4B affinity matrix. 
In contrast, 55% (57 pmol/h) of the applied BC-2-NMT activity remained 
in association with the SAH affinity column, since 12% (12.3 pmol/h), and 32% 
(32.2 pmol/h) of the applied activity was recovered in the flow-through and 
wash fractions, respectively. 
Discussion: 
Affinity 
SAH-CH-Sepharose 4B 
Chromatography 
These results are discouraging since a mere 1.4-fold purification was 
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achieved with respect to BC-2-NMT activity, beginning with application to the 
SAH column (specific activity, 135 pmol/h/mg protein) and ending wilh the 
buffered 1 M NaCl elution (specific activity, 194 pmol/h/mg protein). 
Typically purification by ligand-specific affinity methods is much greater. 
The final eluate did not remove all of the remaining BC-2-NMT activity. In 
fact, 57 pmol/h BC-2-NMT activity and 0.068 mg of total protein remained 
bound to the affinity column. This is equivalent to 838 pmol/h/mg protein BC-
2-NMT specific activity stiII retained by the SAH-CH-Sepharose column. 
These results indicate that a more efficient means of eluting BC-2-NMT 
activity from the SAH-CH-Sepharose 4B affinity column is required, such as 
dilute acetic acid, or affinity elution with SAH or SAM. Due to the high cost of 
SAH and SAM, affinity elution would be quite expensive compared to elution 
with acid. In addition, since BC-2-NMT exhibits a higher affinity for SAH (IC5 o 
= 14 µM) than SAM (KM = 85 µM), it may be impractical to elute BC-2-NMT 
activity from the SAH column using affinity elution with SAM. 
Regarding the preparation and use of SAH-CH-Sepharose affinity 
columns in future studies, the following suggestions are made: 
( 1) preparation of a new affinity matrix, since literature indicates 
that efficiency of an SAR-column decreases as a function of storage 
time (Harvima et al. 1985) 
(2) utilization of more SAH in the coupling reaction 
(3) evaluation of the efficiency of coupling using the method 
described by Harvima et al. (1985), in which a small aliquot of 
coupled gel was hydrolyzed and the liberated SAH analyzed 
using HPLC 
(4) "affinity" elution using an adenosine solution. 
Preparation and Evaluation of B-Carboline-Sepharose 
Affinity Chromatography Column 
Materials and Methods: Experiment I 
Couplin~ Reaction 
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The goal was to prepare an affinity chromatography matrix in which a 
BC was covalently attached to Sepharose 6B. This was done by reacting harmol 
with epoxy-activated Sepharose 6B (EAS) under basic conditions (Figure 33). 
The methods were similar to those described by Hermanson et al. (1992) and in 
the Pharmacia technical literature (Pharmacia 1993a). 
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Figure 33. Scheme for preparation of BC-affinity chromatography column. 
Epoxy-activated Sepharose 6B was purchased as a lyophilized powder from 
Sigma Chemical Company, St. Louis, MO (Catalog # E-6754). The following 
information was provided by the manufacturer: 
Activated group: Sepharose-(1,4-bis(2 :3-epoxypropoxy)butane 
Extent of activation: 19 - 40 µmole per ml of gel 
Spacer-arm length: 12 atoms 
Swelling properties: 1 g swells to 3 ml of gel 
Harmol (1-methyl-9H-pyrido[3 ,4-b ]indol-7-ol) hydrochloride dihydrate was 
purchased from Sigma (FWT 270.7, Catalog #H-1000). 
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Sodium carbonate buffer (100 ml, 0.1 M, pH 10) was prepared by 
dissolving 1.06 g of sodium carbonate (Na2C03, FWT 105.99, Sigma Chemical Co.) 
in 80 ml of Milli-Q water. The solution pH was adjusted to pH 10 and the 
solution brought to 100 ml using Milli-Q water. 
Lyophilized epoxy-activated-Sepharose 6B (1 g) was suspended in 10 ml 
of Milli-Q water and then transferred to a scintered glass funnel. The gel was 
washed with 200 ml of Milli-Q water, exercising care to keep the gel moist. The 
rinsed gel (3 ml) was then washed with 20 ml of Na2C03 buffer and 
subsequently transferred as a slurry (5 - 6 ml) to a small amber vial. 
Due to the limited solubility of BCs under alkaline conditions, harmol 
was dissolved in dimethylformamide (DMF) prior to addition to Na2C 0 3 buffer. 
Harmol (162 mg, 600 µmoles) was dissolved in 2.5 ml of DMF followed by the 
slow addition of Na2C03 buffer (2.5 ml). The pH of the mixture (pH 7-8) was 
adjusted to pH 10 using 8 N and 1 N sodium hydroxide. Harmol (600 µmole) was 
present in a 5-fold excess relative to the maximum number of epoxy-activated 
sites (120 µmole on 3 ml of gel). 
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Harmol solution was combined with the EAS gel slurry in the amber vial 
and capped. The vial contents (10-12 ml total) were maintained for 18 hours at 
40 °C in a shaking water bath. The gel settled to the bottom of the vial during 
this procedure. Ideally the gel should have been maintained as a suspension 
in order to improve the efficiency of the coupling reaction. 
Determination of Couplin~ Efficiency 
The maximum theoretical quantity of harmol that could be covalently 
attached via the epoxy-activated groups was 40 µmoles of harmol per ml of gel 
(40 nmoles harmol per µl gel). 
A 100 ul aliquot of the coupled gel slurry was transferred to a 1.5 ml 
microcentrifuge tube, and then washed repeatedly with Milli-Q water to 
remove free harmol. The gel was washed with 0.1 M HCl, Milli-Q water, and 
finally 10 mM Na2HP04 (pH 7.4). The rinsed gel (30 µl of settled gel) was 
suspended in 970 µL 10 mM Na2HP04 (pH 7.4). Assuming 100% efficiency of the 
coupling reaction, maximally 1200 nmole (1.2 µmoles) of harmol would be 
covalently bound to the 30 µl of gel. Therefore a standard solution was 
prepared to contain 1.2 µmole/ml of harmol in 10 mM Na2HP04 (pH 7.4). This 
standard was serially diluted with buffer to yield standards ranging from 
0.00012 - 0.12 µmole/ml harmol. The wavelength of maximal absorbance of the 
harmol solution was determined by scanning from 220-500 nm using the 
Gilford Response spectrophotometer. This wavelength was used to measure the 
absorbance for each standard, and linear curve-fitting of the data was used to 
define the equation for the standard curve. Samples were also analyzed at this 
wavelength in small volume quartz cuvettes with a 1 cm path, where buffer 
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was used as in the reference cuvette. Absorbance of the coupled gel was 
determined spectrophotometrically, and coupling efficiency subsequently 
calculated. Coupling efficiency appeared to be low, and therefore in an effort 
to improve coupling, the reaction pH was increased from 10.2 to pH 12.7 by the 
addition of 8 N NaOH. The coupling reaction was mixed at room temperature on 
a rocker plate until absorbance values for samples of the mixture reached a 
plateau and then began to decline. 
Blockin~ of Unreacted Activated Sites 
The coupled gel was transferred to a scintered glass funnel and washed 
extensively with Milli-Q water (200 ml) in order to remove free harmol. In 
addition, the gel was washed with 50 ml each 0.5 N HCl and Milli-Q water. 
Blocking of any remaining epoxy-activated sites was accomplished by shaking 
the gel at 40 °C for 14 hours with 20 ml 1 M ethanolamine (pH 9.4). The gel was 
washed with 100 ml each Milli-Q water and 150 mM KCI. Gel was stored in the 
refrigerator in 150 mM KCl until it was filled into a column (2-3 days). 
BC-Sepharose Column Chromato~raphy 
The BC-Sepharose affinity matrix was filled into an empty PolyPrep 
chromatography column (BioRad); this polypropylene column had a IO ml 
reservoir on top of a bed volume of about 2.5 ml (0.8 cm x 4 cm bed). The 
column was equilibrated with 50 ml of IO mM Na2HP04 containing 1 M NaCl (pH 
7.4). 
A 2 ml aliquot of bovine brain cytosol was thawed and ultradialyzed on a 
Centricon 30 concentrator against equilibration buffer. The cytosol had been 
stored at -80 °C for 1 month in 150 mM KCl, 1 mM OTT, and 10% (w/v) glycerol. 
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Ultradialyzed cytosol (2.5 ml) was applied to the equilibrated BC-Sepharose 
column by gravity flow. The column flow-through was collected and a 1.0 ml 
aliquot concentrated to 300 µI on a Centricon 30 concentrator. The column was 
washed (with the add of a vacuum) using 25 ml of equilibration buffer. The 
wash was collected and a 2.0 ml sample concentrated to 300 µI. BC-2-NMT 
elution was attempted using 2 ml of 10 mM Na2HP04 buffer (pH 7.4) containing 
2 M NaCl and 3 M NaCl in succession. Aliquots (2.0 ml) of these eluates were 
concentrated to 300 µI. Total protein and BC-2-NMT activity were measured in 
each column fraction. 
BC-2-NMT Assay 
Details of the assay, work-up, and RP-HPLC analysis are discussed in 
Chapter 3. Assays, at pH 8.5, were maintained at 37 °C for 45 minutes; 
reactions consisted of 9-MeNH (540 µM), SAM (105 µM, 2.194 µCi), and 100 µI of 
the concentrated column fractions. 
Protein Determination 
Protein measurements were carried-out using a modified Lowry method 
as detailed in Appendix A. 
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Results: BC Affinity Chromatography 
Experiment 2 
Coupling Procedure 
The coupled and rinsed gel was yellow under alkaline conditions and 
colorless in an acidic environment. This suggests that at least some 13C is 
bound to the gel, since free harmol exhibits similar properties. 
The harmol standards exhibited an intense absorbance maxima at 320.5 
nm (A320,5). Therefore, this wavelength was utilized to determine the 
concentration of harmol present in the standards and samples. The harmol 
standard curve is represented in Figure 34. 
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Figure 34. Standard curve for harmol in 10 mM Na2HP04 (pH 7.4). 
Analysis of these data resulted in the following equation: 
A32o.5 = 0.03 + 13.251( µmoles/ml harmol). 
The 30 µl sample of coupled gel (in 1 ml total volume) exhibited an A320.5 of 
0.2107, corresponding to 0.013 µmoles harmol per 30 µl gel. Therefore, the 
quantity of harmol coupled per ml of gel was 0.45 µmoles. This value 
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represented only 1-2% of theoretical quantity. The reaction pH was increased 
from pH 10.2 to pH 12.7 in an effort to improve coupling efficiency. After 
mixing for one hour at room temperature a 30 µl aliquot was analyzed for 
harmol bound to gel as described above. For this sample, A32o.5 = 0.6802, which 
corresponds to 2.33 µmoles harmol per ml gel. This value represents 6-12% of 
theoretical value of 19-40 µmoles/ml. The reaction was allowed to proceed 20 
hours at room temperature. Analysis showed a decrease in A310.s to 0.3956 (i.e., 
0.92 µmoles harmol/ml gel), therefore coupling reaction was terminated and 
the blocking reaction was initiated. 
BC-Sepharose Column Chromatography 
The results of this experiment were very difficult to interpret because 
the HPLC traces appeared similar--much like background, with no discernable 
peaks. Approximately 10.6 mg of total protein was applied to the column; 9.9 
mg (93%) of that was retained by the column initially and subsequent washing 
removed 4.2 mg protein (40% of applied). This indicates that 5.7 mg of total 
protein (54% of applied) remained bound to the BC-Sepharose column after 
washing with equilibration buffer. No additional protein was eluted by 
subsequent buffer solutions containing 2 M or 3 M NaCl . 
Discussion: BC-Sepharose Affinity Chromatography 
Experiment 1 
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It is possible that the BC-2-NMT activity was removed from the column 
during the first wash step, but that its presence there was undetectable due to 
dilute nature of the wash. It is more reasonable to speculate that the BC-2-NMT 
activity remained bound to the BC-Sepharose column, since 54% of the protein 
applied remained in association with the column foIIowing extensive washing. 
It is conceivable that the high salt buffers used in this experiment -- a 
condition that favors hydrophobic interaction -- may have actually 
strengthened the interaction between the hydrophobic HC (attached to the 
matrix) and protein or HC-2-NMT -- rather than lessened the interaction as 
planned. FoIIow-up experiments were carried out using buffers of lower ionic 
strength in order to address this concern. 
Materials and Methods: 
BC-Sepharose Affinity Chromatography 
Experiment 2 
Column Chromato~raphy 
The HC-Sepharose column prepared in "Materials and Methods: BC-
Sepharose Affinity Chromatography (Experiment 1) was utilized in 
"Experiment 2". The major differences in this experiment compared to 
"Experiment 1" were, (1) sample was applied under lower ionic strength 
buffer conditions, (2) wash volume was decreased, and (3) an attempt was 
made to elute BC-2-NMT activity from the column with norharman ("affinity 
elution"). The column was equilibrated in buffer containing 20 mM Na2H PO 4 
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(pH 7.3) and 150 mM KCI. Bovine brain cytosol (5 ml), in the same buffer was 
applied to the column by gravity flow. Column flow-through was collected and 
filtered through a 0.22 µm polysulfone syringe filter (13 mm diameter). The 
entire fraction was concentrated completely on a Centricon 30 concentrator. 
The column was washed with 6 ml of equilibration buffer, and the wash was 
collected and treated like previous fraction. Norharman (2.0 ml, 1 mM in 
equilibration buffer) was used to elute BC-2-NMT from the column. The 
norharman (NH) wash was repeated three additional times. These fractions 
were ultradialyzed (three solvent exchanges) to remove norharman, and 
simultaneously concentrated on a Centricon 30 concentrator. 
Centricon 30 concentration proceeded overnight at 0-5 °C. 
Equilibration buffer (300 µI) was added to each retentate; buffer was not added 
to the initial column flow-through since its volume measured 450 µ1 "as-is". 
These concentrated solutions were used in the BC-2-NMT assay and for protein 
de termination. 
BC-2-NMT Assay 
Details of the assay, work-up, and RP-HPLC analysis are discussed in 
Chapter 3. Assays, at pH 8.5, were maintained at 37 °C for one hour; reactions 
consisted of 9-MeNH (540 µM), SAM (105 µM, 3.112 µCi), and 100 µl of respective 
concentrated column fraction. 
Protein Determination 
Protein measurements were carried-out using a modified Lowry method 
as detailed in Appendix A. 
Results: BC-Sepharose Affinity Chromatography 
Experiment 2 
The results of this experiment are summarized in Table 20. 
Table 20.--BC-Sepharose Affinity Chromatography Results 
Column Protein BC-2-NMT Specific Activity 
Fraction (mg) (pmol/h) (pmol/h/mg) 
Cytosol 34.0 671 19.7 
Flow-through 6.8 65.7 9.5 
Wash 4.3 145 33.8 
NH (1st) 0.37 38.8 101 
NH (2nd) 0.27 32.5 122 
NH (3rd) 0.14 40.8 283 
NH (4th) 0.09 16.6 178 
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The BC-Sepharose column was equilibrated in 20 mM Na2HP04 (pH 7.3) 
containing 150 mM KCI. Bovine brain cytosol ("Cytosol") in same buffer was 
applied to the column and "Flow-through" collected. Column was washed with 
equilibration buffer ("Wash"), and BC-2-NMT subsequently eluted using four 
sequential volumes of 1 mM norharman solution (NH 1st - 4th). 
Approximately 35% (12.0 mg) of the total applied protein was accounted 
for in all fractions, indicating that 65% of total protein remained on the 
column. With respect to BC-2-NMT activity, 60% of the applied activity was 
accounted for ( 405 pmol/h), with 31 % of the applied activity in the combined 
flow-through and wash fractions (211 pmol/h), suggestive of poor hinding of 
BC-2-NMT under these conditions. Affinity elution of BC-2-NMT activity with 
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norharman solution resulted in the release of 19% of the applied activity 
(129.0 pmol/h), and approximately 50% of the applied BC-2-NMT activity 
remained in association with the BC-Sepharose column (339 pmol/h). The 
specific activity of the combined norharman fractions was 148 pmol/h/mg 
protein; therefore, the overall purification from cytosol to norharman eluates 
was 7.5-fold with a 19% yield. 
Discussion: BC-Sepharose Affinity Chromatography 
Experiment 2 
More total protein remained bound to the column in this experiment 
compared to "Experiment 1'', 65% compared to 54%, respectively. This may 
indicate that non-specific binding of protein is increased at lower ionic 
strength used in "Experiment 2" or that other interactions -- such as ionic 
interaction with the ethanolamine used to block reactive sites -- may be 
occurring. The lack of BC-2-NMT binding during cytosol application to the 
column and subsequent washing indicates that binding of BC-2-NMT may be 
favored under conditions of higher ionic strength utilized in "Experiment 1". 
The incomplete elution of bound BC-2-NMT by a 1 mM NH solution was 
unexpected, and the 7 .5-fold purification atypical for a true affinity column. 
These data suggest that a more concentrated NH solution may be required for 
complete BC-2-NMT displacement from the column. It is also possible that a pH 
change may facilitate complete elution of BC-2-NMT activity. These 
experiments have not been done. 
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Discussion: Affinity Chromatography 
General Comments 
Purification of BC-2-NMT activity using SAH and BC affinity columns in 
sequence would likely be a powerful approach to BC-2-NMT purification. In 
theory the SAH-column could be used bind SAM-dependent 
methyltransferases, including BC-2-NMT. Obviously it is necessary to identify 
an efficient means of eluting BC-2-NMT activity from the SAH-CH-Sepharose 
4B affinity column. The BC-2-NMT-containing fraction from the SAH-column 
could subsequently be applied to the BC affinity column under conditions that 
bind this activity efficiently -- perhaps at a pH similar to pH optimum for 
enzyme assay (pH 8.5). In theory a tremendous purification of BC-2-NMT could 
be achieved at this step, since a relatively small number of proteins are 
presently known to specifically interact with BCs. A few proteins expected to 
bind to a BC-affinity column include, (1) those that catabolize BCs, (2) 
monoamine oxidase (BCs inhibit MAO), and (3) the benzodiazepine receptor to 
which BCs bind. As with the SAR-column, an effective procedure for elution 
of BC-2-NMT from the BC-column is fundamental to the success of this method. 
Consideration should also be given to the possibility that the BC-column may 
act as a nonspecific hydrophobic matrix due to the hydrophobic nature of the 
BC molecule. 
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Overall Purification Summary 
Ammonium sulfate fraction followed by DEAE-Scphadcx batch 
chromatography resulted in a nearly 20-fold purification of BC-2-NMT activity 
-- from a cytosolic activity of 20 pmol/h/mg protein to nearly 400 pmol/h/mg 
protein. Purification of BC-2-NMT varied depending upon the purification 
protocol utilized (Figure 35). 
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Figure 35. Summary of BC-2-NMT purification (see this chapter for details). 
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Key: each bar represents 1-2 steps in sequence 
llil4lz.Si4_60-80%/DEAE: 60-80% ammonium sulfate fraction from bovine brain cytosol 
dissolved in pH 7 imidazole buffer, then subjected to batch chromatography on DEAE-
Sephadex (anion exchange matrix). BC-2-NMT activity (represented by har) was eluted 
from the matrix with pH 7 imidazole buffer containing 0.3 M NaCl. 
Green 19/Green 5: Bovine brain cytosol was applied to a Green 19 dye column, eluate from 
this column was applied to a Green 5 dye column. BC-2-NMT activity (represented by bar) 
was eluted from Green 5 dye column using pH 7.4 Na2HP0 4 containing 3 M NaCl. 
DEAE/SAH-Affinity: DEAE-Sephadex batch chromatography elute (above) applied to an S-
adenosyl-L-homocysteine affinity column. BC-2-NMT activity (represented by bar) was 
eluted from the column with pH 7 imidazole buffer containing I M NaCl. 
BC-Affinity: Bovine brain cytosol in 20 mM Na2HP0 4 (pH 7.3)/150 mM KC! was applied to 
a B-carboline affinity column. BC-2-NMT activity (represented by bar) was eluted from the 
column using a l mM buffered norharman solution . 
.LN141.i.Sl4~ supernatant from 40% ammonium sulfate fractionation was applied to a 
octyl-agarose (C8) hydrophobic interaction chromatography column. BC-2-NMT activity 
(represented by bar) was measured in application flow-through. 
!Nli.4_lz.Sl4lC.i.:. supernatant from 40% ammonium sulfate fractionation 
pentyl-agarose (C5) hydrophobic interaction chromatography column. 
(represented by bar) was measured in application flow-through. 
was applied to a 
BC-2-NMT activity 
Green 19: column chromatography (same conditions as above) on a Green 19 dye column 
60-80% fNH!lz.SJ4,;_ the 60-80% ammonium sulfate fraction (desalted) 
40-60% CNH!lz.SJ4.:. the 40-60% ammonium sulfate fraction (desalted) 
Cytosol: bovine brain cytosol, typically the starting material for each step above. 
CHAPTERS 
MEASUREMENT OF 6-CARBOLINE-2N-METHYLTRANSFERASE 
AND 6-CARBOLINE-9N-METHYLTRANSFERASE ACTIVITIES 
IN POST-MORTEM HUMAN BRAIN FROM CONTROL AND 
PARKINSON'S DISEASE SUBJECTS 
Back~round 
6-carboline-N-methyltransferases (6C-NMTs) and the products of their 
catalytic activities, neurotoxic N-methylated 6-carbolinium cations (Me6Cs+), 
may play a role in the pathogenesis of idiopathic Parkinson's disease (Collins 
1994; Collins and Neafsey 1985). To explore this hypothesis, supernatant and 
particulate fraction 6C-2N-methyltransferase and 6C-9N-methyltransferase 
activities were measured in human postmortem brains. These activities were 
assessed in substantia nigra, putamen, and frontal cortex from control (N= 11) 
and Parkinson's disease (N=12) cases. If 6C-2N- and/or 6C-9N-
methyltransferase contributes to the development of PD, the hypothesis 
predicts that these activities may be increased relative lo control brain 
activities -- probably early in the disease process. In addition, it is predicted 
that these activities may be elevated in brain areas primarily affected in PD, 
namely the substantia nigra and/or putamen. However, if these enzyme 
activities are indeed elevated early in pre-symptomatic PD, that elevation may 
be undetectable since the tissue used here was obtained from patients with 
well-developed PD. 
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Materials and Methods 
Brain Tissue 
Frozen sections of postmortem human brain were obtained from three 
different brain banks: (1) National Neurological Research Specimen Bank, 
V AMC Wadsworth Division, Los Angeles, CA 90073 (supported by NINDS/NIMH, 
National Multiple Sclerosis Society, Hereditary Disease Foundation, 
Comprehensive Epilepsy Program, Tourette Syndrome Association, Dystonia 
medical Research Foundation, and Veterans Health Services and Research 
Administration, Department of Veterans Affairs); (2) The Rush Brain Bank, 
Chicago, IL (supported by NIA AG09466 and AG10161); and (3) The Loyola 
University/Hines VA Brain Bank, Loyola University Medical Center, Maywood, 
IL (supported by the Department of Pathology). 
Sections evaluated in this study included substantia nigra, putamen, and 
frontal cortex obtained at autopsy from control subjects and patients diagnosed 
with Parkinson's disease. Table 21 shows pertinent information regarding 
these tissues by region, including: subject age, postmortem interval, and sex. 
Due to the limited availability of Parkinson's tissue it was not possible to obtain 
samples that were strictly age-matched to control tissue, although the age 
ranges were roughly equivalent for the two groups. 
Table 21.--Characteristics of Postmortem Brain Tissue 
Brain Region 
Substantia nigra 
N 
Male/Female 
Age 
PMI 
Putamen 
N 
Male/Female 
Age 
PMI 
Frontal cortex 
N 
Male/Female 
Age 
PMI 
Group 
Control 
6 
214 
73±9 (64-88) 
16.6±6.9 (8-25.5) 
7 
611 
68±3a(64-73) 
14.9±7.lb (7-25.5) 
7 
611 
67±3C (64-73) 
13.3±5.5 (7.0-20.0) 
Parkinson's 
8 
414 
76±4 (69-81) 
12.9±5.0 (6.5-23.5) 
7 
512 
76±5 (69-83) 
8.6±2.8 (5.5-13) 
7 
512 
77±4 (72-83) 
10.2±6.3 (5.5-23.5) 
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Note: Values for age (years) and PMI (hours) represent mean ± s.d., with the 
range in parentheses. Superscripts indicate (a) significantly different than 
PD (p<0.005), (b) significantly different than PD (p<0.05), (c) significantly 
different than PD (p<0.0005). 
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A total of 48 different samples were evaluated in random order; each day 
three tissue samples were prepared for the BC-NMT assays. The frozen sections 
were thawed slightly, and approximately 100 mg of tissue was removed using a 
clean tissue punch. In sections of substantia nigra or pulamen this sample 
was taken from the center of the structure. In coronal sections of frontal 
cortex, samples were removed from the superficial surface of the middle 
frontal gyrus. The tissue sample was weighed, placed in a 2 ml glass 
homogenizer on ice, and homogenized at 0-5 °C in 5 volumes of homogenation 
buffer (5 µ1 buffer per mg tissue). Homogenation buffer (pH 7 .2) consisted of 
150 mM potassium chloride, 20 mM sodium phosphate (Na2HP04), 1 mM 
dithiothreitol, and 1 mM ethylenediaminetetraacetic acid disodium. 
Homogenation was achieved with five up and down strokes of a motor-driven 
(300 rpm) teflon pestle. Homogenate was transferred to a 1.5 ml 
microcentrifuge tube where centrifugation at 10,000g for thirty minutes 
yielded crude particulate and supernatant fractions. Particulate fraction was 
diluted with 200 - 400 µI of homogenation buffer prior to use in BC-NMT assays, 
and supernatant was used "as-is". 
Reagents 
6-Carboline substrates, 9-methylnorharman (9-MeNH) hydrochloride or 
2-methylnorharmanium iodide (2-MeNH+), were synthesized in our laboratory 
according to Rubottom (Rubottomand Chabala 1974) or Matsubara (Matsubara 
et al. 1992b), respectively. Unlabeled S-adenosyl-L-methionine 
(toluenesulfonate salt) was purchased from Sigma Chemical (St. Louis, MO), 
and tritiated S-[methyI-3H]-adenosyl-L-methionine (60-85 Ci/mmol) was 
obtained from Dupont (New England Nuclear, Boston, MA). 
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The BC-N-Methyltransferase Assays 
These activities catalyze the transfer of the tritiated methyl moiety from 
S-adenosyl-L-methionine (SAM) to 9-MeNH or 2-MeNH+ to form SAH and 
2(3H-methyl)-9-McNH+ or 2-9(3H-methyl)-NH+ (Figure 36). 
! 9-McNH 
I SAM I 
* H C~l3 Adenine 
HOOC·~·(Cllz)z1..C~l2 O 
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H H 
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Figure 36. Human brain BC-NMT assay scheme. 
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The BC substrates, 9-MeNH and 2-MeNH+, were used to assess BC-2-NMT 
and BC-9-NMT activities, respectively, in both particulate and supernatant 
fractions from each brain region. Enzyme assays were done in 1.5 ml 
polypropylene microcentrifuge tubes by mixing concentrated stock solutions 
of B-carboline (540 µM final), SAM (105 µM final), and 3H-SAM (4.6 µCi) with 
supernatant or diluted particulate fraction. Stock solutions of SAM were 
prepared in water, and BC was dissolved in a buffer mixture consisting of 50 
mM Na2HP04 plus 50 mM bicine at pH 8.5. Assay volume was 370 µl (pH 8.5), 
comprised of the following stock solutions: 50 µl 3H-SAM (4.6 µCi), 20 µl 
non-radioactive SAM (1.943 mM), 200 µl BC (1 mM), and 100 µl of supernatant 
or particulate fraction. 
Each tube was gently vortexed and incubated at 37 °C in a shaking water 
bath for one hour. Following this incubation each sample was placed on ice 
and protein precipitated by the addition of 200 µl 0.5 N perchloric acid (HC104). 
The mixture was centrifuged to pellet precipitated protein (7000g for 5 
minutes), with the supernatant transferred to a glass culture tube containing 
1 ml of 1% (w/v) ammonium hydroxide (NH40H) and 100 µl of 1 N potassium 
hydroxide. The protein pellet was vigorously resuspended in 500 µl 0.01 N 
H C 10 4 and centrifuged at 10,000g for 5 minutes, with the resulting supernatant 
combined with the initial supernatant. This solution was then slowly applied 
to a Sep-Pak® C18 Plus solid-phase extraction (SPE) cartridge (360 mg, 
Millipore-Waters part no. 20515). The cartridge was pretreated with 5 ml of 
methanol:5 N acetic acid (3:1, v/v), methanol, and 1% (w/v) NH40H in that 
sequence. Slow application (2 to 5 drops per second) of all solutions to the SPE 
cartridge was achieved using a vacuum manifold. Following the initial sample 
application, the SPE cartridge was washed with 8 ml of 1 % (w/v) NH.iOH and 
then by 5 ml methanol; these washes were discarded since they contained 
compounds that could contribute to the background radioactivity during 
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subsequent analysis. The final wash (5 ml), consisting of 3: 1 (v/v) methanol:5 
N acetic acid, promoted elution of tritiated 2,9-Me2N H + from the cartridge into a 
clean glass culture tube. This eluate was evaporated to dryness at 30-40 °C 
using a Speed Vac concentrator (Savant Instruments Inc., Hicksville NY). 
Reverse-Phase High Performance 
Liquid Chromatography 
Activities of BC-NMTs were quantitated by measuring tritiated 2,9-
Me2NH + product using reverse-phase HPLC. The residues from the Speed Vac 
concentration step were dissolved in 200 µI HPLC mobile phase by sonication 
and vortexing. Samples were filtered through a 0.45 µm nylon membrane filter 
(Micro-Spin, Chrom-Tech Inc.) prior to injection (150 µI) onto the HPLC 
system. Isocratic HPLC analysis was carried out under ambient conditions on a 
Bondclone 10 µm C18 column (Phenomenex™, 300 mm x 3.9 mm). The mobile 
phase was a mixture of 17% (v/v) HPLC grade acetonitrile and 83% (v/v) 
aqueous buffer. The buffer contained 50 mM triethylamine in 250 mM sodium 
phosphate adjusted to a pH of 3 with phosphoric acid (final mobile phase pH 
3.4). The HPLC system included a Shimadzu SIL-9A programmable autosampler, 
a Beckman 1 IOA pump (0.8 ml/minute), and an in-line radioactive flow 
detector (Radiomatic Instruments Flo-One\B). Ultima-Flo™ AP (Packard 
Instruments) liquid scintillation cocktail was used at a flow rate of 2.8 ml per 
minute, resulting in a scintillation fluid to mobile phase mixing ratio of 7:2. 
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The radioactive flow detector was equipped with a 2.5 ml liquid flow cell and an 
automatic stream splitter. It was necessary to bypass the radioactive flow 
detector by splitting the HPLC column effluent to waste until about ten minutes 
into the run. Splitting to waste reduced interference due to tritiated materials, 
primarily 3H-SAM and its degradation products, present in the samples. 
Radioactive peak area corresponding to 2,9-Me2 NH+ (retention time 12 - 13 
minutes) was calculated using Radiomatic Flo-One\B system software; the 
resulting integrated area was reported as total cpm under the 2,9-Me2 N H + peak. 
BC-NMT activities are reported as pmoles 2,9-Me2 N H + formed per hour per mg 
protein (pmol/h/mg protein) and were calculated using experimentally 
defined values for detector counting efficiency and the quantity of 3 H - SAM 
added to the BC-NMT assay. Counting efficiency and 3H-SAM added to BC-NMT 
assays were determined on each day of HPLC analysis. Total protein was 
determined in particulate and supernatant fractions using a modified Lowry 
method as described by Scopes (1994d) and in Appendix A. 
Data Analysis 
Kaleidagraph™ (Abelbeck/Synergy Software, Reading, PA) was used for 
graphical analysis, and for determination of correlation coefficients for each 
BC-NMT activity as a function of age or PMI. Statistical analysis of data was 
done using SPSS for Windows. A three-way factorial ANOVA was used to 
compare BC-2-NMT or BC-9-NMT activity as a function of fraction (particulate 
vs. supernatant), disease-state (control vs. PD), and brain region (substantia 
nigra vs. putamen vs. frontal cortex). 
Results 
Analysis of Variance 
(ANOVA) 
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The detailed results of the factorial ANOV A for BC-2-NMT activity and BC-
9-NMT activity as a function of fraction, brain region, an<l disease-state arc 
presented in Appendix D. 
BC-2-NMT Activity 
The three-way ANO VA was significant (F(4,79)=4.037, p=0.005), but of the 
three factors tested only the fraction factor had a significant main eff cct (F 
(1,79)=11.997, p=0.001), consistent with the generally higher level of activity 
in the supernatant fraction that can be seen in Figures 32-34. No significant 
F-value was found for disease-state or brain region factors with respect to BC-
2-NMT activity. A one-way ANOVA run on the 12 distinct "conditions" 
(fraction*disease-state*brain region; see Figure 37) failed to reach statistical 
significance (F(l 1, 79)=1.7427, p=0.0824), and Bonferroni post-hoc mulliple 
comparisons tests revealed that no two groups were significantly different 
with respect to BC-2-NMT activity. Thus the higher BC-2-NMT activity in the 
supernatant fraction appears to be a general effect. 
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± s.e.m. with the range in parentheses. 
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BC-9-NMT Activity 
The three-way ANOVA was significant overall (F(4,83)=4.947, p=0.001), 
with a significant main effect for fraction (F(l,83)=14.354, p=0.0003) and a 
significant interaction effect for brain region and disease-state (F(2,83)=5.020, 
p=0.009). No significant main effects were found for disease-state or brain 
region regarding BC-9-NMT activity. A one-way ANOVA run on the 12 
"conditions" (fraction*disease-state*brain region; see Figure *) was 
significant (F(l 1, 83)=3.4806, p=0.0006). Post-hoc Bonferroni multiple 
comparison tests found that frontal cortex supernatant BC-9-NMT activity in 
Parkinson's disease was significantly higher than control frontal cortex BC-9-
NMT activity (p<0.05) as can be seen in Figure 38. In fact, Parkinson's frontal 
cortex supernatant BC-9-NMT activity was significantly higher than BC-9-NMT 
activity for all other groups (p<0.05), except for control substantia nigra and 
control putamen activity. 
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Discussion 
This is the first description of BC-9N-mcthyltransfcrasc activity in 
human brain; only rat and guinea pig brain activity was previously described 
(Collins et al. 1992; Matsubara et al. 1992b). The 13-fold higher SAM 
concentration used in the BC-9-NMT assay in this study likely accounted for 
the detection of BC-9-NMT activity; i.e., Matsubara ct al. (1993) use of 8 µM SAM 
may have been insufficient for detection of BC-9-NMT activity. These data 
confirm the presence of BC-2N-methyltransferase activity in postmortem 
human brain, a finding originally reported by Matsubara ct al. (Matsubara ct 
al. 1993). The study presented here expands upon Matsubara's work by 
examining BC-NMT activities in Parkinson's disease brain, as well as 
distinguishing between particulate and supernatant fraction activities. It was 
found that both BC-NMT activities were higher in the supernatant compared to 
the particulate fraction, indicating a predominantly cytosolic localization for 
these enzymes. Higher supernatant BC-2-NMT activity is consistent with the 
results reported in Chapter 3 for bovine brain BC-2-NMT activity. Most 
importantly, the data reported here indicate that frontal cortex supernatant 
BC-9-NMT activity is significantly elevated in Parkinson's disease compared LO 
controls (p<0.05). 
Age and Postmortem Interval Eff ccts 
The significant age differences between the control and Parkinson's 
groups for putamen and frontal cortex specimens arc unfortunate, but likely 
not important since BC-NMT did not vary with subject age. In contrast, PMI 
could be considered a confounding variable in our study, since particulate 
fraction BC-9-NMT activity varied with PMI in control tissue from putamen 
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and frontal cortex. This suggests that there may in fact be a difference 
between control and PD cases for pellet BC-9-NMT activity in putamen, but that 
a significant difference was not found due to the effect of PMI this activity 
(i.e., a Type II statistical error may have been committed). 
Basal Ganglia Findings 
No assumptions were made a priori that BC-NMT activities would be the 
same across the brain regions evaluated. However, since the nigrostriatal 
system is most dramatically affected in PD, the hypothesis logically predicts 
that BC-2-NMT and/or BC-9-NMT activity may be higher in the substantia 
nigra and/or putamen relative to the frontal cortex. These data do not directly 
support this prediction, because although mean BC-2-NMT activity in the 
substantia nigra of control tissue is higher than in PD tissue, the difference is 
not statistically significant. It is possible that in the PD brain, regional 
distribution of measurable BC-NMT activity is confounded by the MeBC+-
induced death of the neurons that, before death, possessed high BC-NMT 
activity. Note that selective elevation of BC-NMT activity in the nigrostriatal 
system is not a requirement in this model since selective uptake of neurotoxic 
MeBCs+ into this system would also confer neurotoxic selectivity to the 
nigrostriatal system. Consistent with the idea of selective uptake, MeBCs+ do 
modestly inhibit dopamine uptake into rat synaptosomes (Drucker et al. 1990), 
implying that these compounds are substrates for the dopamine transporter. 
Frontal Cortex Findings 
The significant elevation of supernatant BC-9-NMT activity in the 
frontal cortex of PD brain compared to controls (p<0.05) was unexpected. 
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Furthermore, considering only Parkinson's tissue, frontal cortex supernatant 
BC-9-NMT activity was significantly higher compared to suhstantia nigra or 
putamen activity. It is believed that these differences are real and arc not 
accounted for by differences between group age or PMI, since supernatant BC-
9-NMT activity did not correlate with PMI or age in any tissue. It is speculated 
that this observation may reflect both a general elevation of supernatant BC-
9-NMT activity in PD brain, and a selective, local vulnerability of the 
nigrostriatal neurons to the effects of resultant 2,9-Me2BC s +. Death of the 
nigrostriatal neurons, originally containing the BC-9-NMT activity, would lead 
to a commensurate loss of detectable BC-9-NMT activity in the nigrostriatal 
nuclei. Perhaps early in the disease process, well before profound cell-death, 
BC-NMT activities are higher in PD relative to controls. Cortical neurons that 
exhibit increased supernatant BC-9-NMT activity, but are resistant to the toxic 
effects of resultant MeBCs+, would remain viable and consequently make 
measurement of enzyme activity possible. Consistent with the postulate that 
cortical neurons may be resistant to these toxins, it is interesting to note that 
dopaminergic neurons projecting to the frontal cortex from the ventral 
tegmental area are spared in PD. 
However, it is equally conceivable that elevated supernatant BC-9-NMT 
activity in the frontal cortex is a compensatory response to the death of 
adjacent dopaminergic nigral neurons occurring in Parkinson's disease. 
Parkinson's Disease 
The hypothesis in this lab implies that BC-2-NMT and/or BC-9-NMT 
activity is higher in Parkinson's disease compared to controls, resulting in the 
formation of excessive neurotoxic MeBCs+ in PD brain and consequent 
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neuronal death. Furthermore, one would expect that BC-NMT activity would be 
elevated during the subclinical or early stages of PD -- a hypothesis that can 
not be readily investigated. As discussed above the original hypothesis is 
partially supported by elevated supernatant BC-9-NMT activity in the frontal 
cortex of PD tissue. Since MeBCs+ are able to penetrate the blood-brain barrier, 
these compounds probably cross plasma membranes. Therefore, MeBCs+ 
formed in the frontal cortex could enter the CSF, and subsequently exert toxic 
effects on the nigrostriatal system. 
Conversely, if elevated BC-9-NMT activity in the frontal cortex is truly a 
local effect it is proposed that formation of MeBCs+ in the frontal cortex may 
result in the death of a discrete population of vulnerable cortical neurons at 
the site of MeBC+ formation. Perhaps cells that exhibit high BC-9-NMT activity 
are resistant to resultant MeBCs+, while other cells in close proximity are 
vulnerable. It follows that the death of these vulnerable cells could manifest 
clinically as dementia or depression -- two nonmotor symptoms documented in 
many PD patients (Koller and Pahwa 1995). 
While these data certainly do not provide compelling evidence for a 
global elevation of BC-NMT activity in Parkinson's brain, a role for MeBCs+ m 
the neuropathogenesis of idiopathic PD remains viable considering the 
following parallel hypothesis. If MeBCs+ are elevated in PD, it is conceivable 
that their BC-NMT-catalyzed formation is similar to that of controls, but that 
catabolism of MeBCs+ is impaired in PD. In PD brain a deficiency in the 
catabolism of MeBCs+, to nontoxic compounds, could also lead to elevated levels 
of these compounds -- culminating in cell death in brain regions where this 
hypothetical catabolic deficiency occurs. Indeed, studies have been reported 
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which indicate that abnormalities in xenobiotic metabolism may contribute to 
the development of PD (Williams 1995). 
It is also possible that persons afflicted with PD are exposed to higher 
levels of substrates of BC-NMT, and consequently form higher levels of toxic 
MeBCs+ throughout life, until sufficient neurons are killed to manifest in the 
clinical symptoms of PD. This is consistent with a recent report indicating that 
plasma levels of norharman and barman -- substrates of the BC-2-NMT activity 
investigated in this report -- are elevated in individuals diagnosed with 
Parkinson's disease (Kuhn et al. 1995). Studies are underway in our laboratory 
in which levels of MeBCs+ will be compared in postmortem human brain tissue 
from PD and control individuals. Those experiments, in combination with the 
results reported here, should clarify the picture regarding the contribution of 
N-methylated-6-carbolines to the pathogenesis of Parkinson's disease. 
CHAPTER6 
EVIDENCE THAT B-CARBOLINE-2N-METHYLTRANSFERASE 
ACTIVITY IS DUE TO A PHENYLETHANOLAMINE 
N-METHYLTRANSFERASE-LIKE ENZYME 
It was hypothesized that BC-NMT activity may be due to a previously 
characterized CNS-residing N-methyltransferase -- such as 
phenylethanolamine-N-methyltransferase (PNMT) -- this enzyme catalyzes 
the formation of epinephrine from norepinephrine. PNMT is a cytosolic SAM-
dependent enzyme that is found in the adrenal medulla, brain, and other 
tissues (Kennedy et al. 1995). To test this hypothesis that BC-NMT activity may 
be due to PNMT several experiments were performed. 
The first experiment was designed to determine if purified bovine-
adrenal PNMT catalyzes N-methylation of either 9-MeNH or 2-MeNH+, for the 
assessment of BC-2-NMT and BC-9-NMT activity, respectively. 
The second experiment confirmed the presence of PNMT catalytic 
activity in bovine-brain cytosol by measuring the conversion of 
norepinephrine to epinephrine in the presence of tritiated-SAM. 
The third experiment evaluated the effect of L Y134046 on BC-2-NMT 
activity; LY134046 is a selective inhibitor of brain and adrenal PNMT. If BC-2-
NMT is the same as PNMT, one would expect an inhibition of BC-2-NMT in the 
presence of L Y134046. 
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In the fourth and fifth experiments several PNMT substrates were 
evaluated for their ability to inhibit BC-2-NMT activity. If BC-2-NMT is PNMT, 
then substrates of PNMT should inhibit BC-2-NMT activity, since these 
substrates would compete with the BC for PNMT. 
The sixth experiment assessed BC-2-NMT activity in human medulla 
oblongata and human adrenal medulla. Both tissues exhibit documented PNMT 
activity, particularly the adrenal medulla. If BC-2-NMT is PNMT one would 
expect BC-2-NMT activity in these tissues. 
In the final experiment PNMT was immunoprecipitated from bovine-
brain cytosol. The resulting supernatant was evaluated for BC-2-NMT activity, 
with the expectation that activity would be reduced or absent following PNMT 
immunoprecipi ta ton. 
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Experiment I: 
BC-N-Methylation by PNMT 
Materials and Methods 
This experiment was repeated twice, and in each study replicate samples 
were prepared at each condition. Assay conditions were as follows: 
9-MeNH or 2-MeNH+ 
SAM 
3H-SAM 
PNMT 
Stock solutions used were: 
540 µM 
105 µM 
3.60 µCi (study I) 
6.74 µCi (study 2) 
3.3 units 
9-MeNH or 2-MeNH+ (1 mM stock in buffer "A") 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (3.60 or 6.74 µCi in Milli-Q water) 
PNMT Solution (0.033 units/~}) 
Total volume 
200 µl 
20 µl 
50 µl 
100 ul 
370 µl 
Buffer "A" contained 50 mM bicine and 50 mM Na2HP0 4 dibasic at pH 8.5. 
Sources of substrates are described in Chapter 5. Replicate assays were 
prepared to contain either 2-MeNH+, 9-MeNH, or no BC (blank assay). Final 
assay pH was 8.5. PNMT (25 units per vial) was obtained as a lyophilized 
powder in a rubber-stoppered vial from Sigma Chemical Company (St. Louis, 
MO). The contents of the vial were dissolved in 800 µl Milli-Q water. Label 
information regarding this enzyme is listed in Appendix E. BC-2-NMT assays 
were maintained at 37 °C for one hour. The assay work-up and measurement 
of 2,9-Me2NH+ by RP-HPLC were performed as described in Chapter 5. 
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Results 
Bovine adrenal PNMT catalyzes the 2N-methylation of 9-McNH, but does 
not carry-out 9N-methylation of 2-MeNH+ (Table 22). Within each experiment, 
a 2-tailed t-test was used to compare the assay results without ~C (blank) to 
assays containing ~C. The reaction with 2-MeNH+ as substrate did not differ 
from the blank reaction with respect to 2,9-Me2N H + formation. However, the 
reaction with 9-MeNH was statistically different than the blank assay 
(Study 1 **p<0.0005, Study 2 *p<0.005). 
Conditions 
Study 1 
Blank (no ~C) 
plus 2-MeNH+ 
plus 9-MeNH 
Study 2 
Blank (no ~C) 
plus 2-MeNH+ 
plus 9-MeNH 
Table 22.-- Bovine Adrenal PNMT-Catalyzed 
2N- and 9N-Methylation of ~Cs 
6C-N-Methylation Activity (mean ± s.e.m,, N=2) 
2,9-Me2NH+ Formed 
(pmol/h) 
2.7 ± 0.9 
1.4±0.7 
58.8 ± 1.4** 
18.1 ± 5.6 
26.6 ± 0.5 
80.1 ± 0.4 * 
2,9-Me2NH+ Formed 
Cpmol/h/unit PNMT) 
0.8 ± 0.3 
0.4 ± 0.2 
17.8 ± 0.4** 
5.7 ± 1.7 
8.1 ± 0.2 
24.3 ± 0.1* 
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Recall that 2N-methylation is activity measured when 9-MeNH is used as 
the substrate, and that 9N-methylation represents activity determined with 2-
Me NH+ as the substrate. Net 2N-methylation activity was calculated for each 
experiment by subtracting 2N-methylation in the blank assay from 2N-
methylation in the presence of 9-MeNH. Net 2N-methylation of 9-McNH in 
Study 1 was 17.0 ± 0.5 pmol/h/unit PNMT, and net 2N-mcthylation in Study 2 
was 18.6 ± 1.7 pmol/h/unit PNMT. 
Conclusion 
These data show that PNMT can 2N-methylate a BC-substrate and 
therefore do not refute the hypothesis that BC-2-NMT and PNMT are the same 
or similar enzymes. 
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Experiment 2: 
PNMT Activity in Bovine Brain Cytosol 
Materials and Methods 
PNMT activity in bovine brain cytosol was assessed using 
L-norepinephrine as the substrate. Similar studies were not done with 
octopamine and phenylethanolamine due to difficulties encountered with the 
extraction procedure for their N-methylated derivatives. The final substrate 
concentrations were: 
SAM 105µM 
1.034 µCi 3H-SAM 
L-norepinephrine 0, 10, 40, 100, and 250 µM 
The total volume of the assay was 370 µl and the final pH was 8.5. Duplicate 
assays were prepared in 1.5 ml polypropylene microcentrifuge tubes as 
follows: 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (1.034 µCi in Milli-Q water) 
L-norepinephrine (stock in buff er "A") 
Bovine brain cytosol ( 1.156 mg protein) 
20 µl 
50 µl 
200 µl 
100 µl 
L-norepinephrine bitartrate stock solutions utilized were: 18.5 µM, 74 µM, 185 
µM, 462.5 µM. A blank assay was prepared that lacked L-norepinephrine. 
Assays were incubated at 37 °C for one hour. 
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The assay work-up was done according to the method descrihed hy 
Chatelain et al. (1990). The PNMT assay was terminated by its transfer to a 13 x 
100 mm glass culture tube containing 250 µI of 1 N HCI. Solid NaCl (1 g) was 
added, and the mixture was extracted with 6 ml of 1 N HCI-washed butanol. A 5 
ml portion of the butanol layer was evaporated to dryness in a Speed Vac 
concentrator at 40 °C. The residue was dissolved in 5 ml of EconoSafc liquid 
scintillation cocktail, and subsequently transferred to 20 ml pol ypropy Jene 
scintillation vial. The culture tube was rinsed with 5 ml of EconoSafe, and this 
rinse was added to the scintillation vial. Additional EconoSafe (I 0 ml) was 
added to each scintillation vial, and the contents were mixed on a lab vortexer. 
Tritium was measured in these vials using a Beckman LS 6500 liquid 
scintillation counter. Background radioactivity (represented by the blank 
assay) was subtracted from the results for each assay that contained 
norepinephrine. Results are presented as pmoles of epinephrine formed per 
hour (pmol/h/mg protein). 
Results 
Bovine brain cytosol exhibits PNMT activity as evidenced by the 
conversion of norepinephrine to epinephrine (Figure 40). The maximal 
velocity (V max) was 1.8 nmol/h/mg protein, and the KM for norepinephrine 
was 63 µM. 
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Figure 40. Hanes plot for formation of epinephrine from norepinephrine in 
bovine brain cytosol. Substrates were SAM (105 µM, 1.034 µCi) and L-
norepinephrine (0, 10, 40, 100, and 250 µM) at pH 8.5. 
Conclusion 
This study simply confirms the presence of PNMT in the same bovine-
brain preparation that was utilized in experiments that evaluated BC-2-NMT 
activity, indicating that BC-2-NMT and PNMT exist in the same cytosol. 
Experiment 3: 
Inhibition of BC-2-NMT Activity by LY 134046 
Materials and Methods 
The final assay concentrations of substrates and the PNMT-inhihitor 
LY134046 were: 
100 µM 
105 µM 
3.54 µCi 
9-MeNH 
SAM 
3H-SAM 
LY134046 1 nM, 1 µM, 500 µM, 1 mM, or 5 mM 
Assay volume was 370 µl at a final pH of 8.5. Assays were prepared in 1.5 ml 
polypropylene microcentrifuge tubes as follows: 
9-MeNH (740 µM stock in buffer "A") 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (3.54 µCi in Milli-Q water) 
L Yl34046 (stock in buffer "A") 
Bovine brain cytosol (0. 711 mg protein) 
50 µl 
20 µl 
30 µl 
170 µl 
100 µl 
LY134046 stock solution concentrations utilized were: 2.176 nM, 2.176 µM, 
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1.088 mM, 2.176 mM, or 10.882 mM. A control BC-2-NMT assay, in the ahsence of 
L Y134046, contained 170 µl buffer "A" in place of L Y134046. Two distinct kinds 
of blank assays were prepared in which each blank lacked 9-MeNH: one blank 
contained 1 mM L YI 34046 ("inhibitor-control"), whereas the other blank 
lacked L Y134046. L Y134046 was purchased from Research Biochemicals 
International (Natick, MA); information regarding the inhibitor is listed in 
Appendix E. BC-2-NMT assays were incubated at 37 °C for one hour. The assay 
work-up and measurement of 2,9-Me2NH+ by RP-HPLC were performed as 
described in Chapter 5. The appropriate blank N-methylation activity was 
subtracted from values obtained in complete assays. 
The resulting data were plotted in three ways: 
(1) percent of control BC-2-NMT activity as a function of LY 134046 
concentration. 
(2) percent of control J3C-2-NMT activity as a function of log 
L Yl34046 concentration. The ICso was determined from this plot. 
l/BC-2-NMT activity as a function of L Y134046 
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( 3 a Dixon plot, 
concentration. The Ki for L Yl34046 was determined from this plot. 
Results 
L Y134046 inhibited BC-2-NMT in a concentration-dependent manner. 
Enzyme activity was nearly completely inhibited at 500 µM LY134046, and 
complete inhibition of activity was observed at L Y134046 concentrations 
greater than or equal to 1 mM (Figure 41). 
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Figure 41. Inhibition of bovine brain cytosol BC-2-NMT activity by L Y134046. 
Substrates were 9-MeNH (100 µM), SAM (105 µM, 3.54 µCi), and inhibitor 
L Y134046 (0-5 mM) at pH 8.5. 
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A linear relationship exists between percent of control BC-2-NMT 
activity and LY 134046 concentration when inhibitor concentration 
(range 1 nM-1 mM) is plotted on a log scale. The IC50 value -- the 
concentration of LY134046 required to inhibit BC-2-NMT activity hy 50 percent 
-- was 1.2 µM LY134046 (Figure 42). 
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Figure 42. Determination of ICso for L Yl34046 dependent inhibition of 
BC-2-NMT activity. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-
MeNH, 0-1 mM LY134046, 105 µM (3.54 µCi) SAM. 
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The Dixon plot for competitive inhibition is defined by the following equation: 
This equation predicts that slope = (KM/Vmax*[S]*Ki), when I/Velocity is 
plotted against inhibitor concentration. In Chapter 3, Vmax and KM for BC-2-
NMT with respect to 9-MeNH were determined to be 48 pmol/h/mg protein and 
75 µM, respectively. Graphical analysis of inhibition of BC-2-NMT activity by 
L Y134046 predicts a Ki = 0.4 µM (Figure 43). 
--- I/Velocity = 0.04877 + 0.04215 [LY134046] 
(r = 0.996) 
Slope = (~/ V max* K)(Il[S]) = 0.00024 
KM = 75 µM, V = 48 pmole/h/mg protein 
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Figure 43. Dixon plot for LY134046 inhibition of BC-2-NMT activity. Assay at 
pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-1.5 µM LY 134046, 
105 µM (3.54 µCi) SAM. 
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Conclusion 
These results support the hypothesis that BC-2-NMT is PNMT or a PNMT-
like enzyme. However, the Ki for LY134046 inhibition of BC-2-NMT is higher 
than its Ki (24 nM) for inhibition of brainstem PNMT (Fuller et al. 1981 ). 
Experiment 4: 
Inhibition BC-2-NMT by PNMT Substrates 
Materials and Methods 
PNMT N-methylates norepinephrine, octopamine and normetanephrine 
to form epinephrine, synephrine, and metanephrine, respectively. If BC-2-
NMT and PNMT are equivalent, one would expect BC-2-NMT activity to be 
reduced in the presence of these PNMT substrates. Final concentrations of 
substrates in this study were: 
9-MeNH 
SAM 
3H-SAM 
PNMT substrate 
540 µM 
105 µM 
3.54 µCi 
1 mM 
Assay volume was 370 µl at a final pH of 8.5. Assays were prepared in 1.5 ml 
polypropylene microcentrifuge tubes using the stock solutions listed: 
9-MeNH (1.332 mM stock in buffer "A") 
SAM (3.89 mM stock in Milli-Q water) 
3H-SAM (3.02 µCi in Milli-Q water) 
PNMT substrate (stock in buffer "A") 
Bovine brain cytosol (0.525 mg protein) 
150 µl 
10 µl 
10 µl 
120 µl 
80 µl 
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Blanks assays were prepared for each PNMT substrate as described in 
Experiment 2 above. BC-2-NMT assays were maintained at 37 °C for one hour. 
The assay work-up and measurement of 2,9-Me2N H + by RP-HPLC were 
performed as described in Chapter 5. Results are reported as percent of 
control BC-2-NMT activity. Control activity represents BC-2-NMT activity in 
the absence of PNMT substrate. 
Results 
The three PNMT substrates evaluated inhibited BC-2-NMT activity to 
varying degrees. BC-2-NMT activity was inhibited to 26% of control by 
octopamine, to 74% of control by normetanephrine, and to 80% of control by 
norepinephrine. 
Conclusion 
These data indicate that PNMT substrates are competing with 9-MeNH for 
BC-2-NMT, consistent with the hypothesis that BC-2-NMT and PNMT are the 
same enzyme. 
Experiment 5: 
Concen trati on-Dependcn t I nhi bi ti on 
of BC-2-NMT Activity 
by PNMT Substrates 
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In this series of experiments a range of PNMT substrate concentrations 
was utilized -- this range bracketed the Ii terature KM of the rcspecti ve 
substrate for PNMT. Note that the concentration of 9-MeNH was reduced Lo 100 
µM, from the 540 µM concentration used in Experiment 3, since an inhibitor 
(i.e., the PNMT substrate) is more effective when the substrate (9-MeNH) is 
present at or below its KM (75 µM). For each of the PNMT substrates evaluated, 
the data were plotted in two ways: 
( 1) percent of control BC-2-NMT activity as a function of PNMT 
substrate concentration 
( 2) a Dixon plot, 1/BC-2-NMT activity as a function of PNMT 
substrate concentration -- the Ki for the PNMT substrate (i.e, 
inhibitor) was determined from this plot. 
Materials and Methods: 
BC-2-NMT Inhibition 
by L-Norepinephrine 
Final concentrations of substrates and inhibitor (norepinephrinc) in the 
assays were: 
9-MeNH 
SAM 
3H-SAM 
L-norepinephrinc 
100 µM 
105 µM 
2.31 µCi 
0, 10, 40, 100, and 250 µM 
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The total volume of the assay was 370 µl and the final pH was 8.5. Assays were 
prepared in 1.5 ml polypropylene microcentrifuge tubes as follows: 
9-MeNH (370 µM stock in buffer "A") 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (2.31 µCi in Milli-Q water) 
L-norepinephrine (stock in buffer "A") 
Bovine brain cytosol (1.156 mg protein) 
100 µl 
20 µl 
50 µl 
100 µl 
100 µl 
L-norepinephrine stock solutions utilized were: 37 µM, 148 µM, 370 µM, 925 µM. 
Blank assays were prepared containing no 9-MeNH, without and with 
norepinephrine (250 µM final). Background N-methylation was subtracted 
from values obtained in complete assays. L-norepinephrine bitartratc was 
obtained from Sigma Chemical Company (St. Louis, MO); information 
regarding this reagent is listed in Appendix E. 
Results: 
BC-2-NMT Inhibition 
by N orepinephrine 
Norepincphrine inhibited 2N-methylation of 9-MeNH in a 
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concentration-dependent manner. BC-2-NMT activity was inhibited 50% in the 
presence of 48 µM norcpinephrine (Figure 44). The biphasic nature of the 
curve suggests the presence of two enzymes that are diffcrcnlially inhibited 
by norepinephrine. 
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Figure 44. Concentration-dependent inhibition of BC-2-NMT act1v1ly by 
norepinephrine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-
MeNH, 0-250 µM norepinephrine, 105 µM (2.31 µCi) SAM. 
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The Dixon plot (Figure 45) confirms a concentration-dependent 
inhibition of BC-2-NMT activity by norepinephrine. From this experiment 
alone, the type of inhibition could not be determined. Using the equations for 
competitive, noncompetitive, and uncompetitive inhibition, the calculated Ki 
for norepinephrine is probably in the range 21-36 µM. 
l/v = 0.021 + 0.001 [ norepinephri ne] 
(r = 0.945) 
0.4 
0.35 
0.3 
.._ 0.25 ..... 
.... 
u 
0 0.2 
a) 
> 
....... 0.15 
-
0.1 
0.05 
0 
-50 0 50 100 150 200 250 300 
[Norepinephrine, µM] 
Figure 45. Dixon plot for norepinephrine inhibition of BC-2-NMT act1v1ty. 
Assay at pH 8.5 for I hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-250 µM 
norepinephrine, 105 µM (2.31 µCi) SAM. 
Materials and Methods: 
BC-2-NMT Inhibition 
by DL-Octopamine 
The final concentrations of substrates and inhibitor in the assays were: 
9-MeNH 
SAM 
3H-SAM 
DL-octopamine 
lOOµM 
105 µM 
3.33 µCi 
0, 3, 12, 30, and 75 µM 
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The total volume of the assay was 370 µl and the final pH was 8.5. Assays were 
prepared in 1.5 ml polypropylene microcentrifuge tubes as follows: 
9-MeNH (370 µM stock in buffer "A") 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (3.33 µCi in Milli-Q water) 
DL-octopamine (stock in buffer "A") 
Bovine brain cytosol ( 1.156 mg protein) 
100 µl 
20 µl 
50 µl 
100 µl 
100 µI 
DL-octopamine stock solutions utilized were: 11.1 µM, 44.4 µM, 111 µM, 277 .5 µM. 
Blank assays were prepared containing no 9-MeNH, without and with 
DL-octopamine (75 µM final). Background N-methylation was subtracted from 
values obtained in complete assays. DL-octopamine hydrochloride was 
obtained from Sigma Chemical Company (St. Louis, MO); information regarding 
this reagent is listed in Appendix E. 
Results: 
BC-2-NMT Inhibition 
by DL-Octopamine 
Octopamine inhibited 2N-methylation of 9-MeNH in a concentration-
dependent manner. BC-2-NMT activity was inhibited 50% in the presence of 
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31 µM octopamine (Figure 46). The biphasic curve indicates the presence of 
two enzymes. 
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Figure 46. Concentration-dependent inhibition of BC-2-NMT act1vlly by 
octopamine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-
75 µM octopamine, 105 µM (3.33 µCi) SAM. 
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The Dixon plot also reveals a concentration-dependent inhibition of 
BC-2-NMT activity in the presence of octopamine (Figure 47). From this 
experiment alone, the type of inhibition could not be determined. Using the 
equations for competitive, noncompetitive, and uncompetitive inhibition, the 
calculated Ki for octopamine is probably in the range 9.2-21.4 µ M. 
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Figure 47. Dixon plot for octopamine inhibition of BC-2-NMT activity. 
Materials and Methods: 
BC-2-NMT Inhibition by 
DL-Phe n y I e th ano I amine 
The final concentrations of substrates and inhibitor rn the assays were: 
9-McNH 
SAM 
3H-SAM 
D L-phe ny I e th an o 1 amine 
lOOµM 
105 µM 
2.78 µCi 
0, 40, 160, 400, and I mM 
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The total volume of the assay was 370 µl and the final pH was 8.5. Assays were 
prepared in 1.5 ml polypropylene microcentrifuge tubes as follows: 
9-MeNH (370 µM stock in buffer "A") 
SAM (1.943 mM stock in Milli-Q water) 
3H-SAM (2.78 µCi in Milli-Q water) 
DL-phenylethanolamine (stock in buffer "A") 
Bovine brain cytosol (1.156 mg protein) 
100 µI 
20 µI 
50 µI 
100 µI 
100 µI 
DL-phenylethanolamine stock solutions utilized were: 148 µM, 592 µM, 
1.48 mM, 7.7 mM. Blank assays were prepared containing no 9-McNH, without 
and with DL-phenylethanolamine (1 mM final). Background N-methylation 
was subtracted from values obtained in complete assays. DL-
phenylethanolamine was obtained from Sigma Chemical Company (St. Louis, 
MO); information regarding this reagent is listed in Appendix E. 
Results: 
BC-2-NMT Inhibition by 
Ph en yle th anol amine 
Phenylethanolamine inhibited the 2N-methylation of 9-MeNH in a 
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concentration-dependent manner. BC-2-NMT activity was inhibited 57% in the 
presence of 1000 µM phenylethanolamine (Figure 48); concentrations higher 
than 1000 µM were not evaluated. Linear curve-fitting of these data after 
plotting of BC-2-NMT activity as a function of the log of the 
phenylethanolamine concentration predicts an ICso value of 1750 µM . 
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Figure 48. Concentration-dependent inhibition of BC-2-NMT by 
phenylethanolamine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-
MeNH, 0-1 mM phenylethanolamine, 105 µM (2.78 µCi) SAM. 
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The Dixon plot confirms a concentration-dependent inhibition of 
BC-2-NMT activity in the presence of phenylethanolamine (Figure 49). From 
this experiment alone, the type of inhibition could not be determined. Using 
the equations for competitive, noncompetitive, and uncompetitive inhibition, 
the calculated Ki for octopamine is probably in the range 156-365 µM. 
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Figure 49. Dixon plot for phenylethanolamine inhibition of BC-2-NMT activity. 
Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-1 mM 
pheoylethanolamine, 105 µM (2.78 µCi) SAM. 
Conclusion 
All three PNMT substrates inhibited BC-2-NMT activity in a 
concentration-dependent manner. The rank order Ki's of the three PNMT 
substrates for BC-2-NMT inhibition were: 
octopamine < norepinephrine 
(9-21 µM) (21-36 µM) 
< phenylethanolamine 
(156-365 µM) 
This rank order is consistent with the KM 's of these same substrates for 
monkey brainstem PNMT (Lew et al. 1977): 
octopamine $ norepinephrine 
(21 µM) (22 µM) 
< phenylethanolamine 
(200 µM) 
The hypothesis that BC-2-NMT and PNMT are the same enzyme is 
supported by these data. The PNMT substrates with the lowest KM 
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(norepinephrine and octopamine) exhibit the lowest Ki for inhibition of BC-2-
NMT. These data show inhibition of BC-2-NMT by PNMT substrates with a rank 
order that is comparable to the KM 's of these substrates for brain PNMT. 
Experiment 6: 
BC-2-NMT Activity in Human Medulla Ohlongata 
and Human Adrenal Medulla 
Materials and Methods 
Frozen postmortem human medulla oblongata or adrenal medulla was 
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obtained from the Loyola University/Hines VA Tissue Bank, Loyola University 
Medical Center, Maywood, IL 60253. Frozen tissue was thawed slightly and 
approximately 100 mg of tissue was removed using a clean tissue punch. Tissue 
was weighed and placed in a 2 ml glass homogenizer on ice, and was 
homogenized in 5 volumes (5 µ1 per mg) of homogenation buffer. 
Homogenation buffer (pH 7.2) consisted of 150 mM potassium chloride, 20 mM 
sodium phosphate (Na2HP04), 1 mM ethylenediaminetetraacetic acid disodium, 
and 1 mM dithiothreitol. Homogenation was accomplished with five up and 
down strokes of a motor-driven (300 rpm) teflon pestle. Homogenate was 
transferred to a 1.5 ml microcentrifuge tube, where centrifugation at 10,000g 
for thirty minutes afforded crude particulate and supernatant fractions. 
Particulate fraction was diluted with about 200 - 400 µI of homogenation buffer 
prior to use in ~C-NMT assays; supernatant was not diluted prior to assay. BC-
NMT activity was not determined in the particulate fraction from medulla 
oblong at a. 
The ~C-NMT assay, work-up, and RP-HPLC analysis was done according to 
the methods described in Chapter 5. Prior to plotting these data, background 
N-methylation (in the absence of BC) was subtracted from the corresponding 
data obtained in the presence of BC. 
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Results 
BC-2-NMT or BC-9-NMT activily was not discernahlc from background 
when the supernatant fraction from human medulla oblungata was used as the 
enzyme source. 
BC-2-NMT was activity was highest in the supernatant fraction derived 
from human adrenal medulla. Very little particulate fraction BC-2-NMT 
activity was detected. Particulate and supernatant BC-9-NMT activity was 
approximately 4-fold lower than supernatant BC-2-NMT activity (Figure 50). 
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Figure 50. BC-NMT activities in particulate and supernatant fractions from 
human adrenal medulla. 
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A large tritiated peak was present in blank particulate fraction assays; 
this peak was not observed when BC-substrates were included in the 
incubations. The retention time of the unknown peak was approximately 2 
minutes later than the retention time for 2,9-Me2 N H +. The peak corresponded 
to the incorporation 61.6 ± 17 .6 pmol of tritiated methyl group/h/mg protein. 
Conclusions 
PNMT catalytic activity is present in the medulla oblongata and the 
adrenal medulla (Axelrod 1971; Kitabchi et al. 1969; Kopp et al. 1979). The 
absence of BC-2-NMT activity in the human medulla oblongata is therefore 
inconsistent with the idea that BC-2-NMT is PNMT. 
However, the presence of supernatant BC-2-NMT activity in the adrenal 
medulla -- a tissue that exhibits high PNMT activity supports the hypothesis 
that BC-2-NMT and PNMT are the same enzyme. 
Experiment 7: 
Measurement of BC-2-NMT Activity 
in Bovine Brain Cytosol After 
Immunoprecipitation of PNMT 
Materials and Methods 
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If BC-2-NMT is synonymous with PNMT, one would predict a loss in BC-2-
NMT after immunoprecipitation of PNMT from bovine brain cytosol. The 
protocol for this study was a modification of the method described by Anderson 
and Blobel (1983). 
PNMT antibody was purchased from lncstar Corporation (Catalog 
#22572, Stillwater, MN). This polyclonal antisera was obtained from rabbits 
immunized with bovine adrenal PNMT. According to Incstar, this anti-PNMT 
cross-reacts with brain PNMT from various species. ImmunoPure® 
Immobilized Protein A/G Gel was obtained from Pierce (Catalog #20421, 
Rockford, IL). This gel has protein A (isolated from Staphylococcus aureus) 
and protein G (from Streptococcus species) covalently attached to agarose gel. 
Proteins A and G bind the Fe portion of the constant region on 
immunoglobulins derived from numerous species. Bovine brain cytosol was 
concentrated using a Centricon 30 concentrator. The theoretical interaction 
of PNMT from bovine brain cytosol, anti-PNMT, and protein A/G is diagramed 
in Figure 51. 
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Figure 51. Proposed immunoprecipitation of PNMT from bovine-brain cytosol. 
The contents of each of two vials containing lyophilized anti-PNMT 
were reconstituted using 100 µl Milli-Q water, and the resulting solutions 
combined. Concentrated bovine brain cytosol (60 µl) was added to each of 
seven 1.5 ml polypropylene microcentrifuge tubes. Tubes designated as 
"control-cytosol" also received 80 µl of IO mM Na2HPO 4 buffer (pH 7.3); total 
volume was therefore 140 µI. Anti-PNMT was added to the remaining four 
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tubes -- 10, 30, 50, or 80 µl of antisera were added -- final volume of these four 
tubes was also brought to 140 µl with buffer. The tubes were gently vortexed 
and then set at room temperature for one hour, prior to refrigeration for 19 
hours. The samples were centrifuged at 12,000g for 15 minutes, and portion of 
the resulting supernatants (130 µl) was transferred to clean 1.5 ml 
microcentrifuge tubes. 
Immobilized Protein A/G was equilibrated in 100 mM Na2HP04 (pH 7.3) 
and then diluted with buffer to yield a 1:1 suspension of gel:buffer. This 
suspension (800 µl) was added to each of five clean 1.5 ml microcentrifuge 
tubes. Tubes were centrifuged to pack the gel (400 µl), and resulting 
supernatant was discarded. Equilibration buffer (50 µI) was added to each of 
these tubes, as well as to two empty tubes. "Control-cytosol" from the previous 
step -- i.e., cytosol not exposed to anti-PNMT -- was added to each of the 2 tubes 
containing only equilibration buffer; these controls were never exposed to 
anti-PNMT or Protein A/G. The final control was designated "A/G-Control": it 
was prepared by adding "control-cytosol" to Protein A/G gel. To the 
remaining four tubes that contained Protein A/G gel, the supernatants 
resulting from anti-PNMT incubation were added. All tubes were agitated 
gently on a lab rocker for 3 hours at room temperature. The mixture was 
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centrifuged at 12,000g for 15 minutes to pack the gel. In theory the packed gel 
should contain the PNMT - PNMT antibody - Protein A/G agarose complex. A 
portion of the resulting supernatant (150 µI) was transferred Lo clean 
microcentrifuge tubes, and 100 µI of each of these soluLions were analyzed for 
BC-2-NMT activity. BC-2-NMT assays and work-up were done as described in 
Chapter 5. 
Results 
BC-2-NMT activity was apparently unaffected by immunoprecipitation 
of PNMT, because supernatant from bovine-brain cytosol that was exposed to 
anti-PNMT and immobilized protein A/G exhibited the same BC-2-NMT activity 
as supernatant from the protein A/G control incubation. 
Conclusion 
Assuming that PNMT was precipitated from the cytosol, this experiment 
does not support the hypothesis that BC-2-NMT and PNMT arc Lhc same enzyme. 
Summary of Results 
The results of experiments (a) through (e), to be discussed further in 
detail, are consistent with the hypothesis that BC-2-NMT and PNMT are the 
same enzyme: 
(a) purified bovine adrenal PNMT 2N-methylates 9-MeNH 
( b) LY 134046 inhibits BC-2-NMT in concentration-dependent manner 
( c) PNMT substrates inhibit BC-2-NMT in a concentration-dependent 
fashion 
( d) supernatant fraction derived from human adrenal medulla catalyzes 
the 2N-methylation of 9-MeNH 
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( e) demonstration of PNMT activity in bovine-brain cytosol as determined 
by the conversion of norepinephrine to epinephrine in the presence of 
SAM 
However, the results of experiments (f) and (g), taken at face value, do 
not support the hypothesis that BC-2-NMT and PNMT are equivalent enzymes: 
( f) the apparent absence of BC-2-NMT activity in the supernatant 
fraction isolated from human medulla oblongata 
( g) the lack of effect on BC-2-NMT activity of immunoprecipitation of 
PNMT from bovine-brain cytosol 
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Discussion 
PNMT 2N-Methylates 9-MeNH 
The most compelling evidence to support the equality of BC-2-NMT and 
PNMT is that purified bovine adrenal PNMT catalyzes the 2N-melhylation of 9-
MeNH, but not 2-MeNH+. Similarly, 9-MeNH is 2N-methylaled 4-fol<l more 
effectively than 2-MeNH+ is 9N-methylated in the presence of the crude 
supernatant fraction derived from human adrenal medulla -- a tissue with 
high PNMT activity. In addition, these data suggest that BC-2N-methylation 
and BC-9N-methylation may be catalyzed by two different enzymes. The 
specific activity of bovine adrenal PNMT toward 9-MeNH was 1.8% (17 .8 
pmol/h/unit PNMT) of PNMT's labeled activity toward a more standard 
substrate, normetanephrine (1 nmole/h/unit PNMT). A comparable ratio is 
obtained for bovine brain cytosol when the V max for PNMT ( 1.8 nmol 
epinephrine/h/mg protein) is compared to the V max for BC-2-NMT (48 
pmol/h/mg protein) under identical assay conditions -- 9-MeNH methylation 
is 2.7% of that for norepinephrine. These observations imply that 9-MeNH is a 
poor substrate for PNMT, but that PNMT can nonetheless 2N-methylate a f3C. 
BC-2-NMT Activity in the 
Adrenal Medulla 
Supernatant BC-2-NMT activity in human adrenal medulla was 43.7 
pmol/h/mg protein. Data from Chapter 5 of this dissertation show that 
supernatant BC-2-NMT activity in human brain varied regionally from 13.3 -
31.3 pmole/h/mg protein. Taken together these experiments indicate that BC-
2-NMT activity in the human adrenal medulla is 140 - 328% of BC-2-NMT 
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activity in human brain. These results are consistent wilh those reported for 
human PNMT, where adrenal medulla activity was 450% of cerebrum activity 
(Kitabchi and Williams 1969). The presence of the large unknown peak in the 
blank assay (without BC substrate) from the particulate fraction of adrenal 
medulla was surprising. It is postulated that this peak represents the 
methylated product of an endogenous BC or catecholamine -- an endogenous 
substrate whose methylation is inhibited in the presence of 9-MeNH or 
2-MeNH+. 
Inhibition of BC-2-NMT by PNMT 
Substrates and a PNMT Inhibitor 
The concentration-dependent inhibition of BC-2-NMT by the specific 
PNMT inhibitor, LY134046, supports the hypothesis that the BC-2-NMT and 
PNMT are the same enzyme. The Ki for inhibition of rat brain PNMT by 
LY134046 is 24 nM (Fuller et al. 1981), lower than the 400 nM Ki value for 
L Y134046 inhibition of BC-2-NMT reported here. The Ki for an inhibitor is 
dependent upon assay conditions, and those conditions differed between this 
study and that of Fuller et al. (1981). Specifically, Fuller utilized 
partially-purified PNMT derived from rat brainstem supernatant, and an assay 
pH of 7 .0. The present study used crude supernatant fraction from whole 
bovine brain, and an assay pH of 8.5. It is reasonable to speculate that 
differences in species and assay pH between experiments could account for the 
differences rn Ki values for L Yl34046 determined in the two studies 
Three distinct PNMT substrates -- norepinephrine, octopamine, and 
phenylethanolamine -- inhibited BC-2-NMT activity in a concentration-
dependent manner, indicating a competition between 9-MeNH and Lhose PNMT 
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substrates for the same enzyme. The biphasic nature of the inhibition plots 
suggests the presence of two different enzymes, or isozymes of the same 
enzyme, that are differently inhibited in the presence of the PNMT substrates. 
Dixon plots of reciprocal BC-2-NMT activity as a function of PNMT substrate 
(BC-2-NMT inhibitor) concentration were each linear. The mechanism of 
inhibition by these substrates cannot be confirmed with out further 
experiments done at various 9-MeNH concentrations. 
Recall that when SAM donates its methyl group to a substrate during a 
N-methyltransferase-catalyzed reaction, the products are the N-methylated 
substrate and SAH. SAH inhibits most SAM-dependent methyltransferases in a 
competitive manner. It is therefore reasonable to consider that BC-2-NMT 
inhibition in the presence of PNMT substrates could be due to the SAH that is 
formed as PNMT methylates its substrates. When norepinephrine alone was 
utilized in the PNMT assay, the calculated V max for epinephrine formation was 
1.8 nmoles/h/mg protein -- an equivalent amount of SAH would be the co-
product of this reaction. This amount of SAH (1.8 nmoles/h/mg protein) 
corresponds to a concentration of 4.9 µM SAH in the BC-2-NMT assay. BC-2-NMT 
activity would only be inhibited to 72% of control activity at this SAH 
concentration (refer to Chapter 3 for SAH inhibition curve), quite different 
than the 10% of control BC-2-NMT activity observed in the norepinephrine 
inhibition experiment. Moreover, SAH probably does not accumulate during a 
methyltransferase reaction, since it may be removed by the action of cytosolic 
SAH hydrolase and adenosine deaminase to form inosine (Chiang et al. 1996). 
Therefore it is improbable that SAH accounts for the observed inhibition of 
BC-2-NMT in the presence of norepinephrine. 
BC-2-NMT Activity in the 
Medulla Oblongata 
The lack of BC-2-NMT activity in the medulla oblongata is disturbing 
since this brain region ("C 1 area", dorsal to the mid portion of the inferior 
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olive) has a high level of PNMT activity (Fuller 1982; Kopp et al. 1979; Lew et al. 
1977; Mefford 1988), and one would expect a high level of BC-2-NMT activity in 
this brain region if PNMT and BC-2-NMT are the same enzyme. The 
supernatant used in my experiment was not dialyzed, and it is possible that 
dialyzable endogenous compounds (e.g., epinephrine or other catecholamines) 
may have been present that inhibited BC-2-NMT activity. PNMT is inhibited at 
high concentrations of endogenous catecholamines, including epinephrine 
and norepinephrine (Pohorecky et al. 1973 ). Unfortunately a positive control 
for PNMT activity -- conversion of norepinephrine to epinephrine -- was not 
included in this study. This experiment should be repeated using 2-3 different 
medulla oblongatas in which the supernatant fraction is dialyzed to remove 
endogenous inhibitors. In addition, positive controls should be included in 
each case to assure that PNMT activity with norepinephrine as the substrate is 
detectable under the assay conditions. 
Immunoprecipitation of PNMT 
lmmunoprecipitation of PNMT, followed by the assessment of BC-2-NMT 
activity in the resulting supernatant, is a practical approach to addressing the 
equivalency of PNMT and BC-2-NMT. It is possible that the results reported 
here are false-negative results due to technical problems such as insufficient 
precipitation of PNMT. Therefore, the experiment should be repeated with a 
positive control that would assure that adequate anti-PNMT is utilized. 
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Overall Conclusions 
In summary, taken together these data provide strong evidence that 
BC-2-NMT activity is due to PNMT. Purification of BC-2-NMT and comparison of 
its properties and primary sequence to that of PNMT would provide definitive 
proof of their equivalency. Assuming that BC-2-NMT is equivalent to PNMT, 
there is substantial circumstantial evidence that PNMT-catalyzed formation of 
cytotoxic 2-MeBCs+ may play a key role in the pathogenesis of PD. This 
evidence is discussed in subsequent text. A new hypothesis regarding the 
etiology of Parkinson's disease -- a hypothesis that incorporates a role for 
PNMT -- is presented at the end of that discussion. 
Evidence That is Consistent With a Role For PNMT 
in the Pathof;enesis of Parkinson's Disease 
PNMT Co-Localization With PD Pathology 
PNMT catalytic activity and immunoreacti vity are present in regions of 
human brain that are affected by PD. Primary pathological findings in PD 
include nerve cell loss and the presence of Lewy bodies in the substantia 
nigra, locus ceruleus, and peripeduncular nucleus (Forno 1995). These same 
human brain nuclei exhibit PNMT activity ranging from trace activity in the 
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interpeduncular nucleus to an activity of 2.6 pmole/h/mg protein in the locus 
coeruleus (Kopp et al. 1979). In addition, several other loci that frequently 
demonstrate pathology in PD also express PNMT, such as the hypothalamus, 
dorsal motor nucleus of the vagus, raphe nuclei, and the olfactory tubercle. It 
is conceivable that PNMT-catalyzed formation of neurotoxic 2-MeBCs+ in these 
nuclei contributes to the specific neuronal loss in PD. Further investigation 
may reveal a high degree of correlation between PNMT (BC-2-NMT) activily 
and brain pathology in PD. 
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Consistent with this speculation, Gai et.al (1993) reported a selective loss 
of PNMT-positive neurons in PD. Specifically, in PD medulla oblongata the 
number of neurons in the Cl cell group was reduced to 47% of control, and m 
the C3 area numbers were 12% of control values. It is plausible that this 
decrease in cell number could be a result of PNMT-catalyzed formation of 
neurotoxic 2-MeBCs+ within the Cl and C3 neurons early in the disease process. 
Cell death induced by 2-MeBCs+ would manifest as a loss in PNMT-posilive cells. 
In addition, PNMT activity is reduced in the hypothalamus and pallidum of PD 
brains (Nagatsu et al. 1977, 1984 ), areas that express PNMT, and consequently 
could generate 2-MeBCs+. Epinephrine in the CSF from PD patients is either 
unchanged (Tohgi et al. 1990) or decreased (Eldrup et al. 1995), the later being 
consistent with decreased brain PNMT activity resulting from loss of 
PNMT-posi ti ve neurons. 
Adrenal Medulla Pathology in PD 
The adrenal medulla exhibits high PNMT activity compared lo other 
tissues. Evidence presented in this chapter demonstrates the presence of 
substantial BC-2-NMT activity and trace BC-9-NMT activity in human adrenal 
medulla. The sequential action of BC-2-NMT (PNMT) followed by BC-9-NMT 
activity would form 2-MeBCs+ and then 2,9-Me2BCs+ in the adrenal medulla 
toxins that may kill those cells in which they are formed. Interestingly, many 
PD patients demonstrate pathology, including Lewy bodies, in the adrenal 
medulla (den Hartog Jager 1970; Stoddard 1994). In a recent review article 
addressing the condition of the adrenal medulla in PD (Stoddard 1994 ), 
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Stoddard concluded Lhat adrenal tissue, plasma, and urinary catecholamines 
are decreased in PD cases relative to control subjects. These results would be 
consistent with those expected subsequent to PNMT-catalyzed formation of 
toxic MeBCs+ in the adrenal medulla. As the PNMT-posiLive cells die due to the 
toxicity of MeBCs+, the capacity of the medulla to synLhesize epinephrine 
would also be expected to decrease. Perhaps this inability to synthesize 
epinephrine contributes to the hypotension observed in idiopathic PD. It is 
noteworthy that PC 12 cells -- an immortalized cell-line derived from adrenal 
tissue -- are susceptible to the toxicity induced by MeBCs+ (Cobuzzi ct al. 1994). 
Peripheral BC-2-NMT (PNMT) Activity 
Demonstration of BC-2-NMT and BC-9-NMT activity in the adrenal 
medulla is interesting because it implies that MeBCs+ could be formed 
peripherally following exposure to BCs (substrates for BC-2-NMT). 
Furthermore, Matsubara recently reported that 2-MeNH+ and 2,9-Me2NH + are 
able to penetrate the blood-brain barrier (Matsubara et al. 1996). Taken 
together these observations suggest that 2-MeBCs+ formed in adrenal medulla 
have access to the brain. Within the brain 2-MeBCs+ could be selectively 
transported into dopaminergic neurons via the dopamine transporLer, and 
therein exert their toxic effects (Drucker et al. 1990). 
PD, Stress, and PNMT 
Physiological stress results in increased brain and adrenal PNMT 
activity (Turner et al. 1979; Turner et al. 1978). Assuming that BC-2-NMT is 
PNMT, then in theory during a stressful situation 2-MeBC+ formaLion would be 
concomitantly increased (if substrates were present). Eatough ct al. (1990) 
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reported that PD patients experienced significantly greater extreme stress 
during life, especially in childhood, compared to control individuals. Perhaps 
also relevant is the report which indicates a higher incidence of PD in 
survivors of prisoner of war camps (Gibberd et al. 1980). It is possible that the 
association between extreme physiological stress and PD is due to cxcessi ve 
formation of MeBCs+ resulting from increased PNMT activity. 
The PNMT Hypothesis of 
Parkinson's Disease 
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This expanded hypothesis includes an early, and possibly precipitating, 
role for PNMT in the pathogenesis of Parkinson's disease (Figure 52). This 
hypothesis states that physiological stress, which is suggested as a 
predisposing factor to PD, increases PNMT (BC-2-NMT) activity both in the 
adrenal medulla and brain (Turner et al. 1978, 1979). Norharman, a substrate 
for BC-2-NMT, is elevated in the plasma of PD patients (Kuhn et al. 1995). PNMT 
(BC-2-NMT) may catalyze the formation of cytotoxic 2-MeBCs+ (e.g., 2-MeNH+) 
peripherally and centrally in PNMT-containing cells. The MeBCs+ could 
remain in the cells in which they were formed, or may exit and enter 
dopaminergic neurons via the dopamine transporter (Drucker et al. 1990). 
These 2-MeBCs+ and/or their N,N-dimethylated metabolites (2,9-Me2BCs+) 
inhibit mitochondrial respiration (Albores et al. 1990; Fields et al. 1992), 
thereby depleting ATP and causing neuronal death. Mitochondrial inhibition 
may also increase oxidative stress within affected neurons (Takeshige and 
Minakami 1979; Zeevalk and Bernard 1996; Zoccarato et al. 1988) --
neurofilaments may become oxidatively damaged, and consequently prone to 
aggregation and Lewy body formation (Hill 1996; Montine et al. 1995; Troncoso 
et al. 1995). 
(b) 
(e) 
superimposed 
upon a mitochondrial 
DNA defect 
236 
(c) 
_c_at_a_b_o_li_s_n_1 ---•.- non toxic 
catabolites 
inhibition of 
mitochondrial 
(proposed) 
oxidatively 
damaged 
neurofilaments V (proposed) 
Lewy body formation 
Figure 52. The PNMT hypothesis for Parkinson's disease: a proposal that the 
risk for development of PD increases as the number of factors (a-e) present 
increases. Each of this factors has an association with PD (see test for details). 
Factors are: (a) increased stress, (b) increased load of BC substrates, (c) 
decreased xenobiotic metabolism, (d) increased BC-9-NMT activity, (e) 
decreased mitochondrial function due mtDNA defect. 
CHAPTER 7 
SUMMARY AND SPECULATIONS 
Summary 
It is hypothesized that B-carboline-N-methyltransfcrascs (BC-NMTs) 
and/or the neurotoxic products of their catalytic activities, N-mcthylated 
B-carbolinium cations (MeBCs+ ), may play a role in the pathogenesis of 
idiopathic Parkinson's disease (Collins 1994; Collins and Neafsey 1985). The 
primary focus of this dissertation was J3-carboline-2N-methyltransferase 
activity (BC-2-NMT), but J3-carboline-9N-methyltransferase (BC-9-NMT) 
activity was also studied, although much less rigorously. 
The most important finding was that in the frontal cortex of 
Parkinson's disease (PD) brains, supernatant BC-9-NMT activity is increased 
relative to activity in control tissue. This implies that higher levels of 2,9-
Me2J3Cs+ may be formed in PD brain compared to normal brain. It is possible 
that brain BC-9-NMT activity is globally elevated in PD -- particularly early in 
the disease process -- but that with disease progression, elevated BC-9-NMT 
activity becomes undetectable due to MeBC+-induced death of the cells that 
originally contained the enzyme. 
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An equally important and exciting finding is the detection of relatively 
high BC-2-NMT activity in human adrenal medulla, suggesting that neurotoxic 
2-MeBCs+ may be formed in this tissue. There are at least four possible fates 
for adrenal-derived 2-MeBCs+: (1) liver metabolism to nontoxic compounds, (2) 
toxic effects on adrenal cells, (3) entry into the central nervous system, and 
(4) conversion to more toxic 2,9-Me2BCs+ by the action of adrenal and brain 
BC-9-NMT. Notably, this dissertation is the first report describing BC-9-NMT 
activity in human brain, as well as the measurement of l3C-2-NMT and l3C-9-
NMT activities in human adrenal medulla. 
The presence of BC-2-NMT activity in the adrenal medulla is consistent 
with a new hypothesis proposed in this dissertation (Figure 52). A fundamental 
aspect of this hypothesis is that BC-2-NMT activity is due to the epinephrine-
synthesizing enzyme, phenylethanolamine-N-methyltransferase (PNMT) or 
an enzyme very similar to PNMT. This hypothesis is supported by three key 
observations: (1) purified bovine adrenal PNMT catalyzes the 2N-methylation 
of 9-methylnorharman, (2) L Y134046, a selective inhibitor of PNMT, also 
inhibits BC-2-NMT, and (3) substrates of PNMT inhibit BC-2-NMT activity in a 
concentration-dependent manner. 
Another observation that may have relevance to PD is that l3C-2-NMT 
activity is increased 2-fold in the presence of iron (Fe2+ or Fe3+ ). Iron 
concentration is high in the substantia nigra compared to other brain 
regions, and its level appears to be higher in PD brain compared to control 
tissue. Perhaps elevated nigral iron in PD brain increases BC-2-NMT activity, 
which results in increased local formation of neurotoxic 2-Mel3Cs+ there. 
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Only a panial purification of BC-2-NMT was achieved in this study. 
However, the observations and suggestions presented here, regarding BC-2-
NMT purification, should be useful if this project is continued by another 
investigator -- however the development of less labor-intensive assay should 
be a priority. The inhibition experiments presented in Chapter 6 indicate that 
BC-2-NMT activity may be due to two enzyme activities; this would also 
complicate purification of BC-2-NMT activity. 
Speculations 
As summarized in Figures 52 and 53, it is hypothesized that PNMT may 
play a key role in the pathogenesis of PD. Stress-induced elevation of PNMT 
(presumably BC-2-NMT) could result in excessive formation of 2-MeBCs+ both 
in the adrenal medulla and brain. Resultant 2-MeBCs+ could then be 9N-
methylated by BC-9-NMT -- the activity that is elevated in PD brain -- to the 
more toxic 2,9-Me2BCs+. Local formation of MeBCs+ may culminate in cell death 
due to neurotoxin-induced mitochondrial inhibition. In addition, 2-MeBCs+ 
may cross the plasma membrane and subsequently enter other cells either 
passively or actively via the dopamine transporter. Active transport into 
dopaminergic cells may explain why nigrostriatal neurons are more severely 
affected in PD. It is interesting to consider that BC-2-NMT (PNMT) may also 
catalyze the formation of other proposed N-methylated dopaminergic 
neurotoxins, such as N-methylated derivatives of tetrahydroisoquinolines 
(Naoi et al. I 989b). Perhaps an early event associated with the pathogenesis of 
PD is N-methylation of several distinct classes of azaheterocycles (including 
BCs) to form mildly to moderately neurotoxic derivatives. Chronic exposure to 
these compounds over several years could eventually kill sufficient 
dopaminergic neurons to manifest the clinical symptoms of Parkinson's 
disease. 
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It is fascinating to consider the role that microbe-catalyzed formation of 
2-MeBCs+ may play in the pathogenesis of PD. Both Kitasatosporia setae and 
Nocardia asteroides are Actinomycetes, which are vegetable parasites that 
reside in soil. Kitasatosporia setae cultures transform norharman to 2-MeNH+ 
(Peczynska-Czoch et al. 1987), and mice inoculated with Nocardia asteroides 
develop a parkinsonian-syndrome (Kohbata and Beaman 1991 ). It is plausible 
that Nocardia asteroides may also be able to produce neurotoxic 2-MeBCs+ from 
simple BCs. Thus human ingestion or inhalation of these soil pathogens could 
provide "additional enzymatic machinery" able to produce neurotoxic 2-
MeBCs +. Perhaps the association between rural living and PD is closely related 
to exposure to these soil (groundwater?) pathogens. Regarding this 
speculation, two questions arise: (1) does Nocardia asteroides possess BC-2-NMT 
activity, and/or (2) in PD, is there evidence of Kitasatosporia setae infection? 
Overall Model of Parkinson's Disease 
An overall model for the etiology of idiopathic Parkinson's disease is 
presented in Figure 53 -- with BC-NMT-catalyzed formation of MeBCs+ playing 
a key role. Steps that are marked with an asterisk (*) were either discovered 
or studied during the development of this dissertation. Steps marked with a 
question-mark (?) have been postulated by the author or proposed by other 
investigators. 
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Figure 53. N-methylated-8-carboline hypothesis of Parkinson's disease. 
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APPENDIX A: 
PROTEIN ASSAYS 
Solution preparation was modified from Scopes (1994d ). 
Lowry Reaction 
Solution A: Copper Sulfate Solution 
Dissolve 500 mg copper sulfate heptahydrate (CuS04•5H20) and 1 g sodium 
citrate tribasic in 100 ml of Milli-Q water. Scopes states that is more stable than 
the commonly used copper tartrate solution and may be stored indefinitely. 
Solution B: Sodium Carbonate Solution 
Dissolve 10 g of sodium carbonate (Na2C03) and 2 g sodium hydroxide (NaOH) m 
500 ml Milli-Q water 
Solution C: Make fresh the day of protein assay, by m1xmg 50 ml (50 parts) of 
solution B and 1 ml (1 part) of solution A. This solution will be very basic (~ pH 
10). Use 2 ml of this solution per protein assay. 
Solution D: Dilute Folin-Ciocalteau reagent with an equal volume of Milli-Q 
water. Prepare a total volume that is sufficient to carry out all assay -- use 200 
µl per protein assay. 
Standard and Sample Preparation 
Standard Preparation: 
Bovine serum albumin (BSA, Fraction V) was dissolved in 1 mM sodium dodecyl 
sulfate (SDS) to a final concentration of 1 µg/µl (BSA stock)). Tubes for 
generation of the protein standard curve were prepared according to Table 23. 
Standards were prepared in triplicate. The reference (blank) sample was the 
same as the standard that did not contain BSA. 
Table 23.--Preparation of BSA Standards 
~ 
1 
2 
3 
4 
5 
6 
BSA/tube Cu~) 
0 
20 
50 
100 
150 
200 
Sample Preparation: 
BSA Stock Cul) 
0 
20 
50 
100 
150 
200 
1 mM SDS Cul) 
200 
180 
150 
100 
50 
0 
Concentrated samples (homogenates, extracts, or column fractions) were 
diluted in 1 mM SDS; the dilution usually varied from 1 :5 to 1 :50. Dilute samples 
were not diluted prior to analysis for protein. Diluted or undiluted samples 
were assayed in triplicate if sufficient sample was available. A predetermined 
volume of sample was added to a tube, and the volume was brought to 200 µl 
using 1 mM SDS. 
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Assay: 
To each standard and sample tube added 2.0 ml of "Solution C". Tubes were 
vortexed and set at room temperature for 5-10 minutes. Then 200 µ 1 of 
"Solution D" was added to each tube. It is important that tubes were mixed 
quickly after addition of "Solution D", therefore tubes were vortexed in sets of 
10-15 following the addition of "Solution D". Tubes remained at room 
temperature for 20-30 minutes. Solutions developed a blue color, the 
absorbance of which was determined at 700 nm using a Gilford Response 
spectrophotometer. Polystyrene disposable semi-micro cuvettes were used ( 1.5 
ml, 1 cm light path). Standards were analyzed using the standard curve 
program on the spectrophotometer; this program automatically generates the 
curve and the corresponding linear equation with correlation coefficient. 
The samples are run following standard analysis according to the prompts on 
the spectrophotometer monitor. The program uses the standard curve 
information to calculate the protein (µg) per sample cuvettc. Protein in the 
original sample is then calculated taking into account sample dilution prior to 
assay. 
Coomassie Blue Dye Binding 
Mix 600 mg of Coomassie Brilliant Blue G-250 with 1000 ml of a 2% perchloric 
acid solution. This solution is stable indefinitely. Filter to remove undissolved 
material. Use 2-3 ml of this solution per protein assay. this solution will color 
blue glassware and plasticware. This color can be removed with either 
methanol or a detergent solution. 
Standard. Sample Preparation. and Assay 
These steps were identical to the Lowry method with two exceptions. Following 
standard or sample preparation, 3 ml of Coomassie blue dye solution as added to 
each tube. Tubes were vortexed and maintained at room temperature for 
between 2 and 30 minutes. Standard and sample absorbance was determined at 
595 nm. 
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APPENDIXB: 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
Preparation of HPLC Mobile Phase 
RP-HPLC Mobile Phase Composition 
83% (v/v) 0.25 M NaH2P04 plus 50 mM TEA in water (pH 3) 
17% (v/v) Acetonitrile 
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To make 2 L of mobile phase: In a 2 L beaker equipped with magnetic stir bar, 
add 49.8 g sodium phosphate monobasic (NaH2P04, fwt 120), 1500 ml Milli-Q 
water, and 7.0 ml of triethylamine (TEA). Stir until all solids are dissolved (15-
30 minutes). Adjust pH to 3.0±0.1 using concentrated phosphoric acid. 
Transfer this solution to 2 L graduated cylinder an dilute to a final volume of 
1660 ml using Milli-Q water. Transfer back to the 2 L beaker and mix. Add 340 
ml of HPLC grade acetonitrile while mixing. Vacuum filter through a 0.2 µm 
nylon membrane filter (47 mm diameter). Stir under house vacuum in order 
to degas the mobile phase. The final mobile phase pH is approximately pH 3.4. 
SCX-HPLC Mobile Phase 
60% (v/v) 0.3 M NH4Cl plus 0.2 M NH40Ac in water (pH 4) 
40% (v/v) Acetonitrile 
In a 2 L beaker equipped with magnetic stir bar, add 19.4 g ammonium chloride 
(NH4Cl, fwt 53.9), 18.5 g ammonium acetate (NH40Ac, fwt 77.08), and 1000 ml of 
Milli-Q water. Stir for 15-30 minutes to dissolve solids. Adjust the pH to 4.0±0. 1 
using glacial acetic acid (90-120 ml required). Transfer this solution to a 2 L 
graduated cylinder and dilute to 1200 ml with Milli-Q water. Transfer back to 
the 2 L beaker, mix, and add 800 ml HPLC-grade acetonitrile. Mix, filter, and 
degas as described above. The final pH of the mixture is approximately pH 5. 
Fluorescence Detector 
Model: Perkin-Elmer LC240 
Wavelengths: Excitation 310 nm, Emission 450 nm (optimal for 2,9-Me2NH +) 
AF: usually set at 1024 (decreasing this value will increase sensitivity) 
Response: usually set at 5 
Note: after turning instrument on, press "58 control" to prevent lamp from 
automatically turning off after 30 minutes 
Inte&rator (used with fluorescence detection) 
Model: Shimadzu C-R 1 B Chromatopac Reporting Integrator 
Usual settings are: 
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Width = 20 (width is set to peak width at 0.5*peak height for narrowest peak in 
trace) 
Slope = 800-1000 (decreasing slope will increase detection of small changes 
from baseline -- if slope is too low, noise in baseline will be reported as peaks) 
Speed (of chart) = 2 
Att (attenuation) = 5-6 for normal BC-NMT assays (decreasing attenuation value 
will increase sensitivity) 
Min Area (minimum area) = variable (represents the minimum area for peaks 
that are to be included in the integrating report -- if this value is too low, the 
report will include many small peaks that really represent only noise 
Stop Time = 15-20 minutes (the time that data collection is terminated --
depends upon compounds that are present) 
Radioactive Detector 
Model: Radiomatic Flo-One\Beta (supported by Packard Instruments) 
Program Disk is needed to boot system and change operating parameters, while 
the Run (data) disc is needed to store runs. 
Determination of background is done with mobile phase and scintillation 
cocktail flowing through flow cell. The settings below were used for the 
background determination prior to the beginning of sample analysis: 
Condition = H-3 
Update Time = 10 
Mode = Scaler 
Results = Net cpm 
Cell type = liquid 
Cell size = 2.5 
Auto pump = yes 
Pump flow rate = 2.8 
HPLC Flow rate = 0.8 
Scaler time = 1 
Spitter Ratio = 100 
Fraction collector channel = 0 
Discriminator settings = 
Background subtract = 0 
Channel 1 
1-40 
Channel 2 
5-100 
Channel 3 
the background check was run for 10 minutes. Total cpm reported is divided by 
10 to give the average cpm in minute (usually 40 cpm). this value is used in 
the "background subtract" field during sample analysis. 
Typical instrumenl setlings for sample analysis were: 
Condition = H-3 
Update Time = 10 
Mode = Integrate 
Results = Net cpm 
Cell type = liquid 
Cell size = 2.5 
Auto pump = yes 
Pump flow rate = 2.8 
HPLC Flow rate = 0.8 
Scaler time = 1 
Spitter Ratio = 100 
Fraction collector channel = 0 
Discriminator settings = Channel 1 Channel 2 Channel 3 
1-40 5-100 
Background subtract = 40 
Minimum peak area: 80 (i.e., 2x background subtract) 
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APPENDIXC 
SYNTHESIS OF 9-METHYLNORHARMAN HCL 
The synthesis was a modification of that described by Rubotlom and Chabala 
(1974). 
Reaction 
The reaction was carried-out in an oven-dried 25 ml round-bottom singlc-
necked flask equipped with a magnetic stir bar. Norharman free base (NH, 
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678.5 mg, 3.95 mmole) was dissolved in 14 ml of hexamethylphosphoramide 
(HMPA) that had been stored over molecular sieves at least overnight. Sodium 
amide (NaNH2, 1.04 g, 3.4 equivalents with respect to NH) was washed into the 
reaction flask with the aid of about 2 ml HMPA. The flask headspace was 
purged with nitrogen and immediately stoppered to minimize exposure of the 
reaction to moisture. The contents of the flask were stirred for five hours at 
room temperature. The mixture was light yellow, with a blue-tint at the air-
mixture interface. 
After the five hour stir, the reaction was chilled to 5-10 °C. Methyl 
iodide (CH31, 4.35 mmole, 271 µl, 1.1 equivalents with respect to NH) was 
quickly added. The mixture became blue and then green. The mixture was 
sampled after 15 minutes so that the extent of the reaction could be determined 
by SCX-HPLC (see Chapter 1 and Appendix B). After 15 minutes the reaction 
was green and 50% of the NH remained. After 30 minutes the reaction was 
brownish-green and 30% of the NH was still unreacted. An additional 61 µI 
CH 3! (0.98 mmole) was added and the reaction was stirred for IO minutes at 5-10 
°C. Little to no NH was detected by SCX-HPLC. 
Reaction Work-Up 
Milli-Q water (16 mL) was added to the reaction mixture; the reaction pH was 
13.5. Reaction pH was adjusted to pH 7 using concentrated HCI. mixture was 
mixed vigorously and then transferred to a separatory funnel. Diethyl ether 
(Et2 0, 25 ml) was added to the contents of the separatory funnel. The funnel 
was inverted several times in order to extract the aqueous layer with the Et20. 
The two layers were allowed to separate and the Et20 (upper) layer added to a 
250-ml flask containing anhydrous magnesium sulfate (MgSO.i); the MgS04 
served to remove water from the Et20 extract. The lower aqueous layer was 
extracted four more times using 25 ml of Et2 0 each time. All ether extracts 
were combined with the original extract over MgS04. The Et20/MgS04 mixture 
was filtered to remove MgS04. The Et20 filtrate was evaporated to an oil using a 
Rotovap evaporator. Methanolic- HCl (2.7 ml) was added to the oil, followed by 
the addition of about 5-10 ml of Et20. The mixture was placed at -20 °C to 
expedite crystallization of 9-methylnorharman hydrochloride. The pale 
yellow crystals were filtered through Whatman 40 filter paper, and the 
crystals were washed with cold Et20. The crystals were dried overnight in a 
vacuum oven at 40-50 °C. 
Yield: 495 mg (2.27 mmoles based on a molecular weight of 218) 
Percent yield = (2.27 mmole/3.95 mmole)*IOO = 57% 
Purity: >95% by SCX-HPLC; structure confirmed by NMR (Dr. David Crumrine, 
Department of Chemistry, Loyola University Chicago) 
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Table 24.--ANOVA RESULTS 
Enzyme Activity = f(F + R + G + F*R + F*G + R*G + F*R*G) 
F = Fraction = Particulate or SupernaLanl 
R = Brain Region = Substantia nigra or Putamcn or Frontal Cortex 
G=Group = Control or Parkinson's disease 
BC-2N-Meth):'.I tran sf~rase Activit):'. 
Source S.S. df MS F-ratio p-value 
Main Effects 5488.349 4 1372.087 4.037 0.005 
Fraction (F) 4077.090 1 4077.090 11.997 0.001 
Region (R) 1421.680 2 710.840 2.092 0.131 
Group (G) 3.665 1 3.665 0.011 0.918 
2-way interactions 869.735 5 173.947 0.512 0.766 
F*R 648.584 2 324.292 0.954 0.390 
F*G 4.799 1 4.799 0.014 0.906 
R*G 208.268 2 104.134 0.306 0.737 
3-way interactions 73.634 2 36.817 0.108 0.897 
F*R*G 73.634 2 36.817 0.108 0.897 
Explained 6515.019 11 592.274 1.743 0.082 
Residual 23110.105 68 339.854 
Total 29625.124 79 375.002 
BC-9N-Methyl tran sf~ras~ Activity 
Source SS df MS F-ratio p-value 
Main effects 3477.492 4 869.373 4.947 0.001 
Fraction (F) 2522.520 1 2522.520 14.354 0.0003 
Region (R) 719.763 2 359.882 2.048 0.136 
Group (G) 253.178 1 253.178 1.441 0.234 
2-way interactions 2357.925 5 471.585 2.683 0.028 
F*R 217.100 2 108.550 0.618 0.542 
F*G 408.632 1 408.632 2.325 0.132 
R*G 1764.280 2 882.140 5.020 0.0091 
3-way interactions 770.573 2 385.287 2.192 0.119 
F*R*G 770.573 2 385.287 2.192 0.119 
Explained 6728.328 11 611.666 3.481 0.001 
Residual 12653.152 72 175.738 
Total 19381.480 83 233.512 
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MATERIALS USED IN CHAPTER 6 
Purified Bovine-Adrenal PNMT 
Catalog # I lot # 
Enzyme Commission # 
Source 
Activity 
Contents 
LY134046 CPNMT Inhibitor) 
Catalog # I lot no. 
Molecular weight 
Chemical name 
P-8924 I 15H3891 
EC 2.1.1.28 
bovine adrenal medulla 
"one unit will convert 1.0 nanomolcs of 
normetanephrine to melancphrinc per hr 
at pH 8.5 at 37 °C" 
"lyophilized powder containing approx. 70% 
protein (Biuret); balance is primarily 
phosphate buffer salts, pH 7 .5: 1.1 mg solid, 24 
units/mg solid, 32 units/mg prot." 
L-105 I GG-389A 
252.57 
8, 9-dichloro-2,3 ,4,5-tetrahydro- l H-2-
benzazepine, hydrochloride salt 
Norepinephrine CPNMT substrate) 
Catalog # I lot no. 
Molecular weight 
Chemical name 
Octopamine (PNMT substrate) 
Catalog # I lot no. 
Molecular weight 
Chemical name 
A-9512 I 36H0770 
319.3 
(-)-arterenol, bitartrate salt, or 
2-amino-1-( 3 ,4-dihydroxyphen yl) 
ethanol, bitartrate salt 
0-0250 I 128F0347 
189.6 
1-(p-hydroxyphenyl)-2-ami nocth anol, 
hydrochloride salt 
DL-phenylethanolamine CPNMT substrate) 
Catalog # I lot no. 
Molecular weight 
Chemical name 
H-1754 I 36H2514 
137.2 
D L- ~ -hydroxypheneth y 1 amine 
GLOSSARY 
Allosteric effector: a compound that binds Lo the enzyme at a site other than 
the active site, and affects the reaction catalyzed by the enzyme --
enzyme activity may be increased or decreased 
Allosteric site: a site or sites on an enzyme, distinct form the active site, where 
compounds bind, and consequently affect the catalytic activity of the 
enzyme 
Catalytic constant: kcai. experimentally-defined the rate constant for 
formation of product [P] from the enzyme-substrate complex [ES] 
equivalent to turnover number 
Catalytic site: equivalent to active site -- the site on an enzyme where 
substrate [S] binds and the actual formation of product [P] occurs 
Competitive inhibitor: a compound that binds to free enzyme [E] at the active 
site in competition with the substrate [S] -- the inhibition may be 
overcome by increasing [S] -- inhibitor presence increases the KM of 
the substrate, while V max is unaffected 
Enzyme-substrate complex: [ES], the concentration of enzyme [E] in a complex 
with the substrate [S] 
Free enzyme: [E], the concentration of free enzyme, i.e., the concentration of 
enzyme not in a complex with substrate [S] 
Inhibitor: [I], the inhibitor concentration, an inhibitor decreases the 
activity of an enzyme 
k1: rate constant for the formation of the enzyme-substrate complex from 
free enzyme [E] and substrate [S] 
k_J: rate constant for the dissociation of the enzyme-substrate complex [ES] to 
free enzyme [E] and substrate [S] 
k_2: rate constant for the association of free enzyme [E] and product [P] to 
form the enzyme-substrate complex [ES] -- this constant assumed to be 
negligible in simple Michaelis-Menten kinetics 
Ki: the inhibitor constant, the dissociation constant for the inhibitor-enzyme 
complex 
Michaelis constant: KM, a function of kinetic constants experimentally equal 
to the substrate concentration at which the reaction velocity (v) is 
proceeding at one-half maximal velocity (0.5*V max) 
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Maximum velocity: V max, a kinetic constant which represents the maximum 
velocity for product [PJ formation under stated reaction conditions -- at 
V max the enzyme is said to be saturated with substrate [SJ 
Noncompetitive inhibitor: binds to the enzyme and inhibitor presence 
decreases V max, but does not affect substrate KM 
Product: [P], the product concentration, i.e., the compound formed by action 
of an enzyme on a substrate, in an enzyme-catalyzed reaction 
Substrate: [SJ' the substrate concentration in an enzyme-catalyzed reaction 
Specific activity: the amount of product [PJ formed by an enzyme per unit 
time per mass of protein (e.g., pmol/h/mg protein) -- more precisely 
the units of enzyme per mg protein 
Turnover number: equivalent to kcat -- the number of substrate molecules 
transformed per minute by a single enzyme molecule when the 
enzyme concentration is the rate limiting factor, formerly called the 
molecular or molar activity 
Uncompetitive inhibitor: binds to enzyme and inhibitor presence decreases 
both KM and V max 
Unit: U, the amount of an enzyme that will catalyze the transformation of one 
µmole of substrate [SJ to product [PJ per minute at a specified 
temperature (usually 25 °C), at a defined substrate concentration 
Velocity: v, the rate at which substrate [SJ is converted to product [PJ in an 
enzyme-catalyzed reaction, units are in concentration per unit time 
(e.g., pmoles/hour) 
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